Conditions: Diabetes Mellitus, Type 2
Keywords: Drug Therapy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 152
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg) once daily compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric participants with type 2 diabetes mellitus (T2DM).

Detailed description:
The drug being tested in this study is called alogliptin. Alogliptin is being tested to treat children 10 to 17 years of age who have T2DM and are experiencing inadequate glycemic control. This study will look at HbA1c fluctuations in children who take alogliptin in addition to their background antidiabetic therapy.

The study will enroll approximately 150 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

* Alogliptin 25 mg
* Placebo (dummy inactive pill) - this is a tablet that looks like the tablet containing alogliptin 25 mg but has no active ingredient (that is, has no alogliptin).

All participants will be asked to take one tablet at the same time each day throughout the study in addition to their current background antidiabetic therapy (metformin and/or insulin) if applicable.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 56 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 2 weeks after the last dose of study drug for a follow-up assessment.

Arms:
arm 1: Alogliptin matching-placebo tablets, orally, once daily (QD) for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period. arm 2: Alogliptin 25 mg tablets, orally, QD for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.

Interventions: intervention 1: Alogliptin Benzoate intervention 2: Placebo
Intervention descriptions: intervention 1: Alogliptin benzoate tablets. intervention 2: Alogliptin placebo-matching tablets.

Protocol document:
Prot_000.pdf: 
x
x
x
5JUMF".VMUJDFOUFS3BOEPNJ[FE%PVCMF#MJOE1MBDFCP$POUSPMMFE4UVEZUP&WBMVBUFUIF
&GGJDBDZBOE4BGFUZPG"MPHMJQUJO$PNQBSFE8JUI1MBDFCPJO1FEJBUSJD4VCKFDUT8JUI5ZQF
%JBCFUFT.FMMJUVT
/$5/VNCFS/$5
1SPUPDPM"QQSPWF%BUF"VHVTU
&HUWDLQLQIRUPDWLRQZLWKLQWKLVSURWRFROKDVEHHQUHGDFWHGLHVSHFLILFFRQWHQWLVPDVNHGLUUHYHUVLEO\IURP
YLHZZLWKDEODFNEOXHEDUWRSURWHFWHLWKHUSHUVRQDOO\LGHQWLILDEOHLQIRUPDWLRQ33'RUFRPSDQ\
FRQILGHQWLDOLQIRUPDWLRQ&&,
7KLVPD\LQFOXGHEXWLVQRWOLPLWHGWRUHGDFWLRQRIWKHIROORZLQJ
1DPHGSHUVRQVRURUJDQL]DWLRQVDVVRFLDWHGZLWKWKHVWXG\
3URSULHWDU\LQIRUPDWLRQVXFKDVVFDOHVRUFRGLQJV\VWHPVZKLFKDUHFRQVLGHUHGFRQILGHQWLDO
LQIRUPDWLRQXQGHUSULRUDJUHHPHQWVZLWKOLFHQVHKROGHU
2WKHULQIRUPDWLRQDVQHHGHGWRSURWHFWFRQILGHQWLDOLW\RI7DNHGDRUSDUWQHUVSHUVRQDOLQIRUPDWLRQRU
WRRWKHUZLVHSURWHFWWKHLQWHJULW\RIWKHFOLQLFDOVWXG\
C
C
I


1.0 TITLE PAGE
PROTOCOL
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the 
Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 
Diabetes Mellitus
Phase 3 Alogliptin Pediatric Study
Sponsor:
Takeda Development Center Americas, Inc 
95 Hayden Avenue, 
Lexington, MA 02421 USA
Takeda Development Centre Europe Ltd.
1 Kingdom Street
London, W2 68D
UK
Takeda Development Center Asia Pte. Ltd.
2 Shenton Way, #15-02 SGX Centre 1, 
Singapore 068804
Study Number:
SYR-322_309
IND Number:
69,707
EudraCT Number:
2015-000208-25
Compound:
alogliptin
Date:
17 August 2020
Amendment Number:
9 IT v1
Amendment History: 
Date
Amendment Number
Amendment Type
Region
17 August 2020
Amendment 9 IT v1
Substantial
Italy
13 November 2019
Amendment 8
Substantial
Russia
28 November 2018
Amendment 7
Substantial
Brazil
27 June 2018
Amendment 6
Substantial
Germany
09 February 2018
Amendment 5
Substantial
Germany
17 January 2018
Amendment 4
Substantial
Italy
10 May 2017
Amendment 3
Nonsubstantial
Global
09 November 2016
Amendment 2
Substantial
Global
29 April 2016
Amendment 1
Substantial
Global
28 July 2015
Initial Protocol
Not applicable
Global
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 2 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
1.0
ADMINISTRATIVE INFORMATION
1.1
Contacts 
A separate contact information list will be provided to each site.
Takeda Development Center (TDC) sponsored investigators per individual country requirements 
will be provided with emergency medical contact information cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. 
Contact 
Type/Role
North American Contact
South American Contact
European Contact
Serious 
adverse event 
and 
pregnancy 
reporting
Medical 
Monitor
(medical 
advice on 
protocol and 
compound)
Responsible 
Medical 
Officer 
(carries 
overall 
responsibility 
for the 
conduct of 
the study)
PPD
Property of Takeda: 
a:
Applicable Terms of Use
qui
quirem
rem
i
y each s
each
y
r assigne
assign
E
Ap
o the A
: For Non-Commercial Use Only and Subject to t


Alogliptin
Study No. SYR-322_309
Page 3 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
1.2
Approval 
REPRESENTATIVES OF TAKEDA 
This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!
The ethical principles that have their origin in the Declaration of Helsinki.
!
International Conference on Harmonisation E6 Good Clinical Practice (GCP): Consolidated 
Guideline.
!
All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
rdance
dance
wing:
wing
P): Cons
P): Con
ta priva
a priva
other si
ther s
: For Non-Commercial Use Only and Su


Alogliptin
Study No. SYR-322_309
Page 4 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, and any 
other product information provided by the sponsor. I agree to conduct this study in accordance 
with the requirements of this protocol and also to protect the rights, safety, privacy, and well-being 
of study subjects in accordance with the following:

The ethical principles that have their origin in the Declaration of Helsinki.

International Conference on Harmonisation, E6 GCP: Consolidated Guideline.

All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations.

Regulatory requirements for reporting serious adverse events defined in Section 10.2 of this 
protocol.

Terms outlined in the Clinical Study Site Agreement.

Appendix B - Responsibilities of the Investigator.
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix D of this protocol.
Signature of Investigator
Date
Investigator Name (print or type)
Investigator’s Title
Location of Facility (City, State/Provence)
Location of Facility (Country)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 5 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
1.3
Protocol Amendment No. 9 IT v1 Summary of Changes 
This section describes the changes in reference to the protocol incorporating Amendment 9 IT v1.
The primary reasons for this amendment are to:

Describe how to manage study procedures, data collection, investigational product, and 
statistical analysis during unavoidable circumstances such as the coronavirus disease 2019 
(COVID-19) pandemic. 

Revise the sample size as per United States (US) Food and Drug Administration (FDA) 
recommendation and in accordance with the approved European Medicines Agency (EMA) 
modified Paediatric Investigational Plan (PIP), EMEA-000496-PIP01-08-M08. 

Remove the specific dropout/hyperglycemic rescue rate of 30%, as recommended by the US 
FDA. 

Update the text to include the recent availability of liraglutide for type 2 diabetes mellitus 
(T2DM) treatment in children and adolescents. 

Remove pharmacogenomic sampling.
In this amendment, minor grammatical, editorial, formatting, and administrative changes not 
affecting the conduct of the study are included for clarification and administrative purposes only.
Protocol Amendment 9 IT v1
Summary of Changes Since the Last Version of the Approved Protocol for Italy
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
Section 2.0 STUDY SUMMARY
Section 13.3 Determination of
Sample Size
Reduced the sample size from 100 
subjects per arm to 75 subjects per arm.
To revise the sample size as per US 
FDA recommendation and in 
accordance with the approved EMA 
modified PIP, 
EMEA-000496-PIP01-08-M08.
Section 2.0 STUDY SUMMARY
Section 13.3 Determination of
Sample Size
Removed the specific 
dropout/hyperglycemic rescue rate of 
30%.
To remove the specific 
dropout/hyperglycemic rescue rate 
of 30% as recommended by US 
FDA.
Section 4.1 Background
Updated text to reflect availability of 
liraglutide for children and adolescents 
aged 10 to 17 years.
To update text to include current 
availability of liraglutide for 
treatment of T2DM in children and 
adolescents aged 10 to 17 years.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 6 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Protocol Amendment 9 IT v1
Summary of Changes Since the Last Version of the Approved Protocol for Italy
Sections Affected by Change
Description of Each Change and Rationale
Section 6.1 Study Design
Section 7.6 Criteria for 
Discontinuation or Withdrawal of a 
Study Drug
Section 8.2 Investigational Drug 
Assignment and Dispensing 
Procedures
Section 9.1.1 Alternative 
Approaches to Study Procedures and 
Data Collection Due to Unavoidable 
Circumstances
Section 9.1.9 Procedures for Clinical 
Laboratory Samples
Section 9.3 Schedule of 
Observations and Procedures
Section 13.1 Statistical and 
Analytical Plans
Section 14.2 Protocol Deviations
Appendix A
Schedule of Study 
Procedures
Added instructions for managing study 
procedures, data collection, and 
investigational product during 
unavoidable circumstances (eg, a 
widespread disease outbreak such as 
the COVID-19 pandemic or natural 
disaster).
To provide instruction for 
managing study components 
impacted by unavoidable 
circumstances.
Section 9.1.2.1 Pharmacogenomic 
Informed Consent Procedure
Section 9.1.12 Pharmacogenomic 
Sample Collection
Section 9.4 Biological Sample 
Retention and Destruction
Appendix A
Schedule of Study 
Procedures
Discontinued collection of 
pharmacogenomic sample
As of the date of this amendment, a 
sufficient number of samples have 
been collected and no more are 
needed.
Section 13.1.3 Efficacy Analysis
Added sensitivity analysis for the 
primary endpoint only that excludes 
subjects affected by COVID-19.
To add sensitivity analysis to the 
primary endpoint.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 7 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
TABLE OF CONTENTS
1.0
ADMINISTRATIVE INFORMATION ...........................................................................2
1.1
Contacts.....................................................................................................................2
1.2
Approval....................................................................................................................3
1.3
Protocol Amendment No. 9 IT v1 Summary of Changes............................................5
2.0
STUDY SUMMARY ....................................................................................................13
3.0
STUDY REFERENCE INFORMATION ......................................................................17
3.1
Study-Related Responsibilities.................................................................................17
3.2
Coordinating Investigator.........................................................................................17
3.3
List of Abbreviations ...............................................................................................18
3.4
Corporate Identification...........................................................................................19
4.0
INTRODUCTION.........................................................................................................20
4.1
Background .............................................................................................................20
4.2
Rationale for the Proposed Study.............................................................................22
5.0
STUDY OBJECTIVES AND ENDPOINTS..................................................................22
5.1
Objectives................................................................................................................22
5.1.1
Primary Objective............................................................................................22
5.1.2
Secondary Objectives ......................................................................................22
5.1.3
Exploratory Objectives ....................................................................................23
5.2
Endpoints.................................................................................................................23
5.2.1
Primary Endpoint.............................................................................................23
5.2.2
Secondary Endpoints .......................................................................................23
5.2.3
.....................................................................................24
6.0
STUDY DESIGN AND DESCRIPTION.......................................................................25
6.1
Study Design ...........................................................................................................25
6.2
Pre-Randomization Stabilization Period (if needed).................................................27
6.3
Justification for Study Design, Dose, and Endpoints ................................................28
6.4
Premature Termination or Suspension of Study or Investigational Site.....................29
6.4.1
Criteria for Premature Termination or Suspension of the Study........................29
6.4.2
Criteria for Premature Termination or Suspension of Investigational Sites.......29
6.4.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site(s) .............................................................29
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS..............29
7.1
Inclusion Criteria .....................................................................................................29
7.2
Exclusion Criteria ....................................................................................................30
CCI
Property of Takeda: For Non
SIGN A
SIGN
y Desig
Des
y
re
Commercial Use Only and Subject to the Applicable Terms of Use
2
......2
.........
.....
3
.........
.........
....
.........
......
........
......
.........
....
..........
........
..
.........
.....
........
......
.........
....
S.......
.....
........
......
.........
...
........
.....
ves
es .....
.........
....
point
int..
y Endpo
Endp
y
-Rand
Ra
Just
Justif
4
P
6.
on-C


Alogliptin
Study No. SYR-322_309
Page 8 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
7.3
Additional Randomization Criteria That Must Be Met Following Screening and/or 
Completion of the Pre-Randomization Stabilization Period......................................31
7.4
Excluded Medications..............................................................................................32
7.5
Diet, Fluid, Activity Control ....................................................................................33
7.6
Criteria for Discontinuation or Withdrawal of a Study Drug.....................................33
7.7
Criteria for Discontinuation or Withdrawal from Study Participation .......................34
7.7.1
Voluntary Withdrawal .....................................................................................34
7.7.2
Lost-to-Follow-up............................................................................................35
7.8
Liver Safety Monitoring and Withdrawal Criteria ....................................................36
7.8.1
Liver Function Test Monitoring .......................................................................36
7.8.2
Considerations for Temporary Discontinuation of Study Drug.........................36
7.8.3
Permanent Discontinuation of Study Drug .......................................................37
7.8.4
Re-initiation of Study Drug..............................................................................37
7.9
Renal Safety Withdrawal Criteria.............................................................................38
7.10
Pancreatitis Monitoring and Withdrawal Criteria .....................................................38
7.11
Procedures for Discontinuation or Withdrawal of a Subject......................................39
8.0
CLINICAL TRIAL MATERIAL MANAGEMENT ......................................................39
8.1
Study Medication and Materials...............................................................................39
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling ..................................39
8.1.1.1
Investigational Drug ................................................................................39
8.1.1.2
Companion Medication............................................................................39
8.1.1.3
Sponsor-Supplied Drug............................................................................40
8.1.1.4
Rescue Medications.................................................................................40
8.1.2
Storage ............................................................................................................40
8.1.3
Dose and Regimen...........................................................................................40
8.1.4
Overdose .........................................................................................................40
8.2
Investigational Drug Assignment and Dispensing Procedures ..................................41
8.3
Randomization Code Creation and Storage..............................................................41
8.4
Investigational Drug Blind Maintenance ..................................................................41
8.5
Unblinding Procedure..............................................................................................41
8.6
Accountability and Destruction of Sponsor-Supplied Drugs.....................................42
9.0
STUDY PLAN ..............................................................................................................43
9.1
Study Procedures.....................................................................................................43
9.1.1
Alternative Approaches to Study Procedures and Data Collection Due to 
Unavoidable Circumstances.............................................................................43
9.1.2
Informed Consent Procedure............................................................................45
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 9 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
9.1.2.1
Pharmacogenomic Informed Consent Procedure......................................45
9.1.3
Demographics, Medical History, and Medication History Procedure................45
9.1.4
Physical Examination Procedure......................................................................45
9.1.5
Weight, Height and BMI..................................................................................46
9.1.6
Vital Sign Procedure........................................................................................46
9.1.7
Documentation of Concomitant Medications ...................................................46
9.1.8
Documentation of Concurrent Medical Conditions...........................................47
9.1.8.1
Annual Ophthalmologic Examination......................................................47
9.1.9
Procedures for Clinical Laboratory Samples ....................................................47
9.1.9.1
2-Hour Postprandial Glucose Test............................................................49
9.1.10
Contraception and Pregnancy Avoidance Procedure ........................................50
9.1.11
Pregnancy........................................................................................................50
9.1.12
Pharmacogenomic Sample Collection..............................................................51
9.1.13
ECG Procedure................................................................................................52
9.1.14
52
9.1.14.1
..................................52
9.1.14.2
.............................................................................53
9.1.15
Documentation of Screen Failure or Pre-Randomization Stabilization Failures
........................................................................................................................53
9.1.16
Documentation of Randomization....................................................................53
9.1.17
Blood Glucose Education and Management.....................................................54
9.1.17.1
Education on Hypoglycemia....................................................................54
9.1.17.2
Definitions of Hypoglycemia...................................................................54
9.1.17.3
Criteria for Hyperglycemia Rescue ..........................................................55
9.1.18
Biomarkers of Bone Turnover..........................................................................56
9.2
Monitoring Subject Treatment Compliance..............................................................56
9.3
Schedule of Observations and Procedures................................................................57
9.3.1
Screening.........................................................................................................57
9.3.2
Pre-Randomization Stabilization Period...........................................................58
9.3.3
Week -1...........................................................................................................58
9.3.4
Randomization.................................................................................................58
9.3.5
Double-Blind Treatment Period .......................................................................58
9.3.6
Unscheduled Visit (As Applicable)..................................................................59
9.3.7
End-of-Treatment Visit....................................................................................59
9.3.8
Follow-up Visit................................................................................................59
9.3.9
Projected Week 52 Visit ..................................................................................59
CCI
CCI
CCI
Property of Takeda: F
ni
For Non-Commercial Use Only
.........
.....
Failure 
Failu
.........
.......
Rando
andom
Educati
duca
on on H
on on
init
nitioions
n
Cririteria
ter
i
om
omarke
ark
and Subject to the Applicable Terms of Use
45
....... 46
46
........
......
..........
......
........
....
........
.....
.........
......
........
.....
e ......
....
........
...
........
.......
.........
.......
toring
torin
i
Schedu
Sched
9.3.1
.3.1
9.3.2
9.3
9
and 
nly a


Alogliptin
Study No. SYR-322_309
Page 10 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
9.3.10
Post Study Care ...............................................................................................59
9.4
Biological Sample Retention and Destruction ..........................................................60
10.0
PRETREATMENT EVENTS AND ADVERSE EVENTS ............................................60
10.1
Definitions...............................................................................................................60
10.1.1
PTEs................................................................................................................60
10.1.2
AEs .................................................................................................................60
10.1.3
Additional Points to Consider for PTEs and AEs .............................................61
10.1.4
SAEs ...............................................................................................................63
10.1.5
Special Interest AEs.........................................................................................64
10.1.6
Severity of PTEs and AEs................................................................................64
10.1.7
Causality of AEs..............................................................................................65
10.1.8
Relationship to Study Procedures.....................................................................65
10.1.9
Start Date.........................................................................................................65
10.1.10 Stop Date.........................................................................................................65
10.1.11 Frequency........................................................................................................65
10.1.12 Action Concerning Study Medication ..............................................................65
10.1.13 Outcome..........................................................................................................66
10.2
Procedures...............................................................................................................66
10.2.1
Collection and Reporting of AEs .....................................................................66
10.2.1.1
PTE and AE Collection Period.................................................................66
10.2.1.2
PTE and AE Reporting ............................................................................66
10.2.1.3
Special Interest AE Reporting..................................................................67
10.2.2
Collection and Reporting of SAEs ...................................................................68
10.2.3
Reporting of Abnormal Liver Function Tests...................................................68
10.3
Follow-up of SAEs ..................................................................................................68
10.3.1
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities...68
11.0
STUDY-SPECIFIC COMMITTEES .............................................................................69
11.1
Independent Data Monitoring Committee ................................................................69
12.0
DATA HANDLING AND RECORDKEEPING............................................................69
12.1
CRFs (Electronic)....................................................................................................69
12.2
Record Retention .....................................................................................................70
13.0
STATISTICAL METHODS..........................................................................................70
13.1
Statistical and Analytical Plans ................................................................................70
13.1.1
Analysis Sets ...................................................................................................70
13.1.2
Analysis of Demographics and Other Baseline Characteristics.........................71
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 11 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
13.1.3
Efficacy Analysis.............................................................................................71
13.1.4
Pharmacokinetic Analysis................................................................................72
13.1.5
Safety Analysis................................................................................................72
13.2
Interim Analysis and Criteria for Early Termination ................................................72
13.3
Determination of Sample Size..................................................................................72
14.0
QUALITY CONTROL AND QUALITY ASSURANCE...............................................72
14.1
Study-Site Monitoring Visits ...................................................................................72
14.2
Protocol Deviations..................................................................................................72
14.3
Quality Assurance Audits and Regulatory Agency Inspections ................................73
15.0
ETHICAL ASPECTS OF THE STUDY........................................................................73
15.1
IRB and/or IEC Approval ........................................................................................73
15.2
Subject Information, Informed Consent, and Subject Authorization .........................74
15.3
Subject Confidentiality ............................................................................................75
15.4
Publication, Disclosure, and Clinical Trial Registration Policy.................................76
15.4.1
Publication and Disclosure...............................................................................76
15.4.2
Clinical Trial Registration................................................................................76
15.4.3
Clinical Trial Results Disclosure......................................................................76
15.5
Insurance and Compensation for Injury....................................................................76
16.0
REFERENCES..............................................................................................................77
LIST OF IN-TEXT TABLES
Table 8.a
Dose and Regimen .............................................................................................40
Table 9.a
Clinical Laboratory Tests...................................................................................48
Table 9.b
Flowchart of PPG Test.......................................................................................50
Table 10.a
Takeda Medically Significant AE List................................................................64
LIST OF IN-TEXT FIGURES
Figure 6.a
Schematic of Study Design ................................................................................26
LIST OF APPENDICES
Appendix A
Schedule of Study Procedures............................................................................80
Appendix B
Responsibilities of the Investigator.....................................................................83
Appendix C
Elements of the Subject Informed Consent.........................................................85
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 12 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix D
Investigator Consent to Use of Personal Information..........................................88
Appendix E 
Collection, Shipment, and Storage of Pharmacokinetic Samples.........................89
Appendix F
Collection, Shipment, and Storage of Pharmacogenomic Samples......................92
Appendix G
Determination of Eligibility in Subjects With Elevated ALT Levels...................93
Appendix H
Recommendations for Home Glucose Monitoring..............................................94
Appendix I
Protocol History.................................................................................................95
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 13 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
2.0
STUDY SUMMARY
Name of Sponsor(s):
Takeda Development Center Americas, Inc. 
Takeda Development Centre Europe Ltd.
Takeda Development Center Asia Pte. Ltd.
Compound:
Alogliptin
Title of Protocol: A Multicenter, Randomized, 
Double-Blind, Placebo-Controlled Study to Evaluate the 
Efficacy and Safety of Alogliptin Compared With Placebo 
in Pediatric Subjects With Type 2 Diabetes Mellitus 
IND No.: 69,707
EudraCT No.: 
2015-000208-25
Study Number: SYR-322_309
Phase: 3
Study Design:
This will be a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of 
alogliptin 25 mg once daily (QD) compared to placebo, in children and adolescents 10 to 17 years, inclusive, at the 
time of randomization, with a confirmed diagnosis of type 2 diabetes mellitus (T2DM) and who are experiencing 
inadequate glycemic control. Subjects will enter into a Screening Period of up to 2 weeks. If certain entry criteria are 
not met, subjects will participate in a Pre-Randomization Stabilization Period. On Study Day 1, eligible subjects will 
be randomly assigned in a 1:1 ratio to 1 of 2 treatment groups, alogliptin 25 mg QD or matching placebo. In addition to 
receiving double-blind study medication, subjects will be required to maintain their background antidiabetic therapy, 
at the same dose, throughout the first 26 weeks of the Double-Blind Treatment Period. Subjects who complete the 
52-Week Double-Blind Treatment Period complete an End-of-Treatment Visit and Follow-Up Visit, 2 weeks after the 
End-of-Treatment Visit. Subjects who terminate double-blind study drug prematurely will complete an 
End-of-Treatment Visit and Follow-Up Visit, 2 weeks after the End-of-Treatment Visit, and will continue to be 
followed for the 52-week duration of the study and complete a projected Week 52 Visit.
Primary Objective:
The primary objective of this study will be to evaluate the efficacy of alogliptin 25 mg QD compared to placebo when 
administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination 
of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in 
pediatric subjects with T2DM. 
Secondary Objectives:
To evaluate the HbA1c change from Baseline after treatment with alogliptin as compared with placebo at Weeks 12, 
18, 39, and 52.
To evaluate the safety of alogliptin compared to placebo by assessing: 
!
The incidence of hypoglycemic events, treatment emergent adverse events (TEAEs), clinical laboratory 
parameters, electrocardiogram (ECG) readings, physical examinations, and vital signs at Weeks 26 and 52.
!
The effects on biomarkers of bone turnover (bone-specific alkaline phosphatase and C-terminal telopeptide 
[CTX]) markers at Weeks 26 and 52.
!
The effects on CD26 surface antigen levels at Weeks 26 and 52.
CCI
Property of Takeda: For Non-Co
hange fro
ange fr
ety of alo
ety of 
Fo
nce of hy
ce of 
ers, elect
s, ele
effects o
ffects
CTX
CTX])])
Commercial Use On
-
Only and Subject to the 
valuating
valuatin
cents 10 
ents 1
tus (
us (T2D
T2D
of up to 
of up t
n Period.
n Period
iptin 25
ptin 25
red to ma
d to m
-Blind T
Blind 
d-of
of-f Trea
Tr
e Applicable Terms of Use
of
of
No.
No.:
00208
0208-2
T
App
blind st
blind 
ks after t
after
nd compl
nd comp
e A
e to evalu
to eval
added on
added
ed by the
d by th
U
m
The ef
The
Co
pe
pe
perty of
CCI
C


Alogliptin
Study No. SYR-322_309
Page 14 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Subject Population: Pediatric subjects aged 10 to 17 years, inclusive, with T2DM.
Number of Subjects:
150 randomized subjects
Number of Sites: 
Estimated total: 60 sites in 20 countries
Dose Level(s):
Alogliptin 25 mg QD
Placebo QD
Route of Administration:
Oral
Duration of Treatment:
52 weeks
Period of Evaluation:
Approximately 56 weeks plus a variable 
Pre-Randomization Stabilization Period
Main Criteria for Inclusion:
A confirmed diagnosis of T2DM using American Diabetes Association (ADA) and World Health Organization 
(WHO) criteria (laboratory determinations of FPG ≥126 mg/dL, random glucose ≥200 mg/dL [≥11.10 mmol/L], 
HbA1c ≥6.5%, or 2-hour oral glucose tolerance test [OGTT] glucose ≥200 mg/dL), documented in the subjects’ 
medical record.
Main Criteria for Exclusion:
1.
The subject has a confirmed diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young 
(MODY).
2.
The subject has a hemoglobin level <11.0 g/dL (<110 g/L) for males and <10.0 g/dL (<100 g/L) for females. 
3.
The subject has a history of any hemoglobinopathy that may affect determination of HbA1c levels.
Additional Criteria That Must Be Met Following Screening and/or Completion of the Pre-Randomization 
Stabilization Period and Prior to Randomization:
1.
The subject will be required to have an HbA1c level of ≥6.5% to <11.0% if the subject is on metformin alone or ≥7.0% 
to <11.0% if the subject is on insulin alone or in combination with metformin. 
2.
The subject must not have received any investigational compound within 30 days or 5 half-lives, whichever is 
longer, prior to randomization.
3.
The subject must not have received an antidiabetic agent other than metformin or insulin within the 12 weeks 
prior to randomization.
4.
The subject must not have received oral or parenteral steroids for more than 3 weeks (cumulatively) within the 
6 months prior to randomization or have received a course of oral or parenteral steroids within the 2 months prior 
to randomization.
5.
The subject has a systolic blood pressure <160 mmHg and a diastolic pressure <100 mmHg. (Antihypertensive 
medications will be allowed during the study).
6.
The subject has an alanine aminotransferase (ALT) level <3× upper limit of normal (ULN) or an ALT level 
<5×ULN with a confirmed diagnosis of nonalcoholic fatty liver disease (NAFLD). 
7.
The subject does not plan to leave the geographic area within 1 calendar year following randomization. 
8.
Male or female subjects, 10 to 17 years of age, inclusive, at the time of randomization.
For subjects who have had the diagnosis of T2DM for less than 1 year and/or who are taking insulin prior to 
CCI
Property of Takeda: For Non-Com
t Be Me
t Be M
ior to R
to 
equired to
quired 
ject is on
ect is o
ust not ha
ust not
r to rand
to ra
ject must
ct mu
toto rando
rand
he subjec
he subj
6 mo
month
n
o
toto ra
5.5.
T
mmercial Use Only and Subject to the Applicable
ble
0 countr
coun
ca
n:
Ap
aluation
uatio
mately 56
ately 5
ndomiza
ndomiz
t t
ssociation
ciatio
g/dL, ran
/dL, ra
GTT] glu
GTT] glu
S
type 1 d
ype 1 
l <11.0 
<11.0 g
y hemogl
hemog
se
of Use
of
of
om
pe
pe
ble Terms of


Alogliptin
Study No. SYR-322_309
Page 15 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
randomization, the following criteria must also be met: 
9.
The subject must have a fasting C-peptide concentration ≥0.6 ng/mL (≥0.20 nmol/L) (drawn at least 1 week after 
treatment for ketosis or acidosis, if applicable).
10. No presence of autoantibodies as documented by glutamic acid decarboxylase [GAD] 65 and islet antigen 
[IA]-2 antibodies below the upper limit of the normal reference ranges at randomization.
11. The subject must have a BMI >85th percentile, documented at randomization.
Main Criteria for Evaluation and Analyses:
The primary endpoint for this study is HbA1c change from Baseline at Week 26. 
Secondary endpoints for this study are:
Efficacy
HbA1c change from Baseline at Weeks 12, 18, 39, and 52.
Safety: 
!
Physical examination findings. 
!
Vital sign measurements.
!
12-lead ECG abnormalities. 
!
Adverse events (AEs).
!
Incidence of infections (Total and urinary and respiratory tract infections) and hypersensitivity reactions.
!
Incidence of hypoglycemia.
!
Clinical laboratory evaluations (hematology, serum chemistry, and urinalysis). 
!
Change from Baseline in biomarkers of bone turnover (bone-specific alkaline phosphatase and CTX) at Weeks 26 
and 52.
!
Change from Baseline in CD26 surface antigen levels at Weeks 26 and 52.
CCI
Prope
pe
l Use Only and Subject to the Applicable Terms of Use
of
of
ract infec
act infe
chemistr
chemist
nover (bo
over (b
ntigen le
tigen l
T
pe
perty of Takeda: For Non-Commercial


Alogliptin
Study No. SYR-322_309
Page 16 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Statistical Considerations:
The primary efficacy analysis will be conducted using a contrast at Week 26 derived from a mixed model for repeated 
measures (MMRM) with change from Baseline in HbA1c as the response variable, treatment, visit, and 
visit-by-treatment interaction as fixed categorical effects, and baseline HbA1c and visit-by-baseline HbA1c 
interaction as continuous covariates. 
The secondary efficacy variable will be analyzed using additional contrasts at Weeks 12, 18, 39, and 52 derived from 
the primary analysis model. Continuous exploratory efficacy variables will be analyzed using models similar to the 
primary analysis model. Categorical variables and time to hyperglycemic rescue will be analyzed using logistic 
regression models and a Cox regression model, respectively. 
Safety variables will be summarized using descriptive statistics or frequency counts as appropriate.
Sample Size Justification: A total of 75 randomized subjects per treatment group will ensure at least 90% power to 
detect a difference in mean change from Baseline in HbA1c at Week 26 between alogliptin 25 mg QD and placebo 
assuming a treatment effect of 0.5%, a SD of 0.9%, and a 2-sided false-rejection rate of 5%. 
CCI
Property of Takeda: For Non-Commercial Use Only and Subject t
t t
t to the A
l ensure 
ensur
Applicable Terms of Use
ted d 
2 derived
2 deriv
els simila
s simi
d using l
d using 
propriate
ropriat
of
of
ogliptin 
gliptin
rate of 5
rate of
A
t t


Alogliptin
Study No. SYR-322_309
Page 17 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
3.0
STUDY REFERENCE INFORMATION
3.1
Study-Related Responsibilities
The sponsor will perform all study-related activities with the exception of those identified in the 
Study-Related Responsibilities document. The identified vendors in the template for specific 
study-related activities will perform these activities in full or in partnership with the sponsor.
3.2
Coordinating Investigator
Takeda will select a Signatory Coordinating Investigator from the investigators who participate in 
the study. Selection criteria for this investigator will include significant knowledge of the study 
protocol, the study medication, their expertise in the therapeutic area and the conduct of clinical 
research as well as study participation. The Signatory Coordinating Investigator will be required to 
review and sign the clinical study report and by doing so agrees that it accurately describes the 
results of the study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 18 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
3.3
List of Abbreviations
ADA
American Diabetes Association
AE
adverse event
AESI
adverse event of special interest
ALT
alanine aminotransferase
AST
aspartate aminotransferase
AUC∞
area under the concentration-time curve from time 0 to infinity 
AUC24
area under the plasma concentration-time curve from time 0 to 24 hours
BID
twice daily
BMI
body mass index
CFR
Code of Federal Regulations
Cmax
maximum observed plasma concentration
COVID-19
coronavirus disease 2019
CTX
C-terminal telopeptide
DKA
diabetic ketoacidosis
DMC
Data Monitoring Committee
DPP-4
dipeptidyl peptidase-4
ECG
electrocardiogram
eCRF
electronic case report form
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
FAS
full analysis set
FDA
Food and Drug Administration
GAD
glutamic acid decarboxylase
GCP
Good Clinical Practice
GGT
∀-glutamyl transferase
GLP-1 RA
glucagon-like peptide-1 receptor agonist
HbA1c
glycosylated hemoglobin
hCG
human chorionic gonadotropin
IA
islet antigen
ICF
informed consent form
ICH
International Conference on Harmonisation
ID
Identification
IEC
independent ethics committee
INR
international normalized ratio
IRB
institutional review board
CCI
CC
I
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
hours
ours
orm
orm
ar filtrati
r filtra
cines Ag
nes A
setet
d Drug A
Drug 
lutamic a
utamic
Good 
Good
∀-
ICF
CF
ICH
ICH
I
Com
Take


Alogliptin
Study No. SYR-322_309
Page 19 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
ISPAD
International Society for Pediatric and Adolescent Diabetes
IVRS
interactive voice response system
IWRS
interactive web response system
K2EDTA
potassium ethylenediamine tetraacetic acid
MMRM
mixed model for repeated measures 
MODY
maturity-onset diabetes of the young
MTD
maximum tolerated dose
NAFLD
nonalcoholic fatty liver disease
NOAEL
no-observed-adverse-effect level
OGTT
oral glucose tolerance test
PD
pharmacodynamic(s)
PI
Principal Investigator
PIP
Paediatric Investigational Plan
PK
pharmacokinetic(s)
PPG
postprandial glucose 
PPS
per protocol set
PTE
pretreatment event 
QD
once daily
SAE
serious adverse event
SAP
statistical analysis plan
SUSAR
suspected unexpected serious adverse reaction
T2DM
type 2 diabetes mellitus
TEAE
treatment-emergent adverse event
ULN
upper limit of normal
US
United States
WHO
World Health Organization
3.4
Corporate Identification 
TDC Europe
Takeda Development Centre Europe Ltd.
TDC Americas
Takeda Development Center Americas, Inc.
TDC
TDC Europe, TDC Americas and/or TDC Asia, as applicable
TDC Asia
Takeda Development Center Asia Pte. Ltd.
Takeda
TDC Europe, TDC Americas and/or TDC Asia as applicable
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
plan
lan
pected se
ected 
etes mell
es me
nt-emerg
eme
er limit o
er limit
United St
ited S
World
Wor
orporat
rpor
ope
pe
America
Americ
DC
TDC A
TDC
Tak
T
CCI
CCI


Alogliptin
Study No. SYR-322_309
Page 20 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
4.0
INTRODUCTION
4.1
Background
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder of heterogeneous and 
multifactorial etiology, with a strong hereditary component and genetic predisposition overlaid by 
social, behavioral, and environmental risk factors [1-9]. Information on the underlying 
mechanisms, the phases of pathogenesis, clinical presentation and course, risk factors, attendant 
complications, and treatment is still comparatively sparse for pediatric populations and is being 
widely debated. Overall, however, the pathophysiology of T2DM in children and adolescents 
appears to be similar to that in adults [1,6,10-15].
The incidence of T2DM among children and adolescents is on the rise, largely due to the 
worldwide increase in childhood obesity. In the US, the SEARCH for Diabetes Youth Study 
reported the prevalence of T2DM among children and adolescents (10-19 years) to be 0.46 cases 
per 1000 in 2009, which is a 35% increase from that reported in 2001 [16]. Projections from the 
SEARCH study estimate that the number of children and adolescents with T2DM could quadruple 
over the next 40 years [17].
The global increase in T2DM in children and adolescents has evolved into an important public 
health issue [10,18-20]. T2DM is associated with multiple long-term complications leading to 
morbidity as well as premature mortality, including: accelerated development of cardiovascular 
diseases; nephropathy and kidney failure; retinopathy and blindness; nervous system disease 
including peripheral neuropathy; macrovascular complications; high blood pressure; peripheral 
vascular disease and lower limb amputation; non-alcoholic fatty liver disease, including 
non-alcoholic steatohepatitis; and increased risk of death from infection such as pneumonia. In 
children and adolescents, the increased incidence of T2DM and obesity observed globally during 
the past 2 decades not only places a severe burden on the individual’s physical, psychological, 
emotional, and social well-being, but will also have long-term public health and societal 
consequences, as these patients are at risk of progressing to the aforementioned chronic 
complications at a relatively young age and may experience subsequent loss of their productivity 
as adults [1,10,12,18,21-26]. In addition, the rates of long-term medication use for treatment of the 
diabetes-related complications, of physician contacts, and of hospitalizations are likely to increase.
Although a diverse range of oral antidiabetic agents are available, few of these have been 
evaluated in children and adolescents. Until recently, only metformin and insulin were approved in 
the US and Europe for treatment of T2DM in pediatric patients. Liraglutide, an injectable 
glucagon-like peptide-1 receptor agonist (GLP-1 RA), has become available for children and 
adolescents aged 10 to 17 years with T2DM. According to treatment guidelines set forth by the 
AAP (American Academy of Pediatrics) and the IDF/ISPAD (International Diabetes 
Federation/International Society for Pediatric and Adolescent Diabetes), initial care may require 
insulin until diagnostic classification of T2DM has been confirmed and the patient is metabolically 
stable [27,28]. Once metabolically stable, metformin is the initial pharmacologic treatment of 
choice for children and adolescents with T2DM. However, both metformin and insulin have 
disadvantages. Metformin must be administered twice daily (BID), and is commonly associated 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 21 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
with unpleasant gastrointestinal side effects. Furthermore, most children do not maintain adequate 
glycemic control with metformin alone for the long term. This was recently demonstrated in the 
TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study that evaluated 
metformin and rosiglitazone vs dietary modifications and exercise alone in approximately 700 
pediatric patients with T2DM [29]. The primary outcome of this study was loss of glycemic 
control, defined as a glycated hemoglobin level of at least 8% for 6 months or sustained metabolic 
decompensation requiring insulin. Results of this study showed that metformin alone was effective 
in maintaining durable glycemic control in only one-half of the study participants. This suggests 
that a majority of youth with T2DM may require combination treatment or insulin therapy within 
just a few years after diagnosis [29].
Treatment with insulin is not ideal for the pediatric population as it has several limitations such as 
weight gain and hypoglycemia, and requires multiple daily injections that can lead to poor 
compliance [30]. Therefore, there is a need to investigate alternative oral therapies available for 
children. Having a once daily oral antidiabetic agent available as an alternative or as add-on to 
metformin or insulin may provide benefit to the patient, potentially for newly diagnosed patients as 
well as for those who cannot tolerate metformin or whose diabetes is not controlled on metformin 
and/or insulin.
As part of the pediatric program, 2 studies have been conducted to assess potential alogliptin 
toxicity in the juvenile rat. A 4-week toxicity study was conducted in male and female rats that 
were 4 weeks of age at initiation of dosing. Because the pivotal toxicity studies were conducted 
using rats that were 8 weeks of age at study initiation, this 4-week study was conducted to provide 
alogliptin toxicity information in the young rodent through the age of the rats at initiation of dosing 
in the pivotal repeat-dose toxicity studies (SYR-322-00610). To ensure no effect on the 
developing reproductive organs of the juvenile male, a second toxicity study was conducted in 
4-week old male rats administered alogliptin for 8 consecutive weeks (SYR-322-18040). Doses 
selected for this study were the same as those used in the pivotal 4-week toxicity study in which 
rats were 8 weeks of age at dose initiation. The NOAEL (no-observed-adverse-effect level) in that 
study was 300 mg/kg/day and produced exposure margins (based on area under the plasma 
concentration-time curve from time 0 to 24 hours (AUC24) that were 53- to 58-fold the AUC24 
measured in adult men and women, respectively, at the clinical dose of 25 mg/day.
No toxicologically meaningful effects were noted in juvenile rats (4-weeks of age at dose 
initiation) administered alogliptin daily for 4 consecutive weeks. Similarly, the 8-week 
repeat-dose toxicity study in male juvenile rats (4 weeks of age at dose initiation) did not show any 
alogliptin-related effects on the developing male reproductive organs. Toxicokinetic data in the 
juvenile rats were similar to those obtained in adult rats. 
With regard to reproductive toxicity, alogliptin administered to pregnant rabbits and rats was not 
teratogenic at doses of up to 200 and 500 mg/kg, or 149 and 180 times, respectively, the mean 
exposure in adults at the 25 mg dose. Additionally, doses of alogliptin up to 250 mg/kg (~ 95 times 
the mean exposure in adults at the 25 mg dose) administered to pregnant rats did not harm the 
developing embryo or adversely affect growth and development of offspring.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 22 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Alogliptin has been shown to be safe and effective in the treatment of adults with T2DM in a 
comprehensive clinical program that included 55 clinical studies and involved approximately 
1000 healthy adult subjects and more than 12,000 adult subjects with T2DM. This includes 
phases 1, 2, and 3 controlled and uncontrolled studies (including those conducted in Japan and 
China).
A total of 30 phase 1 and 2 clinical pharmacology studies were conducted using single and 
multiple doses of alogliptin 6.25 to 800 mg, in healthy adults, adults with T2DM, adults with renal 
impairment, and adults with hepatic impairment.
4.2
Rationale for the Proposed Study
As discussed above, there is a need for new antidiabetic therapies, in addition to metformin and 
insulin, for treatment of T2DM in children.
In accordance with the US FDA Pediatric Research Equity Act and the EMA PIP requirements, a 
phase 3 study is being conducted to investigate the safety and efficacy of alogliptin in a pediatric 
population with T2DM aged 10 to 17 years, inclusive. The choice of the age group is supported by 
epidemiologic data that indicates that T2DM in children and adolescents is most commonly 
diagnosed at the time of puberty, between approximately 12 and 14 years, inclusive. 
A phase 1, pediatric, pharmacokinetic (PK)/pharmacodynamic (PD) study of alogliptin 
(SYR-322_104) was completed. This study was conducted to determine the PK and PD profiles, 
safety, and tolerability of a single dose of alogliptin 12.5 mg and 25 mg in subjects with T2DM 
between 10 to 17 years old and adult subjects with T2DM. This phase 3 study will evaluate 
alogliptin 25 mg since it was determined to be the appropriate dose for pediatric subjects based on 
the results of the phase 1 study (see Section 6.3 for dose selection rationale). 
5.0
STUDY OBJECTIVES AND ENDPOINTS 
5.1
Objectives
5.1.1
Primary Objective
The primary objective of this study will be to evaluate the efficacy of alogliptin 25 mg QD 
compared to placebo when administered as monotherapy, or when added onto a background of
metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the 
glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric subjects with 
T2DM. 
5.1.2
Secondary Objectives 
To evaluate the HbA1c change from Baseline after treatment with alogliptin as compared with 
placebo at Weeks 12, 18, 39, and 52.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 23 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
To evaluate the safety of alogliptin compared to placebo by assessing: 
!
The incidence of hypoglycemic events, treatment emergent adverse events (TEAEs), clinical 
laboratory parameters, electrocardiogram (ECG) readings, physical examinations, and vital 
signs for Weeks 26 and 52.
!
The effects on biomarkers of bone turnover (bone-specific alkaline phosphatase and 
C-terminal telopeptide [CTX]) markers at Weeks 26 and 52. 
!
The effects on CD26 surface antigen levels at Weeks 26 and 52.
5.2
Endpoints
5.2.1
Primary Endpoint
HbA1c change from Baseline to Week 26.
5.2.2
Secondary Endpoints
Efficacy
HbA1c change from Baseline at Weeks 12, 18, 39, and 52.
Safety:
!
Physical examination findings. 
!
Vital sign measurements.
CCI
Property of Takeda: For No
nts
rimary 
rimar
change f
change
.2
Efficac
Effica
rty
plicable Terms of Use
Hb
H
Non-Commercial Use Only and Subject to the Appl


Alogliptin
Study No. SYR-322_309
Page 24 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
!
12-lead ECG abnormalities. 
!
Adverse events (AEs).
!
Incidence of infections (Total and urinary and respiratory tract infections) and hypersensitivity 
reactions.
!
Incidence of hypoglycemia. 
!
Clinical laboratory evaluations (hematology, serum chemistry, and urinalysis). 
!
Change from Baseline in biomarkers of bone turnover (bone-specific alkaline phosphatase and 
CTX) at Weeks 26 and 52.
!
Change from Baseline in CD26 surface antigen levels at Weeks 26 and 52.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
ivitity
). 
line pho
ne ph
 and 52
and 5
roperty of Takeda: For Non-Commercial Use Only and Subject to t


Alogliptin
Study No. SYR-322_309
Page 25 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
6.0
STUDY DESIGN AND DESCRIPTION
6.1
Study Design
This will be a multicenter, randomized, double-blind, placebo-controlled 52-week study 
evaluating the efficacy and safety of alogliptin 25 mg QD compared to placebo, in children and 
adolescents 10 to 17 years of age, inclusive, at the time of randomization, with a confirmed 
diagnosis of T2DM and who are experiencing inadequate glycemic control. Subjects who are 
recruited for this study should be on a background of metformin alone, insulin alone, or on a 
combination of metformin and insulin. 
Subjects will enter into a Screening Period of up to 2 weeks. During the Screening Period 
investigators should: 

Assess the subjects’ and their respective guardians’ suitability for the study, in terms of 
study-procedure compliance and long-term commitment.

Educate subjects on diet and exercise consistent with standard of care for T2DM. 

Educate subjects on compliance with protocol procedures.
Subjects who have completed all required Screening Procedures, and who meet all entry criteria 
may proceed to Randomization/Day 1. Eligible subjects will be randomly assigned in a 1:1 ratio to 
1 of 2 treatment groups, alogliptin 25 mg QD or matching placebo. 
Subjects who have not met all of the additional randomization criteria listed in 7.3, will be allowed 
to enter a Pre-Randomization Stabilization Period (see Section 6.2).
In addition to receiving double-blind study medication, subjects will be required to maintain their 
background antidiabetic therapy (if applicable), at the same dose at Day 1 (eg, baseline insulin 
doses, if applicable), throughout the first 26 weeks of the Double-Blind Treatment Period.
Subjects will receive diabetes education and home glucose monitoring training during the 
Pre-Randomization Stabilization Period (if applicable) and during the first 26 weeks of the 
Double-Blind Treatment Period. Subjects will maintain blood glucose diaries which will be 
reviewed at each study visit throughout the study. 
Subjects who complete the 52-Week double-blind treatment period will complete an 
End-of-Treatment Visit and Follow-Up Visit, 2 weeks after the End-of-Treatment Visit. Subjects 
who terminate double-blind study drug prematurely will complete an End-of-Treatment Visit and 
Follow-Up Visit, 2 weeks after the End-of-Treatment Visit and will continue to be followed for the 
52-week duration of the study and complete a projected Week 52 Visit. 
Subjects who are not eligible for randomization will be referred back to their primary care 
physician for resumption of their care. 
This study will be conducted at approximately 60 sites in 20 countries. 
Sites will employ all efforts to see subjects in the clinic for assessments. In unavoidable 
circumstances (eg, a widespread disease outbreak such as the COVID-19 pandemic or natural 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 26 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
disaster), exceptions may be granted for alternative methods for conducting subject visits with 
approval by the medical monitor. Such instances will be documented in the study records. Data 
collected with alternative methods may be handled differently in the final data analyses. This will 
be documented in the statistical analysis plan (SAP).
A schematic of the study design is shown in Figure 6.a. A schedule of assessments is listed in 
Appendix A.
Figure 6.a
Schematic of Study Design
Screening
Pre-Randomization
Stabilization
Period (if needed)
Double-Blind Treatment Period
Weeks 1- 52 After Randomization (a)
End-of-
Treatment 
Visit
Follow-Up 
Visit
Assessment
Screening 
Visit (b)
Every 
3 Months (b) Week -1
Baseline 
Visit
(Day 1)
4
(c)
12
18 
(d)
26
32 
(c)
39
45
(c)
52
54 (c)
Visit windows 
(days)
(Up to 14 
Days)
2
7
7
7
7
7
7
7
2
(a) Subjects who terminate double-blind study drug prematurely will complete an End-of-Treatment Visit and Follow-Up Visit, 2 
weeks after the End-of-Treatment Visit, and will continue to be followed for the 52-week duration of the study and complete a 
projected Week 52 Visit. 
(b) The Screening Visit will be scheduled within 2 weeks prior to Day 1 or the start of the Pre-Randomization Stabilization Period. 
During the Pre-Randomization Stabilization Period, subjects will visit the study center at regular intervals according to the 
investigator’s discretion but at least every 3 months and at Week -1 prior to randomization. 
(c) The Week 4, 32, 45, and 54 visits will be conducted only via telephone call to the subject. 
(d) The Sponsor or its designee will decide whether the Week 18 Visit will be conducted as an in-clinic visit, or optionally, as a 
home health visit.
Alogliptin 25 mg QD
Matching Placebo
HbA1c requirement:
≥6.5% to <11.0% if on metformin alone
≥7.0% to <11.0% if on insulin alone or 
in combination with metformin
Follow-up 
2 Weeks
Screening
Up to 2 Weeks 
Pre-Randomization
Stabilization Period
If needed
DB Treatment 
52 Weeks
Day 1
End of 
DB Meds
Final Visit
Procedures
• HbA1c monitoring
• Adherence
• Safety Monitoring
• Medication adjustments
Eligibility Assessment
(Sections 7.1 and 7.2)
Eligibility Assessment
(Sections 7.1, 7.2, and 7.3)
Wk -1
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 27 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
6.2
Pre-Randomization Stabilization Period (if needed)
Subjects who meet all inclusion and exclusion criteria listed in Sections 7.1 and 7.2, respectively, 
AND who are anticipated to meet the additional entry criteria listed in Section 7.3 following 
medical oversight (ie, washout of prior medications, adjustment to their metformin or insulin doses, 
adjustment to antihypertensive regimen) by the investigator will be allowed entry into the 
Pre-Randomization Stabilization Period.
The Pre-Randomization Stabilization Period is intended to meet the following objectives:

Allow a period of wash-out of prior medications and adjustment of anti-hypertensive 
treatment; 

Evaluate underlying etiology and persistence of elevated alanine aminotransferase (ALT) 
levels;

Allow subjects who are on metformin to reach their maximum tolerated dose (MTD) of 
metformin and maintain that dose for a minimum of 2 months;

Allow for subjects to be monitored for deterioration of glycemic control and potential study 
qualification;

If considered appropriate, initiate insulin therapy in subjects with HbA1c levels >11.0% on 
MTD of metformin alone;

Allow establishment of a stable insulin regimen for participants entering the 
Pre-Randomization Stabilization Period on insulin;

Allow investigators to intensify or wean insulin therapy as appropriate for the management of 
each individual subject;

Subjects treated on insulin should be carefully monitored with a goal to discontinue insulin 
therapy [31]. If the subject is unable to discontinue insulin therapy, the dose of insulin must be 
stable and maintained for 2 months prior to randomization and their HbA1c must be ≥7% to be 
eligible to proceed to randomization.
Regardless of participation in the Pre-Randomization Stabilization Period, investigators should 
ensure the following for all subjects: 

The study site staff adequate time to assess the subjects’ and their respective guardians’ 
suitability for the study, in terms of study-procedure compliance and long-term commitment;

Subjects are encouraged to intensify dietary and exercise regimen; 

Subjects are encouraged to be compliant with all aspects of the treatment regimen.
Subjects will return to the clinic for assessments at regular intervals during the Pre-Randomization 
Stabilization Period at the investigator’s discretion, but at least every 3 months. The duration of 
participation in the Pre-Randomization Stabilization Period will vary for each subject based on 
his/her status.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 28 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
During the Pre-Randomization Stabilization Period, subjects receiving metformin will continue to 
receive metformin with a treatment goal of at least 1000 mg BID or their documented MTD 
without treatment-related side effects nor symptoms of ketosis. Subjects who are already receiving 
metformin 1000 mg BID or their MTD will not need to adjust their dose unless side effects 
associated with metformin, such as gastrointestinal symptoms or other symptoms associated with 
metformin, require a decrease in dose.
In subjects already receiving insulin alone or insulin in combination with MTD of metformin, 
insulin doses can be reduced, and insulin can be discontinued in patients who are able to maintain 
HbA1c levels <8.0%. 
Subjects with HbA1c levels >11% on MTD of metformin alone will be allowed to initiate insulin 
therapy at the discretion of the investigator.
Investigators may intensify or wean insulin therapy as appropriate for the management of each 
individual subject. These subjects should be adequately monitored for potential hypo- or 
hyperglycemia. 
Subjects will receive insulin with the goal of achieving a stable dose required for glycemic control 
before proceeding to randomization. A stable dose of insulin is defined as a period of at least 
1 month during which an insulin dose change is not required to prevent hypoglycemia or 
symptomatic hyperglycemia.
Once subjects meet the objectives of the Pre-Randomization Stabilization Period, they will return 
to the clinic (Week -1) to confirm qualification for all inclusion and exclusion criteria specified in 
Section 7.3. 
6.3
Justification for Study Design, Dose, and Endpoints
The selection of the alogliptin 25 mg dose for the proposed phase 3 pediatric study is based on the 
results of the phase 1 PK/PD study (Study SYR-322_104). Following single oral administration of 
alogliptin 12.5 or 25 mg tablets to children, adolescents and adults with T2DM in Study 
SYR-322_104, the PK and PD of alogliptin appeared to be generally similar between the 2 age 
groups of pediatric subjects (10-13 and 14-17 years of age, respectively), with dose-proportional 
increases in the mean maximum observed plasma concentration (Cmax) and area under the 
concentration-time curve from time 0 to infinity (AUC∞) values of alogliptin and higher mean Emax
(maximum drug-induced effect) and AUEC24 (area under the effect curve from 0 to 24 hours) 
values for dipeptidyl peptidase-4 (DPP-4) inhibition with the 25 mg dose, relative to 12.5 mg. 
Compared to adult subjects receiving 25 mg alogliptin, the mean Cmax and AUC∞ values of 
alogliptin were 54% to 68% lower in pediatric subjects following a 12.5 mg dose and 23% to 29% 
lower at the 25 mg dose. 
Model-based simulations of steady state exposures following dosing of alogliptin 12.5 mg and 
25 mg in pediatric and adult subjects (n=75 each) were performed, assuming similar distribution of 
body weights between pediatric and adult subjects with T2DM. Based on the PK and PD data and 
model simulations, pediatric subjects with T2DM require the 25 mg dose of alogliptin to best 
approach alogliptin exposures and DPP-4 inhibition similar to those in adults with T2DM. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 29 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Therefore, the 25 mg dose is proposed for evaluation in the pediatric phase 3 program. The results 
of these studies are deemed to be adequate to support the safe and effective use of alogliptin in a 
pediatric population whose disease is not adequately controlled with diet and exercise alone or 
with metformin, insulin, or a combination of metformin and insulin. Targeting this patient 
population is clinically important because this strategy focuses on the medical need to improve 
glycemic control regardless of current therapy and is consistent with current pediatric diabetes 
practice of aggressively treating hyperglycemia.
6.4
Premature Termination or Suspension of Study or Investigational Site
6.4.1
Criteria for Premature Termination or Suspension of the Study
The study will be completed as planned unless 1 or more of the following criteria are satisfied that 
require temporary suspension or early termination of the study.

New information or other evaluation regarding the safety or efficacy of the study medication 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for subjects participating in the study.

The independent Data Monitoring Committee (DMC) recommends that the study should be 
suspended or terminated. 

Significant violation of GCP that compromises the ability to achieve the primary study 
objectives or compromises subject safety.
6.4.2
Criteria for Premature Termination or Suspension of Investigational Sites
A study site may be terminated prematurely or suspended if the site (including the Investigator) is 
found in significant violation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study, or as otherwise permitted by the contractual agreement.
6.4.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site(s)
In the event that the sponsor, an institutional review board (IRB)/independent ethics committee 
(IEC) or regulatory authority elects to terminate or suspend the study or the participation of an 
investigational site, a study-specific procedure for early termination or suspension will be 
provided by the sponsor; the procedure will be followed by applicable investigational sites during 
the course of termination or study suspension.
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry criteria in Sections 7.1 and 7.2 will need to be confirmed as part of Screening procedures; 
additional criteria will need to be met prior to randomization (refer to Section 7.3).
7.1
Inclusion Criteria
Subject eligibility is determined according to the following criteria prior to entry into the study: 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 30 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
1. A confirmed diagnosis of T2DM using American Diabetes Association (ADA) and World 
Health Organization (WHO) criteria (laboratory determinations of FPG >126 mg/dL, random 
glucose >200 mg/dL [11.10 mmol/L], HbA1c ≥6.5%, or 2-hour oral glucose tolerance test
[OGTT] glucose >200 mg/dL), documented in the subjects’ medical record.
Note: Previous inclusion criteria numbers 2 through 5 were moved to Section 7.3.
6. The subject is thought to be able to swallow the tablet containing the study medication.
7. A male subject who is sexually active with a female partner of childbearing potential* agrees 
to use adequate contraception* from signing of informed consent throughout the duration of 
the study. 
8. A female subject of childbearing potential* who is sexually active with a male partner agrees 
to use routinely adequate contraception* from signing of informed consent throughout the 
duration of the study.
*Female subjects of childbearing potential are defined as reaching Tanner 
Stage 3. Definitions and acceptable methods of contraception are defined in 
Section 9.1.10 Contraception and Pregnancy Avoidance Procedure and 
reporting responsibilities are defined in Section 9.1.11 Pregnancy.
9. The subject and his/her legal representative (ie, parents or legal guardians) are able and willing 
to provide written informed consent/assent.
10. The subject and his/her legal representative (ie, parents or legal guardians) are capable of 
understanding and complying with the protocol requirements, including scheduled clinic 
appointments.
11. The subject and his/her legal representative (ie, parents or legal guardians) are able and willing 
to monitor their own blood glucose concentrations with a home glucose monitor and complete 
subject diaries. 
For subjects who have had the diagnosis of T2DM for less than 1 year and/or who are taking 
insulin at Screening, additional criteria will need to be met prior to randomization (refer to 
Section 7.3).
7.2
Exclusion Criteria
Any subject who meets any of the following criteria will not qualify for entry into the study: 
1. The subject is treatment-naïve.
2. The subject has a history of hypersensitivity or allergy to alogliptin, other DPP-4 inhibitors, 
metformin, insulin, or related compounds.
3. The subject has a confirmed diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of 
the young (MODY). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 31 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
4. The subject has a hemoglobin level <11.0 g/dL (<110 g/L) for males and <10.0 g/dL 
(<100 g/L) for females.
5. The subject has a history of any hemoglobinopathy that may affect determination of HbA1c 
levels.
6. The subject has a history of bariatric surgery.
7. The subject has a history of proliferative diabetic retinopathy within the 6 months prior to 
Screening. 
8. The subject has had an episode of diabetic ketoacidosis (DKA) at any time after diagnosis of 
T2DM. 
9. The subject has a history of pancreatitis.
10. Serum creatinine 1.5 mg/dL for male subjects or 1.4 mg/dL for female subjects, or 
creatinine clearance <60 mL/min based on calculation by central lab using the Schwartz 
formula [32] for estimated glomerular filtration rate (eGFR) at the Screening Visit.
11. The subject has a documented history of infection with human immunodeficiency virus or 
chronic active viral hepatitis. 
12. The subject has any unstable endocrine, psychiatric or severe rheumatic disorder, or major 
illness or debility that, in the Investigator’s opinion, prohibits the subject from being a suitable 
candidate for and/or completing the study, or may affect the interpretability of his/her efficacy 
or safety data.
13. Female subjects who are pregnant, planning to become pregnant, or who admit to sexual 
activity without appropriate contraception. 
14. The subject and/or his/her legal representative (ie, parents or legal guardians) is unable to 
understand verbal or written English, or any other language for which a certified translation of 
the approved informed consent/assent is available.
15. The subject and/or his/her legal representative (ie, parents or legal guardians) is an immediate 
family member (ie, child or sibling) of a study site employee who is involved in the conduct of 
this study.
7.3
Additional Randomization Criteria That Must Be Met Following Screening and/or 
Completion of the Pre-Randomization Stabilization Period
Subjects must meet the following criteria in order to qualify for randomization:
1. The subject will be required to have an HbA1c level of ≥6.5% to <11.0% if the subject is on 
metformin alone or ≥7.0% to <11.0% if the subject is on insulin alone or in combination with 
metformin. 
2. The subject must not have received any investigational compound within 30 days or
5 half-lives, whichever is longer, prior to randomization.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 32 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
3. The subject must not have received an antidiabetic agent other than metformin or insulin 
within the 12 weeks prior to randomization.
4. The subject must not have received oral or parenteral steroids for more than 3 weeks 
(cumulatively) within the 6 months prior to randomization or have received a course of oral or 
parenteral steroids within the 2 months prior to randomization.
5. The subject has a systolic blood pressure <160 mmHg and a diastolic pressure <100 mmHg. 
(Antihypertensive medications will be allowed during the study).
6. The subject has an ALT level <3× upper limit of normal (ULN) or an ALT level <5×ULN with 
a confirmed diagnosis of nonalcoholic fatty liver disease (NAFLD). (See Appendix G for 
diagnostics leading to confirmation of NAFLD.)
7. The subject does not plan to leave the geographic area within 1 calendar year following 
randomization. 
8. Male or female subjects, 10 to 17 years of age, inclusive, at the time of randomization.
For subjects who have had the diagnosis of T2DM for less than 1 year and/or who are taking 
insulin prior to randomization, the following criteria must also be met: 
9. The subject must have a fasting C-peptide concentration ≥0.6 ng/mL (≥0.20 nmol/L) (drawn at 
least 1 week after treatment for ketosis or acidosis, if applicable).
10. No presence of autoantibodies as documented by glutamic acid decarboxylase [GAD] 65 and 
islet antigen [IA]-2 antibodies below the upper limit of the normal reference ranges at 
randomization.
11. The subject must have a BMI >85th percentile, documented at randomization.
7.4
Excluded Medications
During this study, any medications deemed necessary for the management of any AEs may be 
given at the discretion of the Investigator. However, it is the responsibility of the Investigator to 
ensure that the details regarding the medication are recorded in full in the electronic case report 
form (eCRF).
Treatment with antidiabetic agents (including DPP-4 inhibitors or GLP-1 RA analogues) other 
than study drug, metformin and insulin is not allowed within 12 weeks prior to Screening and 
through the completion of Week 52/End-of-Treatment Visit, with the exception of those subjects 
who require hyperglycemic rescue medications. 
Treatment with any investigational medication is not allowed from 30 days or 5 half-lives prior to 
randomization through the completion of the End-of-Treatment procedures. Chronic treatment 
with inhaled steroids >1000 mcg QD (or Flovent equivalent) should be avoided from 30 days prior 
to randomization through the completion of the End-of-Treatment procedures. Chronic treatment 
with oral or parenteral steroids should be avoided within 2 months prior to randomization and 
through the completion of the End-of-Treatment procedures. It is anticipated that the acute use of 
steroids may be required during the double-blind treatment period of the study; this will be allowed, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 33 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
if required for the medical management of subjects. If a subject requires chronic use of steroids 
during the study, such cases should be discussed with the Medical Monitor prior to consideration 
of study drug withdrawal. The chronic use of steroids, however, is discouraged.
Initiation of treatment with an atypical antipsychotic medication following Screening and 
throughout the first 26 weeks of the Double-Blind Treatment Period is not allowed unless 
discussed prior to initiation with the sponsor or designee.
7.5
Diet, Fluid, Activity Control 
Subjects will be instructed on proper nutrition and exercise, how to recognize signs and symptoms 
of hypoglycemia, and the use of a glucometer. Each study center should provide nutritional 
guidance in accordance with its standard of care for subjects with diabetes [33].
7.6
Criteria for Discontinuation or Withdrawal of a Study Drug
A subject’s study medication may be temporarily suspended or permanently ceased at any time at 
the discretion of the Investigator. Subjects are free to stop taking study medication at any time 
without prejudice to further treatment. If a subject refuses to return to the clinic for study visits, 
specific study visit procedures per Section 7.7, should be collected via telephone contact reports. If 
the subject refuses telephone contact, follow options as per Section 7.7.
The primary reason for permanent discontinuation of the subject from study medication should be 
recorded in the eCRF using the following categories. For screen failure or Pre-Randomization 
Stabilization failure subjects, refer to Section 9.1.15.
1. Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires early 
termination because continued participation imposes an unacceptable risk to the subject’s 
health, or the subject is unwilling to continue because of the PTE or AE.
2. Significant protocol deviation. The discovery post randomization that the subject failed to 
meet protocol entry criteria or did not adhere to protocol requirements, and continued 
participation poses an unacceptable risk to the subject’s health.
3. Lost-to-follow-up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented.
4. Voluntary withdrawal. The subject (or subject’s legally acceptable representative) wishes to 
withdraw from the study. The reason for withdrawal, if provided, should be recorded in the 
eCRF. If a subject chooses to withdraw from study participation due to personal concerns 
CCI
Property of Takeda: For Non-Commercial Use Only a
hdrawa
hdraw
orari
rarily s
y
cts are f
cts are 
t. If a su
. If a
Section
Sectio
ontact, f
ntact,
manent 
manen
ing the 
ng the
ubjects,
ubject
event (P
vent 
n becau
beca
or the su
r the
nificant
ifican
meet pro
meet pr
he Applicable Terms of Use
s 
e signs a
signs
provi
ovide n
de n
tes
tes [33
[3
parti
par
3. L
3.
and Subject to the


Alogliptin
Study No. SYR-322_309
Page 34 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
related to the COVID-19 pandemic (other than a COVID-19-related AE), this should be 
specified as the reason for subject withdrawal in the eCRF.
5. Study termination. The sponsor, IRB, IEC, or regulatory agency terminates the study.
6. Pregnancy. The subject is found to be pregnant. 
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Section 9.1.11.
7. Principal Investigator (PI) discretion. Investigator has determined that the subject should be 
withdrawn from the study for reasons other than the above reasons (1-7). 
8. Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF, including 
unavoidable circumstances (eg, a widespread disease outbreak such as the COVID-19 
pandemic or natural disaster).
Also see Sections 7.8 for liver safety withdrawal criteria, 7.9 for renal safety withdrawal criteria, 
and 7.10 for pancreatitis withdrawal criteria.
In consultation with the Medical Monitor, the Investigator may cease providing study drug to a 
subject at any time during the study when either (1) the subject meets the study drug termination 
criteria described above, or (2) the Investigator determines discontinuation of study drug is in the 
subject’s best interest.
Note: The subject will remain in the study to collect information regarding all assessments of study 
endpoints, unless the subject has explicitly withdrawn consent, as recorded in the source
documents.
7.7
Criteria for Discontinuation or Withdrawal from Study Participation
7.7.1
Voluntary Withdrawal
The subject (or subject’s legally acceptable representative) may discontinue his or her 
participation without giving a reason at any time during the study.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary underlying reason should be recorded (ie, withdrawal due to an AE 
should not be recorded in the “voluntary withdrawal” category).
The following options should be offered to the subject regarding continued participation: 
1. Subject discontinues study medication, but continues to participate in study site visits and 
procedures following the protocol specified visit schedule.
2. Subject discontinues study medication and study procedures, however, continues telephone (or 
other communication) contact following the protocol-specified visit schedule. The Projected 
Week 52 Visit should be at the clinic, if at all possible. Concomitant medications, update 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 35 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
contact information, and serious adverse event (SAE) assessments should be collected at each 
telephone visit (or other communication), at a minimum.
3. Indirect Method: Subject is not willing to have the PI or staff contact them. However, the 
subject will allow the site to contact their Primary Care Physician/Designated Contact, 
preferably every 2 months and at a minimum at the Projected Week 52 Visit to ensure their 
safety.
4. No further contact/withdrawal of consent, preferably in writing-- Subject revokes consent to 
contact them directly or their Primary Care Physician/Designated Contact. Vital status will be 
checked using appropriate available information sources such as public records. 
The subject’s continued level of participation should be clearly documented and updated in the 
subject’s source documents. Should a subject no longer wish any further contact, the primary 
criterion for termination must be recorded as well. In addition, efforts should be made to perform 
all procedures scheduled for the End-of-Treatment Visit, Telephone Follow-up Visit, and 
Projected Week 52 Visit.
Discontinued or withdrawn subjects will not be replaced.
7.7.2
Lost-to-Follow-up
Every effort will be made to ensure that the subject continues to return to the clinic for study visits 
and to avoid “Lost-to-Follow-up” during the conduct of the study. The study staff should make 
diligent attempts to contact subjects who fail to return for study visits by using public information 
websites, institutional databases, subjects’ health professionals, and any other means that comply 
with country, state, and local laws and regulations. At a minimum, after the first missed visit, 
subjects who are considered temporarily Lost-to-Follow-up will have at least 2 documented 
telephone contact attempts and 1 certified letter in an effort to contact subjects. Thereafter, every 
2 months, and at the end of the study, attempts will be made to determine the health status of 
temporarily Lost-to-Follow-up subjects. 
The Investigator must attempt to document assessments of study endpoints and occurrence of 
events through the Projected Week 52 Visit. At randomization, all subjects will be asked to 
provide all (within local legal limits) contact details, which may include, but is not limited to, 
acceptable representative(s), address(es), phone number(s), email address(es), government issued 
identification, health insurance provider, relatives, other contacts, such as primary care physician, 
or other health care provider to ensure final follow-up. At each study visit, subjects should be 
asked about any updates to their contact details. 
If unknown, the subject’s status should be obtained from a reliable contact at approximately 6 
months after subject discontinued drug (if applicable) and at the Projected Week 52 Visit, either by 
speaking with the subject or someone who has knowledge of the subject’s vital status or by 
documented source (eg, lab reports, medical visit records).
In regions where allowed by local law, subject locator services may be used to help ascertain the
health status of subjects believed to be Lost-to-Follow-up. If contact is made with the subject at 
any step in this process, the subject’s preferred method of continued participation in the trial 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 36 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
should be determined and documented in the subject’s source and updated in electronic data 
capture, as appropriate.
Only just prior to the end of the study, and after the above attempts have been exhausted, will a 
subject be considered officially Lost-to-Follow-Up. If subject vital status is known at the end of 
the study, the subject will not be considered Lost-to-Follow-up.
7.8
Liver Safety Monitoring and Withdrawal Criteria
7.8.1
Liver Function Test Monitoring
Liver function will be carefully monitored throughout the study. Additional monitoring may be 
necessary and is recommended for subjects with abnormal liver function tests.
If subjects with normal baseline ALT or aspartate aminotransferase (AST) levels experience ALT 
or AST >3× ULN, follow-up laboratory tests (at a minimum, serum alkaline phosphatase, ALT, 
AST, total bilirubin, -glutamyl transferase (GGT), and international normalized ratio [INR]) 
should be repeated within a maximum of 7 days and preferably within 48 to 72 hours after the 
abnormality was found.
If subjects with elevated baseline ALT or AST levels experience ALT or AST >5× ULN and 
2-fold increases above baseline, follow-up laboratory tests (at a minimum, serum alkaline 
phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be repeated within a maximum of 
7 days and preferably within 48 to 72 hours after the abnormality was found.
If subjects with either a normal or elevated baseline ALT or AST levels experience ALT or AST 
>8× ULN, follow-up laboratory tests (at a minimum, serum alkaline phosphatase, ALT, AST, total 
bilirubin, GGT, and INR) should be repeated within a maximum of 48 hours after the abnormality 
was found.
7.8.2
Considerations for Temporary Discontinuation of Study Drug
If the ALT or AST levels remain elevated >3× ULN in subjects with normal baseline ALT or AST 
levels OR if the ALT or AST levels remain elevated >5× ULN and a 2-fold increase above 
baseline occurs in subjects with elevated baseline ALT or AST levels on 2 consecutive occasions, 
the investigator must contact the Medical Monitor to discuss additional testing, recommended 
monitoring, possible temporary discontinuation of study medication, and possible alternative 
etiologies. 
The abnormality should be recorded as an AE (please refer to Section 10.2.3 Reporting of 
Abnormal Liver Function Tests for reporting requirements).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 37 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
7.8.3
Permanent Discontinuation of Study Drug
If the following circumstances occur at any time during treatment, the study medication should be 
permanently discontinued:
Subject Baseline Aminotransferases
Criteria for Discontinuation of Study Medication
Normal or Elevated ALT or AST (all subjects)

ALT or AST >8 × ULN 
Normal ALT and AST

ALT or AST >5 × ULN and persists for more than 2 weeks

ALT or AST >3 × ULN in conjunction with elevated total 
bilirubin >2 × ULN or INR >1.5

ALT or AST >3 × ULN with appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, 
rash and/or eosinophilia (>5%)
Elevated ALT or AST 

ALT or AST >5 × ULN AND 2-fold increases above 
baseline values and persists for more than 2 weeks

ALT or AST >5× ULN AND 2-fold increases above 
baseline values in conjunction with elevated total bilirubin 
>2 ULN or INR >1.5

ALT or AST >5 × ULN AND 2-fold increases above 
baseline values with appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, 
rash and/or eosinophilia (>5%)
In each of these instances, appropriate clinical follow-up should be instituted (including repeat 
laboratory tests) until a satisfactory conclusion (ie, until the AE resolves, the laboratory value 
returns to Baseline, or the condition becomes stable).
If a subject meets the liver safety criteria and must be discontinued from study medication, the 
subject will continue to be followed per the protocol schedule until the study is completed. If the 
subject refuses to return for the study visits, telephone visits may be conducted; however, this is 
not preferred nor recommended. The reason for discontinuation of study medication should be 
listed as an AE.
If any of the above circumstances occur at any time during the study, the abnormality should be 
documented as an AE, and a Liver Function Test Increase form completed. 
The Investigator must complete the AE/SAE eCRF page. If the event meets serious criteria, the 
SAE eCRF page must be completed and an SAE Fax Notification form must be sent to the sponsor 
or sponsor’s designee within 1 working day of the repeat laboratory test.
7.8.4
Re-initiation of Study Drug
If the study medication is discontinued due to any of the scenarios provided above, study 
medication must not be re-initiated without consultation with the Medical Monitor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 38 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
7.9
Renal Safety Withdrawal Criteria
If a subject does not have renal impairment at Screening or randomization, but later develops renal 
impairment that is confirmed by a repeat test within a maximum of 7 days by the central laboratory 
AND a creatinine clearance <60 mL/min (utilizing the Schwartz formula, and based on a 
calculation by the central laboratory), the subject will discontinue study medication after
consultation with the Medical Monitor. The central laboratory will calculate these values at the 
same visits where a full laboratory panel is performed. If a subject’s calculated creatinine 
clearance indicates moderate or severe renal impairment, a laboratory alert will occur to notify the 
site to discontinue the double-blind study medication.
If a subject discontinues double-blind study medication according to the Renal Safety Withdrawal 
Criteria, the event should be recorded as an AE and the reasons for study drug discontinuation 
must be recorded as an AE. The subject will be required to return for protocol study visits and 
procedures.
7.10
Pancreatitis Monitoring and Withdrawal Criteria
All subjects will be carefully monitored for pancreatitis during the study. Investigators will urge 
subjects to immediately call the study staff if the subject experiences persistent nausea and/or 
vomiting for ≥3 days, with or without abdominal pain.
Blood samples for analysis of serum amylase and lipase by a central laboratory should be obtained 
at the visit, and other additional investigations should be performed in order to establish diagnosis.
Study drug should be interrupted immediately if any of the following circumstances occur at any 
time during treatment:

If pancreatitis is suspected, or

Serum amylase ≥2 × ULN, or

Serum lipase ≥2 × ULN.
The pancreatic enzyme tests should be repeated within 7 days after the first sample (with both 
samples analyzed by the central laboratory), and appropriate imaging tests (as per standard of care) 
should be performed to establish diagnosis. The results of these tests should be recorded in the 
source documents.
All subjects with elevated pancreatic enzymes that meet the above criteria should be kept under 
observation with multiple serum amylase and lipase tests to be followed-up until resolution.
If pancreatitis is confirmed, the study drug should not be restarted.
If any of the circumstances described above occur during the study, the event should be recorded 
as an AE. A Pancreatic AE of Special Interest Form must be completed. If the event meets the SAE 
criteria, an SAE Fax Notification form must be sent to the sponsor or sponsor’s representative 
within 1 working day of the repeat laboratory test.
If a subject discontinues double-blind study medication according to the Pancreatitis Monitoring 
and Withdrawal Criteria, the event should be recorded as an AE and the reason for withdrawal 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 39 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
should be documented as an AE. The subject will be required to return for protocol study visits and 
procedures.
7.11
Procedures for Discontinuation or Withdrawal of a Subject
The Investigator may discontinue a subject’s study participation at any time during the study when 
the subject meets the study termination criteria described in Section 7.6. In addition, a subject may 
discontinue his or her participation without giving a reason at any time during the study. Should a 
subject’s participation be discontinued, the primary criterion for termination must be recorded by 
the Investigator. In addition, efforts should be made to perform all procedures scheduled for the 
End-of-Treatment Visit. Withdrawn subjects will continue to the Week 52/End-of-Treatment 
assessments followed by the Week 54/Follow-up telephone call. The Week 54/Follow-Up Visit 
assessments will be completed 2 weeks following the Week 52/End-of-Treatment Visit 
assessments.
8.0
CLINICAL TRIAL MATERIAL MANAGEMENT
This section contains information regarding all medication and materials provided directly by the 
sponsor, and/or sourced by other means, that are required by the study protocol, including 
important sections describing the management of clinical trial material.
8.1
Study Medication and Materials 
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling
In this protocol, the term study medication refers to all or any of the drugs defined below:
Alogliptin benzoate 25 mg tablet or matching placebo.
Subjects should be instructed to take one tablet daily at the same time with or without food.
8.1.1.1
Investigational Drug
Alogliptin benzoate or matching placebo tablets
Alogliptin benzoate tablets are manufactured by Takeda Pharmaceuticals and are composed of 
25 mg alogliptin drug substance and excipients; the matching placebo tablets consist of excipients 
only. Alogliptin or placebo tablets will be provided in 35 count high-density polyethylene bottles
with a child resistance cap. Tablets are oval biconvex light red, film coated with no markings. 
Bottles will bear a blinded single panel or booklet label containing medication ID, pertinent 
protocol information and required caution statements.
8.1.1.2
Companion Medication
Metformin HCl and/or insulin will be prescribed to subjects on background antidiabetic therapy 
during the double-blind period of the study. 
Insulin: Subjects will continue to receive insulin with the goal of achieving a stable dose required 
for glycemic control dependent on the subject’s requirements, at the Investigator’s discretion.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 40 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Metformin: Subjects will receive metformin with the goal of being treated with at least 1000 mg 
BID or their documented MTD.
8.1.1.3
Sponsor-Supplied Drug
Sponsor-supplied drugs referenced in other sections of the protocol include the following:
Alogliptin benzoate and matching placebo tablets.
8.1.1.4
Rescue Medications 
Subjects who meet protocol-defined hyperglycemia rescue criteria will be rescued with an 
antidiabetic regimen at the Investigator’s discretion as per Section 9.1.17.3: Criteria for 
Hyperglycemia Rescue. 
8.1.2
Storage
Investigational drug must be kept in an appropriate, limited-access, secure place until it is used or 
returned to the sponsor or designee for destruction. Investigational drug must be stored under the 
conditions specified on the label (25°C [77°F] excursions permitted to 15°C to 30°C [59°F to 
86°F]), and remain in the original container until dispensed. A daily temperature log of the drug 
storage area must be maintained every working day.
8.1.3
Dose and Regimen
Table 8.a
Dose and Regimen
Treatment Group
Dose
Treatment Description
Active
Placebo
A
placebo QD
0 active tablets
1 placebo for 25 mg tablet
B
alogliptin 25 mg QD
1 alogliptin 25 mg tablet
0 placebo tablets
Dose interruptions are acceptable based on medical need. The sponsor or designee must be notified 
and consulted for any dose interruptions longer than 14 continuous days.
8.1.4
Overdose
An overdose is defined as a known deliberate or accidental administration of investigational drug, 
to or by a study subject, at a dose above that which is assigned to that individual subject according 
to the study protocol.
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety information consistently in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs associated 
with an overdose will be documented on AE eCRF(s) according to Section 10.0, Pretreatment 
Events and Adverse Events.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 41 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
The SAEs associated with overdose should be reported according to the procedure outlined in 
Section 10.2.2, Collection and Reporting of SAEs.
In the event of drug overdose, the subject should be treated symptomatically.
8.2
Investigational Drug Assignment and Dispensing Procedures
The Investigator or Investigator’s designee will access the interactive voice response system/ 
interactive web response system (IVRS/IWRS) at Screening to obtain the subject study number. 
The Investigator or the Investigator’s designee will utilize the IVRS/IWRS to randomize the 
subject into the study. During this contact, the Investigator or designee will provide the necessary 
subject-identifying information, including the subject number assigned at screening. The 
medication ID number of the investigational drug to be dispensed will then be provided by the 
IVRS/IWRS. If sponsor-supplied drug (alogliptin 25 mg or matching placebo) is lost or damaged, 
the site can request a replacement from IVRS/IWRS. (Refer to the IVRS/IWRS manual provided 
separately.) At subsequent drug-dispensing visits, the Investigator or designee will again contact 
the IVRS/IWRS to request additional investigational drug for a subject.
Subjects will be dispensed blinded study drug at Day 1, and Weeks 12, 26, and 39. Subjects will be
dispensed sufficient bottles for the visit interval. Subjects will be instructed to take their blinded 
study drug QD with or without food and to return their study drug bottles whether empty or full at 
each visit.
On occasion in unavoidable circumstances (eg, a widespread disease outbreak such as the 
COVID-19 pandemic or natural disaster), additional drug supply may be provided to subjects 
(either at an in-person visit or delivered to the subject’s residence) to cover extended periods 
between onsite visits. Any additional resupply must be reviewed and approved in advance by the 
sponsor or designee.
8.3
Randomization Code Creation and Storage
On Study Day 1, qualified subjects will be randomized to 1 of the 2 treatment groups using the 
IVRS/IWRS. 
8.4
Investigational Drug Blind Maintenance
The investigational drug blind will be maintained using the IVRS/IWRS.
8.5
Unblinding Procedure 
The investigational drug blind shall not be broken by the Investigator unless information 
concerning the investigational drug is necessary for the medical treatment of the subject. In the 
event of a medical emergency, if possible, the medical monitor should be contacted before the 
investigational drug blind is broken to discuss the need for unblinding.
For unblinding a subject, the investigational drug blind can be obtained by the Investigator, by 
accessing the IVRS/IWRS.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 42 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
The sponsor must be notified as soon as possible if the investigational drug blind is broken. The 
date, time, and reason the blind is broken must be recorded in the source documents and the same 
information (except the time) must be recorded on the eCRF.
If any site personnel are unblinded, investigational drug must be stopped immediately, and the 
subject must be withdrawn from the study. 
8.6
Accountability and Destruction of Sponsor-Supplied Drugs
Drug supplies will be counted and reconciled at the site before being returned to the sponsor or 
designee.
The Investigator or designee must ensure that the sponsor-supplied drug is used in accordance with 
the protocol and is dispensed only to subjects enrolled in the study. To document appropriate use 
of sponsor-supplied drug, the Investigator or designee must maintain records of all 
sponsor-supplied drug delivery to the site, site inventory, dispensation and use by each subject, and 
return to the sponsor or designee.
Upon receipt of sponsor-supplied drug, the Investigator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantity is correct, and the 
medication is in good condition. If quantity and conditions are acceptable, Investigator or designee 
should acknowledge the receipt of the shipment by recording in IWRS. If there are any 
discrepancies between the packing list versus the actual product received, Takeda or designee 
must be contacted to resolve the issue. The packing list should be filed in the Investigator’s 
essential document file.
The Investigator or designee must maintain 100% accountability for all sponsor-supplied drugs 
received and dispensed during his or her entire participation in the study. Proper drug 
accountability includes, but is not limited to:

Frequently verifying that actual inventory matches documented inventory.

Verifying that all containers used are documented accurately on the log.

Verifying that required fields are completed accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The IVRS/IWRS will include all required information as a separate entry for each subject to whom 
sponsor-supplied drug is dispensed.
The Investigator or designee must record the current inventory of all sponsor-supplied drugs on a 
sponsor-approved drug accountability log. The following information will be recorded at a 
minimum: protocol number and title, name of Investigator, site identifier and number, description 
of sponsor-supplied drugs, date and amount dispensed including initials or signature of the person 
dispensing the drug, and the date and amount returned to the site by the subject, including the 
initials or signature of the person receiving the sponsor-supplied drug. The log should include all 
required information as a separate entry for each subject to whom sponsor-supplied drug is 
dispensed. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 43 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
All study drug that was not returned to the site by a subject must be investigated by the site and 
appropriately documented on the drug accountability log.
Prior to site closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform sponsor-supplied drug accountability and reconciliation before sponsor-supplied 
drugs are returned to the sponsor or its designee for destruction. The Investigator or designee will 
retain a copy of the documentation regarding sponsor-supplied drug accountability, return, and/or 
destruction, and originals will be sent to the sponsor or designee.
9.0
STUDY PLAN
9.1
Study Procedures
The following sections describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the same Investigator or site personnel whenever possible. The 
Schedule of Study Procedures is located in Appendix A. 
9.1.1
Alternative Approaches to Study Procedures and Data Collection Due to 
Unavoidable Circumstances
In unavoidable circumstances (eg, a widespread disease outbreak such as the COVID-19 pandemic 
or natural disaster) that impact the study site’s ability to conduct study procedures according to the 
Schedule of Study Procedures (Appendix A), contingency measures may be implemented. In 
acknowledgement of study site, hospital, local, state, and national restrictions established in 
response to unavoidable circumstances, the following measures are being taken for the current 
study:

For subjects active in the study, all attempts should be made to perform the assessments 
with the subject present at the site using the visit windows. Exceptions may be granted for 
alternative approaches to study procedures and data collection through approval by the 
sponsor or designee. Such instances must be documented in the study records and may 
include the following:
–
Sites impacted by unavoidable circumstances must contact the sponsor or designee to 
discuss individual subject and site circumstances to obtain approval for use of 
alternative approaches to study procedures and data collection.
–
Sites may seek approval from the sponsor or designee to continue subjects in the study 
despite departures from the Schedule of Study Procedures. The principal investigator is 
expected to evaluate the impact to the safety of the study participants and site personnel 
for subjects to continue. In evaluating such requests, the sponsor or designee will give 
the highest priority to the safety and welfare of the subjects. Subjects must be willing 
and able to continue taking study medication and remain compliant with the protocol. 
–
Other than the End-of-Treatment Visit, alternative methods for conducting subject 
visits (eg, video conferencing, telephone visits, or in-home study visits conducted by 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 44 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
study site personnel or designated medical personnel, contingent upon local 
regulations) may be used per approval by the sponsor or designee: 

Under these circumstances, collection of certain study assessments may be 
omitted and visit windows may be extended. 

When approval is given for a subject to miss an in-person study visit, a study 
site physician or other qualified site personnel will speak directly with the 
subject by telephone or other medium (eg, a computer-based video 
communication) during each visit window to assess subject safety and overall 
clinical status. 

The study site physician or other qualified site personnel should conduct the 
following assessments within specified-visit window timeframes: AE 
assessments, documentation of concomitant medication, review of diaries and 
glucometer readings, and drug accountability and an assessment of clinical 
symptoms.

Home nurses or other qualified clinical personnel may be deployed at the 
request of the site, when appropriate. Advance approval from the sponsor or 
designee should be obtained.

Other study assessments may be collected using an alternative method as 
feasible, and may involve audio or video recording where allowed by local 
regulation. This will be documented in the study records.

In some instances, sites may need to split visits or sites may only be able to 
perform a few procedures on site and some procedures may need to be 
performed remotely. Sites should inform sponsor or designee when this occurs.

Sites may seek approval to extend a visit window in order to conduct an on-site 
visit. Assessments that cannot be completed during the protocol-specified 
window or within the visit window granted by the sponsor or designee will be 
considered missing data and such departures will be recorded in the study 
records. 
–
Study site personnel may dispense additional IP to subjects at a visit to allow for 
potentially longer intervals between visits than originally planned per protocol, or IP 
may be supplied to subjects via delivery by site personnel or by courier.
–
The End-of-Treatment Visit should be performed in person. When it is not possible for 
the subject to come to the study site and the protocol-specified visit window cannot be 
extended further, the preferred alternative for the visit is for qualified study site 
personnel or designated clinical personnel to go to the subject’s residence and conduct 
the protocol-specified procedures in that location. Assessments collected at a subject’s 
residence should comply with applicable local regulations. If neither option is available 
with sponsor or designee approval, sites may conduct end-of-treatment procedures 
remotely as is feasible.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 45 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
All subject discontinuations and alternative approaches to study procedures (ie, procedures not 
conducted per the Schedule of Study Procedures) due to unavoidable circumstances (eg, a 
widespread disease outbreak such as the COVID-19 pandemic or natural disaster) must be 
documented in the study records. Data collected using alternative methods may be handled 
differently in the final data analyses. This will be documented in the SAP.
9.1.2
Informed Consent Procedure
The requirements of the informed consent are described in Section 15.2. Informed consent from 
the subject’s legal representative (ie, parents or legal guardians) and assent, as appropriate, must be 
obtained prior to the subject entering into the study, and before any protocol-directed procedures 
are performed.
A unique subject identification number (subject number) will be assigned to each subject at the 
time that informed consent is obtained; this subject number will be used throughout the study.
9.1.2.1
Pharmacogenomic Informed Consent Procedure
As of the date of this amendment, a sufficient number of samples have been collected and no more 
are needed; therefore, pharmacogenomic samples no longer need be taken.
Under previous versions of this protocol, the participation of study subjects and study sites in the 
collection of pharmacogenomic sample(s) was optional and only to be performed in selected 
countries/sites where approved. A separate informed consent/assent form pertaining to storage of 
the sample(s) must have been obtained prior to collecting a blood and/or saliva sample for 
Pharmacogenomic Research for this study. The provision of consent/assent to collect and analyze 
the pharmacogenomic sample is independent of consent to the other aspects of the study.
9.1.3
Demographics, Medical History, and Medication History Procedure
Demographic information to be obtained will include date of birth or age, sex, Hispanic ethnicity 
(US only) and race as described by the subject of the subject at Screening. Medical history to be 
obtained will include determining whether the subject has any significant conditions or diseases 
relevant to the disease under study that stopped at or prior to signing of informed consent. Ongoing 
conditions are considered concurrent medical conditions (see Section 9.1.8).
Medication history information to be obtained includes any medication relevant to eligibility 
criteria and efficacy/safety evaluation stopped at or within 12 weeks prior to signing of informed 
consent.
9.1.4
Physical Examination Procedure
A baseline, complete physical examination (defined as the assessment prior to first dose of 
investigational drug) will consist of the following body systems: (1) eyes; (2) ears, nose, throat; 
(3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic 
system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and 
(11) other. All subsequent physical examinations should assess clinically significant changes from 
the assessment prior to the first dose examination. The brief physical exam will consist of the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 46 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
following body systems: (1) respiratory system; (2) cardiovascular system; (3) nervous system 
(4) dermatologic system; and (5) gastrointestinal system. The brief and complete physical exams 
will be performed as indicated in Appendix A.
Assessment of pubertal development in boys and in girls will be conducted at the Day 1, Week 26, 
and Week 52 Visits. Tanner Stage scoring [34,35] will be assessed at the visits as per Appendix A. 
An examination to assess Tanner Stage scoring is preferred, but subject-reported scoring (using 
diagrams) is acceptable.
Tanner stage for breast development in girls, genital development in boys and pubic hair for both 
sexes should be evaluated. Sites should enter the numerical stage for each of the 2 categories on the 
eCRF for either boys or girls.
For girls, age of onset of menarche will be collected at the Day 1 visit and if menarche had not yet 
occurred, this will be verified at each study visit.
9.1.5
Weight, Height and BMI
The subject should have weight and height measured using a stadiometer (or equivalent) and scale 
while wearing indoor clothing and with shoes off. 
BMI will be calculated by the site prior to randomization using the following formula and Centers 
for Disease Control and Prevention 3rd to 97th Percentile growth charts to determine BMI-for-age 
percentiles (http://www.cdc.gov/growthcharts/clinical_charts.htm#Set2).
BMI = weight (kg)/height (m)2
The values should be reported to 2 decimal places by rounding. The BMI at all other visits and 
BMI Z-scores will be calculated by the Sponsor or designee.
9.1.6
Vital Sign Procedure
Vital signs will include body temperature (oral or tympanic measurement), respiratory rate, blood 
pressure (resting more than 5 minutes), and pulse (beats per minute).
When vital signs are scheduled at the same time as blood draws, the blood draw will take priority 
and vital signs will be obtained within 0.5 hour before or after the scheduled blood draw.
9.1.7
Documentation of Concomitant Medications
Concomitant medication is any drug given in addition to the study medication. These may be 
prescribed by a physician or obtained by the subject over the counter. Concomitant medication is 
not provided by Takeda. At each study visit, subjects will be asked whether they have taken any 
medication other than the study medication (used from signing of informed consent through the 
end of the study), and all medication including vitamin supplements, over-the-counter medications, 
and oral herbal preparations, must be recorded in the eCRF.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 47 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
9.1.8
Documentation of Concurrent Medical Conditions
Concurrent medical conditions are those significant ongoing conditions or diseases that are present 
at signing of informed consent. This includes clinically significant laboratory, ECG, or physical 
examination abnormalities noted at the Screening examination. The condition (ie, diagnosis) 
should be described.
9.1.8.1
Annual Ophthalmologic Examination
Annual dilated and comprehensive eye examinations are recommended for all subjects [36]. 
Results of the annual ophthalmologic examination prior to participation and during the course of 
the study should be reviewed by the Investigator. Any relevant medical history and AEs resulting 
from the annual exam should be reported on the eCRF.
9.1.9
Procedures for Clinical Laboratory Samples
All samples will be collected in accordance with acceptable laboratory procedures. The maximum 
volume of blood at any single visit is approximately 24.5 mL, and the approximate total volume of 
blood for the study is 102 mL. Please refer to Table 9.a and Appendix A on timing of collection for 
clinical laboratory testing.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 48 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Table 9.a
Clinical Laboratory Tests
Hematology
Serum Chemistry 
Urinalysis (a) 
White blood cell count with 
autodifferential
Platelet count
Hemoglobin
Hematocrit
Red blood cell count
Mean corpuscular volume
Mean corpuscular hemoglobin 
Mean corpuscular hemoglobin 
concentration
Albumin
Alkaline phosphatase
Alanine aminotransferase
Aspartate aminotransferase
Blood urea nitrogen
Bicarbonate
Calcium
Magnesium
Chloride
Creatinine
Lactate dehydrogenase
Phosphorus
Potassium
Sodium
Total bilirubin
Direct bilirubin (only if Total 
bilirubin is elevated)
Total protein
Uric acid
GGT 
Lipid panel (total cholesterol, 
high-density lipoproteins, 
low-density lipoproteins (direct), 
and triglycerides) (c)
Serum amylase (d)
Serum lipase (d)
Glucose
Qualitative:
Appearance
Color
pH
Specific gravity
Ketones
Protein (albumin)
Glucose
Nitrite
Urobilinogen
Blood
Quantitative: (e)
Albumin
Creatinine
Albumin/creatinine ratio 
Other
HbA1c
CD26 surface antigen
Bone specific alkaline phosphatase
CTX 
Diagnostic Screening:
Serum
Urine
C-peptide (f) 
hCG 
(female subjects) (g)
eGFR (h)
2-hour postprandial glucose (i)
GAD 65 (f)
IA-2 (f)
hCG 
(female subjects) (g)
hCG=human chorionic gonadotropin.
(a) It is recommended that a follow-up urine culture be obtained within 7 days of clinical recovery from all urinary 
tract infections.
(b) Collected only from those subjects who arrive at the clinic in a fasted state. Always drawn in a separate tube for this 
study.
(c) Collect only at the visits specified in Appendix A.
(d) Serum amylase and serum lipase to be performed at Day 1 (Baseline Visit) for all subjects and at an Unscheduled 
Visit for any subject who experiences persistent nausea and/or vomiting for ≥3 days with or without abdominal pain.
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
f
f Total
f Total
)
nel (total
(to
density li
density
w-density
densi
and trigl
and tr
Serum
Seru
Ser
S
bumin)
umin)
e
obilinog
obilino
Blood
lood
Quan
Qu
A
o
m
Co
g)
g)
andial gl
ndial 
D 65 (f)
D 65 (f)
-2 (f)
2 (f)
n
hCG=h
hCG
(a) 
(a
t
y o Tak


Alogliptin
Study No. SYR-322_309
Page 49 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Table 9.a
Clinical Laboratory Tests
(e) The Week 26 urinalysis will only include quantitative assessments. 
(f) Collected once prior to randomization only in subjects who have had the diagnosis of T2DM for less than 1 year 
and/or who are taking insulin. 
(g) To be completed on all female subjects. If a urine pregnancy test yields a positive result, a serum pregnancy test 
must also be collected at the same visit and submitted to the central laboratory for confirmation of results.
(h) Calculated at Screening and Baseline and at Weeks 26 and 52 by the central laboratory using the Schwartz formula.
(i) Select sites only. See section 9.1.9.1 for additional information.
(j) Collected at Baseline and at Weeks 26 and 52. 
The central laboratory will perform laboratory tests for hematology, serum chemistries, and 
urinalyses. The results of laboratory tests will be returned to the Investigator, who is responsible 
for reviewing and filing these results.
In unavoidable circumstances (eg, a widespread disease outbreak such as the COVID-19 pandemic 
or natural disaster), sites may elect to use local laboratories per approval by the sponsor or 
designee.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
year 
ar 
nancy te
nancy 
ults.
ts.
Schwartz
chwar
f
m chem
chem
m
igator, 
igator
k such a
such
per appr
er app
operty of Takeda: For Non-Commercial Use Only and S


Alogliptin
Study No. SYR-322_309
Page 50 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
9.1.10
Contraception and Pregnancy Avoidance Procedure
This protocol does not condone or endorse under-age sexual activity. Female participants will be 
asked to use contraception if they are going to be sexually active. Age appropriate contraceptive 
pill or condom plus spermicide are advised. It is noted that Investigators will neither prescribe 
contraceptives, nor provide contraceptive advice beyond the protocol requirements; subjects must 
take responsibility for obtaining advice from the appropriate family doctor or family planning 
provider and preferably after discussion with their parents/legal guardians. Contraception use must 
be practiced if sexually active, from the date of the Screening Visit until the last dose of study
medication intake. Parents/legal guardians and the subject will be advised of this during the 
informed consent and assent process, and subjects will be asked to sign an informed assent form or
consent form (as appropriate) stating that they understand the requirements for avoidance of 
pregnancy during the course of the study. 
During the course of the study, regular serum human chorionic gonadotropin (hCG) pregnancy 
tests will be performed for all female subjects (Appendix A). In addition to a negative serum hCG 
pregnancy test at Screening, subjects also must have a negative serum hCG pregnancy test prior to
receiving of study medication. 
9.1.11
Pregnancy
If any subject is found to be pregnant during the study, she should be withdrawn, and any 
sponsor-supplied drug should be immediately discontinued. In addition, any pregnancies in the 
partner of a male subject during the study or for 30 days after the last dose, should also be recorded 
following authorization from the subject’s partner.
CCI
Property of Takeda: For Non-Commercial Use Only and 
nce Proc
e Pr
er-age se
age 
o be sex
be se
d. It is n
d. It is
ve advic
ve adv
ice from
ce fro
ussio
ssion w
n
frfrom
om tht
m
egal
gal gu
g
l
sent proc
nt pro
opriate)
opriat
he cour
he cou
urse of th
se of 
perform
perfor
y test at
y test a
ing of s
ing of 
.1.11
.11
If an
If a
se
s
d Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 51 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
If the pregnancy occurs during administration of active study medication, eg, after Day 1 or within 
30 days of the last dose of active study medication, the pregnancy should be reported immediately, 
using a pregnancy notification form, to the contact listed in Section 1.0.
Should the pregnancy occur during or after administration of blinded drug, the Investigator must 
inform the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatment information, the individual blind should be broken by the Investigator. 
If the female subject and/or female partner of a male subject agrees to the primary care physician 
being informed, the Investigator should notify the primary care physician that the subject/female 
partner of the subject was participating in a clinical study at the time she became pregnant and 
provide details of treatment the subject received (blinded or unblinded, as applicable).
All pregnancies in subjects on active study drug including comparator will be followed up to final 
outcome, using the pregnancy form. Pregnancies will remain blinded to the study team. The 
outcome, including any premature termination, must be reported to the sponsor. An evaluation 
after the birth of the child will also be conducted.
9.1.12
Pharmacogenomic Sample Collection 
As of the date of this amendment, a sufficient number of samples have been collected and no more 
are needed; therefore, pharmacogenomic samples no longer need be taken.
Under previous versions of this protocol, subjects had the option to sign the pharmacogenomic 
sample collection informed consent form (ICF). For those who provided consent to participate in 
the pharmacogenomic sub-study, a 1 mL whole blood sample for DNA isolation, a 2.5 mL blood 
sample for RNA isolation, as well as a saliva sample were to be collected before dosing on Day 1. 
An additional 2.5 mL blood sample was to be collected at the Week 12 Visit. If the baseline RNA 
blood sample collection was missed, the Visit 12 blood draw should not have been done. 
DNA forms the basis for the genes that make the body produce proteins such as enzymes, drug 
transporters or drug targets, and may be evaluated for the genetic contribution how the drug is 
broken down, or how the drug affects the body. RNA has multiple vital roles in the coding, 
decoding, regulation, expression of genes, and sensing and communicating responses to cellular 
signals. Both DNA and RNA samples may be evaluated for the genetic and transcriptional 
contribution on how the drug is broken down, or how the drug affects the body. This is called a 
“Pharmacogenomics research study.” Specific purposes of this study include:

Identifying genetic reasons why certain people respond differently to alogliptin.

Finding out more information about how alogliptin works.

Generating information needed for research, development, and regulatory approval of tests to 
predict response to alogliptin.

Identifying variations in genes related to the biological target of alogliptin.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 52 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
This information may be used, for example, to develop a better understanding of the safety and 
efficacy of alogliptin and other study medications, and for improving the efficiency, design, and 
study methods of future research studies.
Samples taken will be stored for no longer than 15 years after completion of the SYR-322_309 
study. No samples will be stored for longer than permitted by the applicable law and samples will 
be destroyed upon notification from Takeda. “Stored samples” are defined as samples that are 
key-coded (the samples are stripped of all personal identifying information but a key links the 
samples to the clinical data collected from the sample donor) and are used in the analysis of 
investigational drug or related drugs.
9.1.13
ECG Procedure 
A standard 12-lead ECG will be recorded. The Investigator (or a qualified observer at the 
investigational site) will interpret the ECG using 1 of the following categories: within normal 
limits, abnormal but not clinically significant, or abnormal and clinically significant. A copy of the 
ECG tracing should be kept with the subject’s notes.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
309
09
mples wil
ples w
that are
hat ar
ey l
y inks 
ink
analysi
analys
alified o
ified
ng categ
g cate
clinical
clinica
perty of Takeda: For Non-Commercial Use Only and S


Alogliptin
Study No. SYR-322_309
Page 53 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
9.1.15
Documentation of Screen Failure or Pre-Randomization Stabilization Failures 
Investigators must account for all subjects from whom informed consent/assent has been obtained.
If the subject is found to be not eligible during the Screening and Pre-Randomization Stabilization 
Period, the Investigator should complete the eCRF. The IVRS/IWRS should be contacted as a 
notification of screen failure or Pre-Randomization Stabilization failure.
The primary reason for Screen failure/Pre-Randomization Stabilization failure is recorded in the 
eCRF using the following categories:
!
PTE/AE.
!
Did not meet inclusion criteria or did meet exclusion criteria.
!
Significant protocol deviation.
!
Lost-to-follow-up.
!
Voluntary withdrawal <specify reason>.
!
Study termination.
!
Other <specify reason>.
Subject numbers assigned to subjects who fail Screening/Pre-Randomization Stabilization should 
not be reused.
9.1.16
Documentation of Randomization
Only subjects who meet all of the inclusion criteria and none of the exclusion criteria are eligible 
for randomization into the treatment phase.
CCI
Property of Takeda: For Non-Commercial Use Only and Subj
andom
ando
om infor
m info
he Scre
he Scre
eCRF. 
eCRF
omizat
mizatio
e/Pre
/Pre-Ra
es:s:
n cri
cri
n
teri
ter
i
colol devia
dev
l
w-up.
-up
y wi
wi
y
th
th
i dr
y termin
term
y
Other
ther <s
<
Subject 
ubjec
not b
not 
se
ubject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 54 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
If the subject is found to be not eligible for randomization, the Investigator should record the 
primary reason for failure on the applicable eCRF.
9.1.17
Blood Glucose Education and Management
Subjects will meet with a diabetes educator or appropriately trained site personnel at Screening, at 
the Pre-Randomization Stabilization Visits, and at specified Visits through Week 26, who will 
instruct them on how and when to test their blood glucose levels using their glucometer, how to 
recognize the signs and symptoms of hypoglycemia, and how to use supplemental treatment with 
oral glucose, if necessary. Investigators should individualize recommendations for capillary blood 
glucose measurements based on the subjects’ level and stability of glycemic control, initiation of 
or change in therapy, intercurrent illness, and risk of hypoglycemia associated with the type and 
intensity of therapy. Timing of glucose measurements should be based on local guidance on the 
management of T2DM in youths. For recommendations, see Appendix H.
The glucometer will be returned by the subject and reviewed by site personnel at every subsequent 
visit.
9.1.17.1
Education on Hypoglycemia
The diabetes educator will instruct subjects on the signs and symptoms of hypoglycemia and on 
the use of supplemental treatment with oral glucose, if its use is necessary during the study.
Any time a subject experiences signs and symptoms of hypoglycemia, they will be instructed to 
measure their blood glucose level with the glucometer and record the value, along with their signs 
and symptoms in the subject diary. Hypoglycemic events must be recorded in the diary any time a 
subject experiences either of the following:

Signs and symptoms of hypoglycemia (regardless of blood glucose value by finger stick); and

Blood glucose value by finger stick ≤70 mg/dL (3.9 mmol/L) (regardless of symptoms).
For these hypoglycemic events, subjects must record the following information in the diary:

Date and time of hypoglycemic event;

Symptoms;

Blood glucose value by finger stick and time of finger stick.
Subjects who experience symptoms of hypoglycemia, such as hunger, irritation, sweating, etc., 
will be instructed to ingest fast-absorbing carbohydrates such as orange juice. If symptoms persist, 
or if the severity worsens, subjects will be instructed to immediately seek emergency medical 
attention.
9.1.17.2
Definitions of Hypoglycemia 
Subjects will be instructed to test their blood glucose, using their glucometer, on a daily basis and 
at any time they experience signs and symptoms of hypoglycemia, to confirm that it is a 
hypoglycemic episode, as defined below. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 55 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
The following definitions for severity apply:
Mild to Moderate Hypoglycemia Criteria:
Blood glucose <60 mg/dL (3.33 mmol/L) in the presence of symptoms, or
Blood glucose <50 mg/dL (2.78 mmol/L) with or without symptoms.
Severe Hypoglycemia Criterion:
Any episode requiring the assistance of another person to actively administer carbohydrate, 
glucagon, or other resuscitative actions, associated with a documented blood glucose 
<60 mg/dL (3.33 mmol/L) (unless the clinical situation makes obtaining a blood glucose 
difficult [eg, it involves coma or seizure]).
If a subject experiences a severe hypoglycemic event, the subject and/or his/her legal 
representative (ie, parent or legal guardian) should be instructed to notify the study site.
Information regarding any episodes of hypoglycemia should be documented in the eCRF.
Subjects will be discontinued from study medication if they experience severe and/or frequent 
hypoglycemia episodes, defined as ≥1 major or severe episode or recurrent non-major episodes in 
the event where the possibility of down-titration of contributing concomitant medication(s) (other 
than the double-blind study medication) and/or other contributing factors has been evaluated and 
corrected.
Non-major recurrent hypoglycemia is defined as any recurrent hypoglycemia episodes, as 
determined by the Investigator, not meeting the definition of severe hypoglycemia. It is the 
Investigator’s clinical assessment whether the subjects who experience hypoglycemia episodes 
should be discontinued from study medication. 
9.1.17.3
Criteria for Hyperglycemia Rescue 
Subjects will be required to maintain their background antidiabetic therapy, (if applicable) at the 
same dose, throughout the first 26 weeks of the Double-Blind Treatment Period. 
Subjects may be rescued either on the basis of their finger stick measurements or their HbA1c 
measurements as detailed below.
Subjects will be recommended to test their blood glucose levels via glucometer measurements at 
the time points recommended in Appendix H. If the subject’s glucose level (based on 
measurements at any of the specified time points, either fasting or non-fasting) is determined to 
have remained at >300 mg/dL (>16.6 mmol/L) for a period of more than 2 consecutive days, the 
subject should be instructed to contact the site as soon as possible. The subject should also be 
instructed to contact the site immediately if there are symptoms suggestive of decompensation 
such as vomiting, dehydration, lethargy, etc. Upon contact by the subject/subject’s parent or 
guardian, the investigator (or appropriately-trained study coordinator) should assess for signs of 
illness and, if appropriate and warranted, schedule a visit to the site for further assessment of the 
hyperglycemia as well as possible metabolic decompensation, including measurement of ketones.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 56 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Any subject who meets any of the following criteria, will be rescued with antihyperglycemic 
agents:

Subjects with HbA1c values <7.0% at the Baseline Visit will be rescued if their HbA1c 
remains at >8.0% confirmed by a second sample drawn at the next scheduled visit and 
analyzed by the central laboratory. 

Subjects with HbA1c values > 7.0% at the Baseline Visit will be rescued if their HbA1c values 
increase by >1.0% as determined by the central laboratory AND confirmed by a second sample 
drawn at the next scheduled visit and analyzed by the central laboratory.
Upon determining that a subject meets the predefined hyperglycemic criteria, rescue therapy can 
be added and modified as needed to achieve and maintain adequate glycemic control. Subjects 
who meet the criteria for rescue will continue double-blind study medication, and will continue 
participation in the study in order to be evaluated for safety up to 52 weeks.
Please Note: Subjects who require hyperglycemic rescue medications for reasons other than 
efficacy (ie, metabolic decompensation or change in clinical status [eg, DKA]) should be rescued 
at the Investigator’s discretion at any time point during the study. If glucose control worsens 
unacceptably in the judgment of the investigator and requires further intensive investigation and/or 
management, the subject may be scheduled for an early termination visit and withdrawn from the 
study. The circumstances surrounding the decompensation, along with the use and timing of all 
related medications will be documented in the eCRF.
Insulin (or increased doses of insulin) may be administered to treat acute metabolic 
decompensation, which is most commonly due to an intercurrent illness or non-compliance to 
medical treatment. However, if the supplemental use of insulin extends beyond 2 weeks, the 
subject will be considered to have met the hyperglycemic rescue criteria. 
9.1.18
Biomarkers of Bone Turnover
In order to evaluate the effects of alogliptin on bone turnover, biochemical biomarkers will be 
measured during the study. 
Serum concentrations of bone-specific alkaline phosphatase, which is associated with changes in 
bone formation, will be measured. 
Serum concentrations of CTX, which is associated with changes in bone resorption, will be 
measured.
Blood samples for the determination of biochemical biomarkers of bone turnover will be collected 
at the Baseline, Week 26, and the End-of-Treatment Visits. The samples will be collected at the 
same time the safety laboratory specimens (ie, chemistry and hematology) are drawn. 
9.2
Monitoring Subject Treatment Compliance
Subjects will be required to bring study medication containers/unused medications to the next site 
visit. If a subject is persistently noncompliant with the study medication (<70% or >125%) of the 
allocated medication for 2 consecutive visits after randomization), it may be appropriate to 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 57 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
withdraw the subject from the study after consultation with the Medical Monitor. All subjects 
should be reinstructed about the dosing requirement during study contacts. The authorized study 
personnel conducting the re-education must document the process in the subject source records.
9.3
Schedule of Observations and Procedures
The schedule for all study-related procedures for all evaluations is shown in Appendix A. 
Assessments should be completed at the designated visit/time point(s).
For sites not able to conduct onsite visits due to unavoidable circumstances (eg, a widespread 
disease outbreak such as the COVID-19 pandemic or natural disaster), acceptable alternatives to 
assess subject safety and overall clinical status may include, but are not limited to, visits as per 
protocol schedule conducted by delegated site staff speaking directly with the subject by telephone 
or other medium (eg, a computer-based video communication), or sites may send site staff to 
subjects to conduct study assessments, contingent upon local regulations.
The End-of-Treatment Visit should be performed in person. Alternative methods of data collection 
may be considered for this visit when it is not possible for the subject to come to the study site. 
Under such circumstances, a preferred alternative would be for site staff to go to the subject’s 
residence and conduct the protocol-specified procedures in that location. Assessments collected at 
subjects’ residence should comply with applicable local regulations. 
During contact with the subject by an alternative method, the study site physician or other 
qualified site staff should also, at minimum, conduct the following assessments within 
specified-visit window timeframes: AE assessments, documentation of concomitant medication, 
review of diaries and glucometer readings, drug accountability, and assessment of clinical 
symptoms. Other study assessments may be collected remotely as is feasible and may involve 
audio or video recording. Assessments that cannot be completed during the protocol-specified 
window will be considered missing data, and such departures will be recorded in the study records. 
Alternatively, sites may seek approval to extend the visit window up to 3 times the 
protocol-specified window (Appendix A) in order to conduct an onsite visit.
The interval between successive visits when clinical laboratory tests and vital sign measurements 
are performed may not be longer than 8 weeks.
9.3.1
Screening
Subjects will be screened within 14 days prior to randomization/Day 1 or the Pre-Randomization 
Stabilization Period (if applicable) as indicated in Appendix A. Subjects will be screened in 
accordance with predefined inclusion and exclusion criteria as described in Sections 7.1 and 7.2. 
See Section 9.1.15 for procedures for documenting Screening failures. Subjects must also meet all
criteria specified in Section 7.3 to proceed directly to the Day 1 visit (ie, not enter the 
Pre-Randomization Stabilization Period).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 58 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
9.3.2
Pre-Randomization Stabilization Period
Subjects will participate in the Pre-Randomization Stabilization Period until entry criteria and the 
objectives of the Pre-Randomization Stabilization Period have been met (Please refer to 
Section 6.2 for additional information). Subjects will return to the clinic for assessments at regular 
intervals during the Pre-Randomization Stabilization Period at the investigator’s discretion, but at 
least every 3 months, as shown in Appendix A.
Subjects will be informed how to recognize signs and symptoms of hypoglycemia and will 
measure their fasted blood glucose at least once a day. 
See Section 9.1.15 for procedures for documenting Pre-Randomization Stabilization failures.
9.3.3
Week -1
Subjects who participate in the Pre-Randomization Stabilization Period, regardless of the duration, 
will return to the clinic at Week -1 to confirm qualification for all inclusion and exclusion criteria 
specified in Section 7.3. 
9.3.4
Randomization
If the subject has satisfied all of the inclusion criteria (including the additional randomization 
criteria that must be met following Screening and/or completion of the Pre-Randomization 
Stabilization Period) and none of the exclusion criteria for randomization, the subject should be 
randomized using the IVRS/IWRS on Day 1, as described in Section 8.2. Subjects will be 
instructed on when to take the first dose of investigational drug as described in Section 6.1. The 
procedure for documenting Screening and/or Pre-Randomization Stabilization failures is provided 
in Section 9.1.15.
9.3.5
Double-Blind Treatment Period
In addition to receiving double-blind study medication, subjects will be required to maintain their 
background antidiabetic therapy, at the same dose, throughout the first 26 weeks of the 
Double-Blind Treatment Period.
Subjects who meet protocol-defined hyperglycemia rescue criteria (ie, for efficacy reasons) should 
be rescued with antidiabetic medications, at the Investigator’s discretion. (Refer to 
Section 9.1.17.3). Subjects who are administered hyperglycemic rescue therapy prior to Week 26 
will continue double-blind study medication, and will continue participation in the study in order 
to be evaluated for safety up to 52 weeks. 
Subjects who terminate double-blind study drug prematurely will continue to be followed at their 
regularly scheduled study visits time points for the 52-week duration of the study. Subjects will 
complete an End-of-Treatment Visit and Follow-Up Visit, 2 weeks after the last dose of study drug, 
and a Projected Week 52 Visit. 
Some subjects may require temporary suspension of study medication and the use of insulin (or 
increased doses of insulin). If the acute event resolves and insulin is withdrawn or returned to the 
maintenance level within 2 weeks, the subject can continue in the study. If the supplemental use of 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 59 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
insulin extends beyond 2 weeks, the subject will be considered to have met the hyperglycemic 
rescue criteria. 
A schedule of assessments is listed in Appendix A.
9.3.6
Unscheduled Visit (As Applicable)
Subjects may return to the study center for unscheduled visits as needed. Unscheduled study visits 
can be performed when the subject has a study related issue in between regular study visits or as 
needed to ensure subject safety. 
The following procedures should be performed during this visit:

Concomitant medications review.

Other protocol procedures, including collection of blood and urine samples, as deemed 
appropriate by the Investigator. 

AE assessment.

Blood glucose and HbA1c concentration laboratory samples will be collected as directed in 
section 9.1.17.
9.3.7
End-of-Treatment Visit
The End-of-Treatment Visit will be performed at Week 52 or after the last dose of study drug.
For all subjects receiving study medication, the investigator must complete the End-of-Treatment 
eCRF page. A schedule of assessments performed at the end of treatment visit is listed in 
Appendix A.
9.3.8
Follow-up Visit
A follow-up visit will be conducted via telephone with the subject 2 weeks after the 
End-of-Treatment Visit. A schedule of assessments performed at the follow-up visit is listed in 
Appendix A.
9.3.9
Projected Week 52 Visit
Subjects who prematurely discontinue study drug and continue telephone (or other 
communication) contact will follow the protocol-specified visit schedule for the remainder of the 
52-week treatment period. The Projected Week 52 Visit should be conducted at the clinic, if at all 
possible. 
9.3.10
Post Study Care
The study medication will not be provided by the sponsor upon completion of the subject’s 
participation in the study. The subject should be returned to the care of a physician and standard 
therapies should be initiated, as required. Subjects will be offered clinical follow-up examinations 
as considered appropriate per the treating physician.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 60 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
9.4
Biological Sample Retention and Destruction
As of the date of this amendment, a sufficient number of samples have been collected and no more 
are needed; therefore, pharmacogenomic samples no longer need be taken.
Under previous versions of this protocol, specimens for genome/gene analysis were to be collected 
as described in Section 9.1.12. After extraction and purification, the genetic material was to be 
preserved and retained for up to, but not longer than, 15 years or as required by applicable law. The 
sponsor has put into place a system to protect the subjects’ personal information to ensure optimal 
confidentiality and defined standard processes for sample and data collection, storage, analysis, 
and destruction.
The samples were to be sent to a central laboratory that processes the blood sample and serves as a 
secure storage facility. The samples were to be stored initially at PPD Laboratory and then sent to 
Covance Laboratories for long-term storage. The sponsor and researchers working with the 
sponsor will have access to the samples collected and any test results. All samples collected during 
the study will be stored securely with limited access and the sponsor will require anyone who 
works with the samples to agree to hold the research information and any results in confidence.
The sample was to be labeled with a unique sample identifier similar to labeling in the main study 
but using a code that is different from the code attached to the health information and other clinical 
test results collected in the study. The sample and data are linked to personal health information 
with code numbers. This link means that the subject may be identified but only indirectly. The 
code numbers will be kept secure by or on behalf of the sponsor.
Subjects who consented and provided a pharmacogenomic sample for DNA and/or RNA analysis 
could withdraw their consent and request disposal of a stored sample at any time. The sponsor 
should be notified of consent withdrawal.
10.0
PRETREATMENT EVENTS AND ADVERSE EVENTS
10.1
Definitions
10.1.1
PTEs
A PTE is defined as any untoward medical occurrence in a clinical investigation subject who has 
signed informed consent to participate in a study but prior to administration of any study 
medication; it does not necessarily have to have a causal relationship with study participation.
10.1.2
AEs
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a drug; it does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a drug whether or 
not it is considered related to the drug.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 61 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
10.1.3
Additional Points to Consider for PTEs and AEs
An untoward finding generally may:

Indicate a new diagnosis or unexpected worsening of a pre-existing condition. (Intermittent 
events for pre-existing conditions underlying disease should not be considered PTEs or AEs.)

Necessitate therapeutic intervention.

Require an invasive diagnostic procedure.

Require discontinuation or a change in dose of study medication or a concomitant medication.

Be considered unfavorable by the Investigator for any reason.

PTEs/AEs caused by a study procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:

Each event should be recorded to represent a single diagnosis. Accompanying signs (including 
abnormal laboratory values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately as a PTE(s) or as an AE(s).
Laboratory values and ECG findings:

Changes in laboratory values or ECG parameters are only considered to be PTEs or AEs if they 
are judged to be clinically significant (ie, if some action or intervention is required or if the 
Investigator judges the change to be beyond the range of normal physiologic fluctuation). A 
laboratory re-test and/or continued monitoring of an abnormal value are not considered an 
intervention. In addition, repeated or additional noninvasive testing for verification, evaluation 
or monitoring of an abnormality is not considered an intervention.

If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be 
reported appropriately as a PTE or as an AE.
Pre-existing conditions:

Pre-existing conditions (present at the time of signing of informed consent) are considered
concurrent medical conditions and should NOT be recorded as PTEs or AEs. Baseline 
evaluations (eg, laboratory tests, ECG, X-rays etc.) should NOT be recorded as PTEs unless 
related to study procedures. However, if the subject experiences a worsening or complication 
of such a concurrent condition, the worsening or complication should be recorded 
appropriately as a PTE (worsening or complication occurs before start of study medication) or 
an AE (worsening or complication occurs after start of study medication). Investigators should 
ensure that the event term recorded captures the change in the condition (eg, “worsening 
of…”).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 62 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020

If a subject has a pre-existing episodic condition (eg, asthma, epilepsy) any occurrence of an 
episode should only be captured as a PTE/AE if the episodes become more frequent, serious, or 
severe in nature, that is, Investigators should ensure that the AE term recorded captures the 
change in the condition from Baseline (eg “worsening of…”).

If a subject has a degenerative concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condition should only be captured as a PTE/AE if occurring to a greater 
extent to that which would be expected. Investigators should ensure that the AE term recorded 
captures the change in the condition (eg, “worsening of…”).
Worsening of PTEs or AEs:

If the subject experiences a worsening or complication of a PTE after starting administration of 
the study medication, the worsening or complication should be recorded appropriately as an 
AE. Investigators should ensure that the AE term recorded captures the change in the condition 
(eg, “worsening of…”).

If the subject experiences a worsening or complication of an AE after any change in study 
medication, the worsening or complication should be recorded as a new AE. Investigators 
should ensure that the AE term recorded captures the change in the condition (eg, “worsening 
of…”).
Changes in severity of AEs /Serious PTEs:

If the subject experiences changes in severity of an AE/serious PTE, the event should be 
captured once with the maximum severity recorded.
Preplanned surgeries or procedures:

Preplanned procedures (surgeries or therapies) that were scheduled prior to signing of 
informed consent are not considered PTEs or AEs. However, if a preplanned procedure is 
performed early (eg, as an emergency) due to a worsening of the pre-existing condition, the 
worsening of the condition should be captured appropriately as a PTE or an AE. Complications 
resulting from any planned surgery should be reported as AEs.
Elective surgeries or procedures:

Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as PTEs or AEs, but should be documented in the subject’s source 
documents. Complications resulting from an elective surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):

Insufficient clinical response, efficacy, or pharmacologic action should NOT be recorded as an 
AE. The Investigator must make the distinction between exacerbation of pre-existing illness 
and lack of therapeutic efficacy.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 63 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Overdose:

Cases of overdose with any medication without manifested side effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any 
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
10.1.4
SAEs
An SAE is defined as any untoward medical occurrence that at any dose:
1. Results in DEATH.
2. Is LIFE THREATENING.

The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were more severe.
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5. Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:

May require intervention to prevent items 1 through 5 above.

May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.

Includes any event or synonym described in the Takeda Medically Significant AE List 
(Table 10.a).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 64 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Table 10.a
Takeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory distress 
syndrome
Hepatic necrosis
Torsade de pointes / ventricular fibrillation / 
ventricular tachycardia
Acute liver failure
Anaphylactic shock
Malignant hypertension
Acute renal failure
Convulsive seizure
Pulmonary hypertension
Agranulocytosis
Pulmonary fibrosis 
Aplastic anemia
Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens-Johnson 
syndrome
Confirmed or suspected transmission of infectious agent by 
a medicinal product
Neuroleptic malignant syndrome/malignant 
hyperthermia
COVID-19-related-disease
Spontaneous abortion/stillbirth and fetal death
COVID-19 pneumonia
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and followed up in the same manner (see Sections 10.2.2 and 10.3).
10.1.5
Special Interest AEs 
A special interest AE (serious or non-serious) is one of scientific and medical concern specific to 
the compound or program, for which ongoing monitoring and rapid communication by the 
Investigator to Takeda may be appropriate. Such events may require further investigation in order 
to characterize and understand them and would be described in protocols and instructions provided 
for Investigators as to how and when they should be reported to Takeda.
The site is required to actively obtain additional clinical information on the following adverse 
event of special interests (AESIs): Serious hepatic abnormalities, pancreatitis, infections 
(including urinary tract infections), and severe hypersensitivity reactions including angioedema, 
anaphylaxis, and Stevens-Johnson Syndrome. 
Targeted follow-up forms have been developed to further guide the collection of data of AESIs and 
the forms need to be submitted to the sponsor as part of the AEs source documents.
10.1.6
Severity of PTEs and AEs
The different categories of intensity (severity) are characterized as follows:
Mild:
The event is transient and easily tolerated by the subject.
Moderate:
The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe:
The event causes considerable interference with the subject’s usual activities.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 65 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
10.1.7
Causality of AEs
The relationship of each AE to study medication(s) will be assessed using the following 
categories:
Related:
An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug cannot be 
ruled out, although factors other than the drug, such as underlying diseases, complications, 
concomitant drugs, and concurrent treatments, may also be responsible.
Not Related:
An AE that does not follow a reasonable temporal sequence from administration of a drug and/or 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant drugs, and concurrent treatments.
10.1.8
Relationship to Study Procedures
Relationship (causality) to study procedures should be determined for all PTEs and AEs.
The relationship should be assessed as related if the Investigator considers that there is reasonable 
possibility that an event is due to a study procedure. Otherwise, the relationship should be assessed 
as not related. 
10.1.9
Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by the subject 
and/or Investigator.
10.1.10
Stop Date 
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.1.11
Frequency 
Episodic AEs/PTE (eg, vomiting) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.12
Action Concerning Study Medication 

Drug withdrawn – a study medication is stopped due to the particular AE.

Dose not changed – the particular AE did not require stopping a study medication.

Unknown – only to be used if it has not been possible to determine what action has been taken.

Not Applicable – a study medication was stopped for a reason other than the particular AE 
eg, the study has been terminated, the subject died, dosing with study medication was already 
stopped before the onset of the AE.

Dose interrupted – the dose was interrupted due to the particular AE.
Some subjects may require temporary suspension of study medication and the use of insulin. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 66 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
10.1.13
Outcome

Recovered/resolved – Subject returned to first assessment status with respect to the AE/PTE.

Recovering/resolving – the intensity is lowered by one or more stages; the diagnosis or 
signs/symptoms has almost disappeared; the abnormal laboratory value improved, but has not 
returned to the normal range or to Baseline; the subject died from a cause other than the 
particular AE/PTE with the condition remaining “recovering/resolving.”

Not recovered/not resolved – there is no change in the diagnosis, signs or symptoms; the 
intensity of the diagnosis, signs/ symptoms or laboratory value on the last day of the observed 
study period has got worse than when it started; is an irreversible congenital anomaly; the 
subject died from another cause with the particular AE/PTE state remaining “Not 
recovered/not resolved”.

Resolved with sequelae – the subject recovered from an acute AE/PTE but was left with 
permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).

Fatal – the AEs/PTEs which are considered as the cause of death. 

Unknown – the course of the AE/PTE cannot be followed up due to hospital change or 
residence change at the end of the subject’s participation in the study.
10.2
Procedures
10.2.1
Collection and Reporting of AEs
10.2.1.1
PTE and AE Collection Period
Collection of PTEs will commence from the time the subject signs the informed consent to 
participate in the study and continue until the subject is first administered study medication 
(Day 1) or until Screen/Stabilization failure. For subjects who discontinue prior to study 
medication administration, PTEs are collected until the subject discontinues study participation.
Collection of AEs will commence from the time that the subject is first administered study 
medication (Day 1). Routine collection of AEs will continue until the Follow-up Visit.
10.2.1.2
PTE and AE Reporting
At each study visit, the Investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing a 
serious PTE must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to Baseline or there is a satisfactory explanation for the change. 
Non-serious PTEs, related or unrelated to the study procedure, need not be followed-up for the 
purposes of the protocol.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 67 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
All subjects experiencing AEs, whether considered associated with the use of the study medication 
or not, must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to Baseline or until there is a satisfactory explanation for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the eCRF, 
whether or not the Investigator concludes that the event is related to the drug treatment. The 
following information will be documented for each event:
1. Event term.
2. Start and stop date.
3. Severity.
4. Investigator’s opinion of the causal relationship between the event and administration of study 
medication(s) (related or not related) (not completed for PTEs).
5. Investigator’s opinion of the causal relationship to study procedure(s), including the details of 
the suspected procedure.
6. Action concerning study medication (not applicable for PTEs).
7. Outcome of event.
8. Seriousness.
10.2.1.3
Special Interest AE Reporting 
If a special interest AE occurs during the treatment period or the follow-up period, and is 
considered to be clinically significant based on the criteria below, it should be reported to the 
sponsor (described in the separate contact information list) immediately or within 1 business day 
of first onset or subject’s notification of the event. A special interest AE name form or an SAE 
form should be completed, signed, and/or sealed by the PI, and reported to appropriate personnel 
in the separate contact information list within 10 business days.

Laboratory value threshold if applicable.

Premature termination for the special interest AE, if applicable.

Any other specific criteria.
The special interest AEs have to be recorded as AEs in the eCRF. An evaluation form along with 
all other required documentation must be submitted to the sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 68 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
10.2.2
Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A Takeda SAE form must be completed, in English and signed by the Investigator immediately or 
within 24 hours of first onset or notification of the event. The information should be completed as 
fully as possible but contain, at a minimum:

A short description of the event and the reason why the event is categorized as serious.

Subject identification number.

Investigator’s name.

Name of the study medication(s).

Causality assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Section 1.1.
Any SAE spontaneously reported to the Investigator following the AE collection period should be 
reported to the sponsor if considered related to study participation.
Reporting of Serious PTEs will follow the procedure described for SAEs.
10.2.3
Reporting of Abnormal Liver Function Tests 
If a subject is noted to have elevated ALT or AST levels >3 ×ULN please see Section 7.8 for 
instructions for reporting and managing the subject.
10.3
Follow-up of SAEs
If information not available at the time of the first report becomes available at a later date, the 
Investigator should complete a follow-up SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be followed up until resolution or permanent outcome of the event. The timelines 
and procedure for follow-up reports are the same as those for the initial report.
10.3.1
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, including the EMA, 
Investigators and IRBs, as applicable, in accordance with national regulations in the countries 
where the study is conducted. Relative to the first awareness of the event by/or further provision to 
the sponsor or sponsor’s designee, SUSARs will be submitted to the regulatory authorities as 
expedited report within 7 days for fatal and life-threatening events and 15 days for other serious 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 69 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
events, unless otherwise required by national regulations. The sponsor will also prepare an 
expedited report for other safety issues where these might materially alter the current benefit-risk 
assessment of an investigational medicinal product or that would be sufficient to consider changes 
in the investigational medicinal products administration or in the overall conduct of the study. The 
investigational site also will forward a copy of all expedited reports to his or her IRB or IEC in 
accordance with national regulations.
11.0
STUDY-SPECIFIC COMMITTEES
11.1
Independent Data Monitoring Committee
An independent DMC will be established to periodically review study safety data. Details of the 
DMC membership and responsibilities will be detailed in a DMC Charter. The outcome of data 
reviews by the DMC will be communicated to the local IRBs/ECs, where appropriate, as per local 
regulations.
12.0
DATA HANDLING AND RECORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, PTEs, medical history, and concurrent conditions will be coded using the MedDRA (Medical 
Dictionary for Regulatory Activities). Drugs will be coded using the WHODRUG (World Health 
Organization Drug Dictionary).
12.1
CRFs (Electronic)
Completed eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the information collected in the performance of this study to the sponsor and regulatory 
authorities. eCRFs must be completed in English. Data are transcribed directly onto eCRFs.
After completion of the entry process, computer logic checks will be run to identify items such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Corrections are recorded in an audit trail that captures the old information, the new information, ID 
of the person making the correction, the date the correction was made, and the reason for change.
The PI must review the eCRFs for completeness and accuracy and must sign and date the 
appropriate eCRFs as indicated. Furthermore, the Investigator must retain full responsibility for 
the accuracy and authenticity of all data entered onto the eCRF.
The eCRFs will be reviewed for completeness and acceptability at the study site during periodic 
visits by study monitors. The sponsor or its designee will be permitted to review the subject’s 
medical and hospital records pertinent to the study to ensure accuracy of the eCRFs. The 
completed eCRFs are the sole property of the sponsor and should not be made available in any 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 70 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
form to third parties, except for authorized representatives of appropriate governmental health or 
regulatory authorities, without written permission of the sponsor.
12.2
Record Retention
The Investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated ICFs, subject authorization forms regarding the use of 
personal health information (if separate from the ICFs), electronic copy of eCRFs, including the 
audit trail, and detailed records of drug disposition to enable evaluations or audits from regulatory 
authorities, the sponsor or its designees. Any source documentation printed on degradable thermal 
sensitive paper should be photocopied by the site and filed with the original in the subject’s chart 
to ensure long term legibility. Furthermore, International Conference on Harmonisation (ICH) E6 
Section 4.9.5 requires the Investigator to retain essential documents specified in ICH E6 
(Section 8) until at least 2 years after the last approval of a marketing application for a specified 
drug indication being investigated or, if an application is not approved, until at least 2 years after 
the investigation is discontinued and regulatory authorities are notified. In addition, ICH E6 
Section 4.9.5 states that the study records should be retained until an amount of time specified by 
applicable regulatory requirements or for a time specified in the Clinical Study Site Agreement 
between the Investigator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
Investigator should contact and receive written approval from the sponsor before disposing of any 
such documents.
13.0
STATISTICAL METHODS
13.1
Statistical and Analytical Plans
A SAP will be prepared and finalized prior to unblinding of subjects’ treatment assignments. This 
document will provide further details regarding the definitions of analysis variables and analysis 
methodology to address all study objectives. The SAP will address the characterization of study 
subjects potentially impacted by COVID-19 and supportive analyses to assist in the interpretation 
of the overall study results.
A blinded data review will be conducted prior to unblinding of subjects’ treatment assignments. 
This review will assess the accuracy and completeness of the study database, subject evaluability, 
and appropriateness of the planned statistical methods.
13.1.1
Analysis Sets
The safety set will include all subjects who took at least 1 dose of study medication. In safety 
summaries, subjects will be analyzed according to the treatment most often received.
The full analysis set (FAS) will include all randomized subjects in the safety set. For a particular 
variable, the FAS analysis will consist of all subjects who have a baseline assessment and at least 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 71 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
1 postbaseline assessment for the variable. In FAS efficacy summaries, subjects will be analyzed 
as randomized. The per protocol set (PPS) will include all FAS subjects who had no major 
protocol violations. Major protocol violations will be defined prior to database lock.
13.1.2
Analysis of Demographics and Other Baseline Characteristics
Subject disposition will be summarized (frequency, percentage) by treatment group for each 
subject sample, incidence of discontinuation, reason for discontinuation, and incidence of rescue. 
The summary of all randomized subjects will include a breakdown by the stratification factors for 
schedule.
Baseline and demographic information will be listed and summarized by treatment group and 
overall. For continuous variables, the summary will consist of descriptive statistics (number of 
subjects, mean, standard deviation, minimum, median, and maximum). For categorical variables, 
the summary will consist of number and percentage of subjects in each category. 
13.1.3
Efficacy Analysis
The primary efficacy variable will be the change from Baseline in HbA1c at Week 26. The primary 
analysis set will be the FAS. Supportive analyses will be conducted with the PPS. A sensitivity 
analysis that excludes subjects affected by COVID-19 will be performed on the primary endpoint. 
The definition of “affected by COVID-19” will be provided in the SAP.
The primary analysis will be conducted using a contrast at Week 26 derived from a mixed model 
for repeated measures (MMRM) with change from Baseline in HbA1c as the response variable, 
treatment, visit, and visit-by-treatment interaction as fixed categorical effects, and baseline HbA1c 
and visit-by-baseline HbA1c interaction as continuous covariates. An unstructured 
variance-covariance matrix will be used; parameter estimates will be calculated using restricted 
maximum-likelihood estimation. Degrees of freedom will be estimated using the Kenward-Roger 
approximation. Data collected following discontinuation of double-blind study medication or 
hyperglycemic rescue will be censored. 
The secondary efficacy variable will be analyzed using additional contrasts at Weeks 12, 18, 39, 
and 52 derived from the primary analysis model. Continuous exploratory efficacy variables will be 
analyzed using models similar to the primary analysis model. Categorical variables and time to 
hyperglycemic rescue will be analyzed using logistic regression models and a Cox regression 
model, respectively. An appropriate normalizing transformation (eg, natural log) will be applied in 
the event that an exploratory variable is not normally distributed. 
If a subject is diagnosed with MODY during the study, a description of the results will be provided 
separately for each individual subject with MODY, and additional analyses will be performed that 
exclude MODY subjects.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Te
roup for
oup fo
ininciden
cide
stratific
ratific
zed by t
ed by 
escript
scripti
maximum
maximu
bjects in
bjects in
from Ba
rom 
yses wil
es wi
COVID
COV
19” will
19” wi
cted usin
ed us
with ch
with c
eatm
atmen
e
c intera
inter
trix will
ix wi
estimat
estim
ta colle
a coll
rescue w
rescue
ary
ary effic
ef
y
erived f
erived
zed usin
zed us
perglyce
ergly
model
del
th
the e
e
s of Use
I
Terms of


Alogliptin
Study No. SYR-322_309
Page 72 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
13.1.5
Safety Analysis
Safety parameters will be summarized using descriptive statistics or frequency counts as 
appropriate. Separate summaries using (1) data collected prior to discontinuation of double-blind 
study medication or hyperglycemic rescue (if applicable) and (2) all data will be conducted. 
13.2
Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
13.3
Determination of Sample Size
The primary efficacy variable will be the change from Baseline in HbA1c at Week 26. The primary 
analysis set will be the FAS. For this variable and set, a total of 75 randomized subjects per 
treatment group will ensure at least 90% power to detect a difference in mean change from 
Baseline in HbA1c at Week 26 between alogliptin 25 mg QD and placebo assuming a treatment 
effect of 0.5%, a SD of 0.9%, and a 2-sided false-rejection rate of 5%. 
14.0
QUALITY CONTROL AND QUALITY ASSURANCE
14.1
Study-Site Monitoring Visits
Monitoring visits to the study site will be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The Investigator and institution guarantee access to source documents by the sponsor or its 
designee contract research organization and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized), including but not limited to the Investigator’s Binder, 
study medication, subject medical records, informed consent documentation, documentation of 
subject authorization to use personal health information (if separate from the ICFs), and review of 
eCRFs and associated source documents. It is important that the Investigator and other study
personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
14.2
Protocol Deviations
The Investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unavoidable circumstances arise (eg, a 
widespread disease outbreak such as the COVID-19 pandemic or natural disaster) that will require 
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable T
counts a
counts
tion of 
n o
will be 
ill be 
Baseline
aselin
et, a tota
 a to
o de
detect
tec
iptptin 25
in 25
false
alse-r
D QUAL
QUA
g Visits
Visit
dy sisi
y
te w
te 
i
e fo
follo
llow
. Sourc
Sour
d institu
d insti
t researc
t resea
of the stu
f the s
s blindi
blind
medicat
edica i
ect auth
ect aut
CRFs a
RFs
person
pers
pr
p
Use
Terms of Us


Alogliptin
Study No. SYR-322_309
Page 73 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
deviation from protocol-specified procedures, the Investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exemptions (a prospectively approved deviation) from the inclusion or exclusion criteria.
The site should document all protocol deviations in the subject’s source documents. In the event of 
a significant deviation, the site should notify the sponsor or its designee (and IRB or EC, as 
required). Significant deviations include, but are not limited to, those that involve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protocol Deviation Form/eCRF should be completed by the site and electronically 
signed by the sponsor or designee for any significant deviation from the protocol.
14.3
Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assurance audits by the sponsor or designees. In this 
circumstance, the sponsor-designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In 
addition, there is the possibility that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdom Medicines and Healthcare 
products Regulatory Agency, the Pharmaceuticals and Medical Devices Agency of Japan). If the 
study site is contacted for an inspection by a regulatory body, the sponsor should be notified 
immediately. The Investigator and institution guarantee access for quality assurance auditors to all 
study documents as described in Section 14.1.
15.0
ETHICAL ASPECTS OF THE STUDY
This study will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of Helsinki, 
and the ICH Harmonised Tripartite Guideline for GCP. Each Investigator will conduct the study 
according to applicable local or regional regulatory requirements and align his or her conduct in 
accordance with the “Responsibilities of the Investigator” that are listed in Appendix B. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requirements for informed consent and Investigator responsibilities.
15.1
IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable federal/local requirements of each 
participating region. The sponsor or designee will require documentation noting all names and 
titles of members who make up the respective IRB or IEC. If any member of the IRB or IEC has 
direct participation in this study, written notification regarding his or her abstinence from voting 
must also be obtained. Those Americas sites unwilling to provide names and titles of all members 
due to privacy and conflict of interest concerns should instead provide a Federal Wide Assurance 
Number or comparable number assigned by the Department of Health and Human Services.
The sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Investigator’s Brochure, a copy of 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 74 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
the ICF, and, if applicable, subject recruitment materials and/or advertisements and other 
documents required by all applicable laws and regulations, must be submitted to a central or local 
IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and subject 
informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study (ie, before shipment of the sponsor-supplied drug or study specific 
screening activity). The IRB or IEC approval must refer to the study by exact protocol title, 
number, and version date; identify versions of other documents (eg, ICF) reviewed; and state the 
approval date. The sponsor or designee will notify the site once the sponsor has confirmed the 
adequacy of site regulatory documentation and, when applicable, the sponsor has received 
permission from competent authority to begin the study. Until the site receives notification no 
protocol activities, including screening may occur.
Sites must adhere to all requirements stipulated by their respective IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruitment 
materials intended for viewing by subjects, local safety reporting requirements, reports, and 
updates regarding the ongoing review of the study at intervals specified by the respective IRB or 
IEC, and submission of the Investigator’s final status report to IRB or IEC. All IRB and IEC 
approvals and relevant documentation for these items must be provided to the sponsor or its 
designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
15.2
Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, subject authorization form (if applicable), and subject 
information sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the subject’s personal and personal health information for purposes of conducting 
the study. The ICF and the subject information sheet (if applicable) further explain the nature of 
the study, its objectives, and potential risks and benefits, as well as the date informed consent is 
given. The ICF will detail the requirements of the participant and the fact that he or she is free to 
withdraw at any time without giving a reason and without prejudice to his or her further medical 
care.
The Investigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and if applicable, the subject authorization form. The ICF, subject authorization form (if 
applicable), and subject information sheet (if applicable) must be approved by both the IRB or IEC 
and the sponsor prior to use.
The ICF, subject authorization form (if applicable), and subject information sheet (if applicable) 
must be written in a language fully comprehensible to the prospective subject. It is the 
responsibility of the Investigator to explain the detailed elements of the ICF, subject authorization 
form (if applicable), and subject information sheet (if applicable) to the subject. Information 
should be given in both oral and written form whenever possible and in the manner deemed 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 75 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
appropriate by the IRB or IEC. In the event the subject is not capable of rendering adequate written 
informed consent, then the subject’s legally acceptable representative may provide such consent 
for the subject in accordance with applicable laws and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will participate in 
the study, then the ICF and subject authorization form (if applicable) must be signed and dated by 
the subject, or the subject’s legally acceptable representative, at the time of consent and prior to the 
subject entering into the study. The subject or the subject’s legally acceptable representative 
should be instructed to sign using their legal names, not nicknames, using blue or black ballpoint 
ink. The Investigator must also sign and date the ICF and subject authorization (if applicable) at 
the time of consent and prior to subject entering into the study; however, the sponsor may allow a 
designee of the Investigator to sign to the extent permitted by applicable law.
Once signed, the original ICF, subject authorization form (if applicable), and subject information 
sheet (if applicable) will be stored in the Investigator’s site file. The Investigator must document 
the date the subject signs the informed consent in the subject’s medical record. Copies of the 
signed ICF, the signed subject authorization form (if applicable), and subject information sheet (if 
applicable) shall be given to the subject.
All revised ICF must be reviewed and signed by relevant subjects or the relevant subject’s legally 
acceptable representative in the same manner as the original informed consent. The date the 
revised consent was obtained should be recorded in the subject’s medical record, and the subject 
should receive a copy of the revised ICF.
15.3
Subject Confidentiality
The sponsor and designees affirm and uphold the principle of the subject’s right to protection
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 
the sponsor’s clinical study database or documentation via a unique ID number. As permitted by 
all applicable laws and regulations, limited subject attributes, such as sex, age, or date of birth, and 
subject initials may be used to verify the subject and accuracy of the subject’s unique ID number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the sponsor 
requires the Investigator to permit its monitor or designee’s monitor, representatives from any 
regulatory authority (eg, FDA, Medicines and Healthcare products Regulatory Agency, 
Pharmaceuticals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
documents), including, but not limited to, laboratory test result reports, ECG reports, admission 
and discharge summaries for hospital admissions occurring during a subject’s study participation, 
and autopsy reports. Access to a subject’s original medical records requires the specific 
authorization of the subject as part of the informed consent process (see Section 15.2).
Copies of any subject source documents that are provided to the sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s eCRF).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 76 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
15.4
Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1
Publication and Disclosure
The Investigator is obliged to provide the sponsor with complete test results and all data derived by 
the Investigator from the study. During and after the study, only the sponsor may make study 
information available to other study Investigators or to regulatory agencies, except as required by 
law or regulation. Except as otherwise allowable in the clinical study site agreement, any public 
disclosure (including publicly accessible websites) related to the protocol or study results, other 
than study recruitment materials and/or advertisements, is the sole responsibility of the sponsor.
The sponsor may publish any data and information from the study (including data and information 
generated by the Investigator) without the consent of the Investigator. Manuscript authorship for 
any peer-reviewed publication will appropriately reflect contributions to the production and 
review of the document. All publications and presentations must be prepared in accordance with 
this section and the Clinical Study Site Agreement. In the event of any discrepancy between the 
protocol and the Clinical Study Site Agreement, the Clinical Study Site Agreement will prevail.
15.4.2
Clinical Trial Registration
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulations and guidance, Takeda will, at a minimum register 
interventional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov or other 
publicly accessible websites before start of study, as defined in Takeda Policy/Standard. Takeda 
contact information, along with Investigator’s city, state (for Americas Investigators), country, and 
recruiting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in locating trial sites closest to their homes by 
providing the Investigator name, address, and phone number to the callers requesting trial 
information. Once subjects receive Investigator contact information, they may call the site 
requesting enrollment into the trial. The investigative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks additional 
questions beyond the topic of trial enrollment, they should be referred to the sponsor.
Any Investigator who objects to Takeda providing this information to callers must provide Takeda 
with a written notice requesting that their information not be listed on the registry site. 
15.4.3
Clinical Trial Results Disclosure
Takeda will post the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulations.
15.5
Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the site 
where the subject is participating. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study insurance against the risk of injury to clinical study subjects. 
Refer to the Clinical Study Site Agreement regarding the sponsor’s policy on subject 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 77 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
compensation and treatment for injury. If the Investigator has questions regarding this policy, he or 
she should contact the sponsor or sponsor’s designee.
16.0
REFERENCES
1. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the 
young: the evolving epidemic: the international diabetes federation consensus workshop. 
Diabetes Care 2004;27(7):1798-811.
2. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. 
Diabetes Care 2003;26 Suppl 1:S33-50.
3. Barroso I. Genetics of Type 2 diabetes. Diabet Med 2005;22(5):517-35.
4. Blüher S, Kiess W, Böttner A, Raile K, Kapellen T, Blüher M. Type 2 diabetes mellitus in 
children and adolescents: the European perspective. In: Kiess W, Marcus C, Wabitsch M, 
editors. Obesity in Childhood and Adolescence. Basel, Switzerland: Karger; 2004, p. 170-80.
5. Drucker DJ. Incretin-based therapies: a clinical need filled by unique metabolic effects. 
Diabetes Educ 2006;32 Suppl 2:65S-71S.
6. Gungor N, Arslanian S. Pathophysiology of type 2 diabetes mellitus in children and 
adolescents: treatment implications. erratum in: Treat Endocrinol. 2003;2(2):143. Treat 
Endocrinol 2002;1(6):359-71.
7. Gungor N, Hannon T, Libman I, Bacha F, Arslanian S. Type 2 diabetes mellitus in youth: the 
complete picture to date. Pediatr Clin North Am 2005;52(6):1579-609.
8. Rosenbloom AL. Increasing incidence of type 2 diabetes in children and adolescents: 
treatment considerations. Paediatr Drugs 2002;4(4):209-21.
9. Vivian EM. Type 2 diabetes in children and adolescents--the next epidemic? Curr Med Res 
Opin 2006;22(2):297-306.
10. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 
2000;23(3):381-9.
11. Gahagan S, Silverstein J. Prevention and treatment of type 2 diabetes mellitus in children, with 
special emphasis on American Indian and Alaska Native children. American Academy of 
Pediatrics Committee on Native American Child Health. Pediatrics 2003;112(4):e328.
12. Gaylor AS, Condren ME. Type 2 diabetes mellitus in the pediatric population. 
Pharmacotherapy 2004;24(7):871-8.
13. Jacobson-Dickman E, Levitsky L. Oral agents in managing diabetes mellitus in children and 
adolescents. Pediatr Clin North Am 2005;52(6):1689-703.
14. Von Karla V, Hewett ML. Type 2 diabetes in children and adolescents: screening, diagnosis, 
and management. JAAPA 2007;20(3):51-4.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 78 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
15. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. Beta-cell 
function across the spectrum of glucose tolerance in obese youth. Diabetes 
2005;54(6):1735-43.
16. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of 
type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 
2014;311(17):1778-86.
17. Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, et al. Projections of 
type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: 
dynamic modeling of incidence, mortality, and population growth. Diabetes Care 
2012;35(12):2515-20.
18. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, et al. Type 2 
diabetes among North American children and adolescents: an epidemiologic review and a 
public health perspective. J Pediatr 2000;136(5):664-72.
19. Miller JL, Silverstein JH. The treatment of type 2 diabetes mellitus in youth : which therapies? 
Treat Endocrinol 2006;5(4):201-10.
20. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and 
adolescents. J Pediatr 2005;146(5):693-700.
21. Coburn MC, Hixson DC, Reichner JS. In vitro immune responsiveness of rats lacking active 
dipeptidylpeptidase IV. Cell Immunol 1994;158(2):269-80.
22. Copeland KY, Becker D, Cottschalk M, Hale D. Type 2 diabetes in children and adolescents: 
risk factors, diagnosis, and treatment. Pediatr Diabeties 2005;23(4):181-5.
23. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3(3):153-65.
24. Hall CA, Jacques PF. Weighing in on the issues of type 2 diabetes in children: a review. Pediatr 
Phys Ther 2007;19(3):211-6.
25. Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics 
2005;116(2):473-80.
26. International Diabetes Federation. Diabetes Atlas [book online]. Gan D, editor. 3rd ed. 
Brussels, Belgium: IDF; Copyright 2006. Updated 2008. http://www.eatlas.idf.org/. 
27. Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. 
Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and 
adolescents. Pediatrics 2013;131(2):364-82.
28. International Diabetes Federation. Global IDF/ISPAD Guideline for Diabetes in Childhood 
and Adolescence [book online]. Copyright 2011. Accessed 23 June 2014. 
http://www.idf.org/sites/default/files/Diabetes-in-Childhood-and-Adolescence-Guidelines.pd
f. 
29. Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. A clinical trial to maintain 
glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366(24):2247-56.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 79 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
30. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 
2004;27(5):1218-24.
31. Kelsey MM, Geffner ME, Guandalini C, Pyle L, Tamborlane WV, Zeitler PS, et al. 
Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the 
TODAY study. Pediatr Diabetes 2016;17(3):212-21.
32. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin 
J Am Soc Nephrol 2009;4(11):1832-43.
33. Smart CE, Annan F, Bruno LP, Higgins LA, Acerini CL, International Society for P, et al. 
ISPAD Clinical Practice Consensus Guidelines 2014. Nutritional management in children and 
adolescents with diabetes. Pediatr Diabetes 2014;15 Suppl 20:135-53.
34. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis 
Child 1970;45(239):13-23.
35. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 
1969;44(235):291-303.
36. American Diabetes Association. Foundations of Care and Comprehensive Medical Evaluation, 
Section 3. Diabetes Care 2016;39 Suppl 1:S23-35.
37. Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, et al. ISPAD Clinical Practice 
Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent. Pediatr Diabetes 
2014;15 Suppl 20:26-46.
38. Hegazy SK. Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in 
postmenopausal diabetic women. J Bone Miner Metab 2015;33(2):207-12.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 80 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix A
Schedule of Study Procedures
Assessment
Screening
Pre-Randomization 
Stabilization
Period (if needed)
Double-Blind Treatment Period
Weeks 1- 52 After Randomization (a)
End-of-
Treatment 
Visit
Follow
-Up 
Visit
Screening 
Visit (b)
At Least 
Every 
3 Months 
(b)
Week 
-1
Baseline 
Visit
(Day 1)
4
(b)
12
18 
(c)
26
32 
(b)
39
45
(b)
52 (a)
54 
(a,b)
Visit windows (days)
(Up to 14 
Days)
#2
#7
#7
#7
#7
#7
#7
#7
#2
Informed consent and 
assent
X
Inclusion/exclusion
X
X (d)
X (d)
Demographics;
medical history 
(including medication 
history and 
concurrent 
conditions)
X
8-hour fast (e)
X
X
X
X
X
Diabetes education 
(f)
X
X
X
X
X
X
Randomization
X
Complete physical 
examination
X
X
X
X
Brief physical 
examination (g)
X
X
Vital signs
X
X
X
X
X
X
X
X
Temperature
X
X
X
Body weight and 
height 
X
X
X
X
12-lead ECG
X
X
X
X
Issue subject diary 
and glucometer 
X (h)
X
Review diaries and 
glucometer readings
X
X
X
X
X
X
X
Review concomitant 
medications and 
PTE/AEs
X (i)
X
X
X
X
X
X
X
X
X
X
X(i)
Hematology, serum 
chemistry 
X
X
X
X
X
X
Lipid panel
X
X
X
X
X
Amylase/lipase (k)
X
Urinalysis
X
X
X (l)
X
C-peptide (n)
X
X
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Up 
Visit
sit
of
52 (a)
52 (a
ms
er
plic
plic
#
li
7
ab
p ic
e A
e Ap
Appl
pplpl
e App
the
the 
e
d Su
Subjeject to
to th
o th
th
d Su je
o
nd S
nd S
d S
nd S
Only
X
n
ly
n
an
ly
n
ly
Only
X
Onlylylyly
Use O
se O
X
O
Us
U
rc
U
rc
rc
rc
rc
me
m
-C
n-C
n-C
n-C
n-C
No
F
ings
ings
Fo
: F
omitant 
mitant
ns and 
s and 
Es
Es
da
matology
matol
chemistry
emist
f T
L
pe
perty 
CCI
CCI


Alogliptin
Study No. SYR-322_309
Page 81 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Assessment
Screening
Pre-Randomization 
Stabilization
Period (if needed)
Double-Blind Treatment Period
Weeks 1- 52 After Randomization (a)
End-of-
Treatment 
Visit
Follow
-Up 
Visit
Screening 
Visit (b)
At Least 
Every 
3 Months 
(b)
Week 
-1
Baseline 
Visit
(Day 1)
4
(b)
12
18 
(c)
26
32 
(b)
39
45
(b)
52 (a)
54 
(a,b)
Visit windows (days)
(Up to 14 
Days)
#2
#7
#7
#7
#7
#7
#7
#7
#2
eGFR (o)
X
X
X
X
HbA1c 
X
X
X (p)
X
X
X
X
X
X
Tanner Stage scoring 
X
X
X
Serum pregnancy test 
(q)
X
X
X
X
X
Urine (dipstick) 
pregnancy test (q)
X
X
X
In-clinic dosing
X
X
X
X 
(s)
X (t)
Access IVRS/IWRS
X
X
X
X
X
X
Dispense blinded 
study drug (u)
X
X
X
X
Document drug 
accountability
X
X
X
X
CD26 surface antigen
X
X
X
Biomarker labs (v)
X
X
X
GAD 65 and/or IA-2 
(w)
X
X
(a) Subjects who complete the 52-Week double-blind treatment period will complete an End-of-Treatment Visit and Follow-Up 
Visit, 2 weeks after the last dose of study drug. Subjects who terminate study drug prematurely will complete an End-of-Treatment 
Visit and a Follow-Up Visit 2 weeks later and will continue to be followed for the 52-Week duration of the study and complete a 
Projected Week 52 Visit. The same procedures should be conducted at the Projected Week 52 Visit as the End-of-Treatment Visit
for subjects who prematurely discontinue the study. For sites not able to conduct onsite visits due to unavoidable circumstances (eg, 
a widespread disease outbreak such as the COVID-19 pandemic or natural disaster), acceptable alternatives to assess subject safety 
and overall clinical status may include, but are not limited to, visits as per protocol schedule conducted by delegated site staff 
speaking directly with the subject by telephone or other medium (eg, a computer-based video communication), or sites may send 
site staff to subjects to conduct study assessments, contingent upon local regulations. 
The End-of-Treatment Visit should be performed in person. Alternative methods of data collection may be considered for this visit 
when it is not possible for the subject to come to the study site. Under such circumstances, a preferred alternative for the visit would 
be for site staff to go to the subject’s residence and conduct the protocol-specified procedures in that location. Assessments 
collected at subjects’ residence should comply with applicable local regulations. If neither option is available with sponsor or 
designee approval, sites may conduct end-of-treatment procedures remotely as is feasible.
During contact with the subject by an alternative method, the study site physician or other qualified site staff should also, at 
minimum, conduct the following assessments within the visit: AE assessments, documentation of concomitant medication, drug 
accountability, and assessment of clinical symptoms. Other study assessments may be collected remotely as is feasible and may 
involve audio or video recording. Assessments that cannot be completed during the protocol-specified window will be considered 
missing data, and such departures will be recorded in the study records. Alternatively, sites may seek approval to extend the visit 
window up to 3 times the protocol-specified window in order to conduct an onsite visit. The interval between successive visits 
when clinical laboratory tests and vital sign measurements are performed may not be longer than 8 weeks.
(b) The Screening Visit will be scheduled within 2 weeks prior to Day 1 or prior to the start of the Pre-Randomization Stabilization 
Period. During the Pre-Randomization Stabilization period, subjects will visit the study center at regular intervals according to the 
CCI
CCI
Property of Take
f-f
keda: For Non-Com
eek doub
ek dou
of study
study dr
weeks
eeks lat
he same p
he same
urely disco
ely dis
outbreak s
outbrea
status ma
tatus m
y with the
y with 
ubjects to 
bjects t
Treatm
Treat
isis not po
not p
or site staf
r site s
ollected a
ected
designee
desig
Durin
Duri
m
mercial Use Only and Subje
bje
bjejeje
d Su
Su
Subj
Subjbj
d Su j
nd S
nd S
X
S
d S
nd S
Only
n
an
ly
n
se On y
On y
Onlylyly
s
y
Use
X
se
Us
U
X
ia
rc
me
to the Applicable Terms of Use
f
a)
54
54
(a,b
(a
f
er
of
#
ble
7
Te
icic
X
ab
ic
pplic
pplicicicic
pp ic
Ap
App
pp
pp
pp
App
the A
he A
e A
e A
ct to
t to t
o t
o
mme
bject


Alogliptin
Study No. SYR-322_309
Page 82 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Assessment
Screening
Pre-Randomization 
Stabilization
Period (if needed)
Double-Blind Treatment Period
Weeks 1- 52 After Randomization (a)
End-of-
Treatment 
Visit
Follow
-Up 
Visit
Screening 
Visit (b)
At Least 
Every 
3 Months 
(b)
Week 
-1
Baseline 
Visit
(Day 1)
4
(b)
12
18 
(c)
26
32 
(b)
39
45
(b)
52 (a)
54 
(a,b)
Visit windows (days)
(Up to 14 
Days)
#2
#7
#7
#7
#7
#7
#7
#7
#2
investigator’s discretion but at least every 3 months and at Week -1 prior to randomization. The Week 4, 32, 45, and 54 visits will 
be conducted only via telephone call to the subject. A follow-up visit will be conducted via telephone with the subject 2 weeks after 
the End-of-Treatment Visit.
(c) The Sponsor or its designee will decide whether the Week 18 Visit will be conducted as an in-clinic visit, or optionally, as a 
home health visit.
(d) The randomization criteria listed in Section 7.3 will be assessed at the visits before Week -1 and all inclusion and exclusion 
criteria will be assessed at Week -1 prior to randomization.
(e) Subjects who have had the diagnosis of T2DM for less than 1 year and/or who are taking insulin at the time of randomization 
will be required to fast for at least 8 hours prior to the Screening or Week -1 visit for the assessment of fasting c-peptide. Subjects 
who are participating in postprandial glucose testing (refer to section 9.1.9.1) will be required to fast for at least 8 hours prior to the 
visits indicated in the Schedule of Procedures.
(f) Subjects will be instructed on proper nutrition and exercise, how to recognize signs and symptoms of hypoglycemia, and the use 
of the glucometer.
(g) The brief physical exam will consist of the following body systems: (1) respiratory system; (2) cardiovascular system; 
(3) nervous system (4) dermatologic system; and (5) gastrointestinal system.
(h) During the Pre-Randomization Stabilization Period, the site will supply a glucometer to subjects who do not have one or cannot 
obtain access to one. Subjects who do not enter the Pre-Randomization Stabilization Period should receive their glucometer (if 
needed) and diary at the Day 1 Visit.
(i) At the Screening visit, review only concomitant medications. At the Follow-up Visit, review only AEs.
(j) Collected only from those subjects who arrive at the clinic in a fasted state.
(k) Serum amylase and serum lipase to be performed at Day 1 (Baseline Visit) for all subjects, and at an Unscheduled Visit for any 
subject who experiences persistent nausea and/or vomiting for ≥3 days with or without abdominal pain.
(l) The Week 26 urinalysis will only include quantitative assessments.
(m)
(n) Required prior to randomization only for subjects who have had the diagnosis of T2DM for less than 1 year and/or who are 
taking insulin. 
(o) Calculated by the central laboratory.
(p) HbA1c concentration should be ≥6.5% to <11.0% or ≥7.0% to <11.0% if the subject is on insulin. If this criterion is not met, the 
assessment may be repeated every 3 months.
(q) To be completed on all female subjects. If a urine pregnancy test yields a positive result, a serum pregnancy test must also be 
collected at the same visit and submitted to the central laboratory for confirmation of results. 
(s) Subjects may be dosed in the clinic if dose was not self-administered at home.
(t) 
(u) Subjects who meet the criteria for rescue will continue double-blind study medication, and continue to participate in the 
duration of the study. 
(v) The following labs will be collected at Baseline and at Weeks 26 and Week 52/End-of-Treatment: Bone specific alkaline 
phosphatase and C-terminal telopeptide.
(w) Collected once prior to randomization for subjects who have had the diagnosis of T2DM for less than 1 year and/or who are 
taking insulin at time of randomization.
CCI
CCI
CCI
Property of T
) Subjects
bje
u
(t) 
(t) 
(u) S
(u) S
du
d
ty o
CCI
CCI
mmercial Use Only and Subject to the Applicab
, 45, and 
45, and
h the subje
he sub
clinic visit
nic vis
-1 and al
1 and 
taking ins
king in
r the asse
the ass
be requir
be requ
gnize sign
nize si
ms: (1) res
(1) r
nal system
al syste
will supp
will supp
domizatio
miza
edications
dicatio
at the clini
the cli
rmed at D
med at
nd/or vom
/or vom
ude quant
e quan
able Terms of Use
f
a)
54
54
(a,b
(a
f
er
of
#
ble
7
Te
ab
omm
da: For Non-Com
n only for
n only fo
laboratory
laborato
should be
ould b
eated eve
ated ev
d on all fe
on all 
ame visit 
me vis
f Takeda


Alogliptin
Study No. SYR-322_309
Page 83 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix B
Responsibilities of the Investigator
Clinical research studies sponsored by the sponsor are subject to ICH GCP and all the applicable 
local laws and regulations.
The Investigator agrees to assume the following responsibilities:
1. Conduct the study in accordance with the protocol.
2. Personally conduct or supervise the staff who will assist in the protocol.
3. Ensure that study related procedures, including study specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of written 
approval from relevant governing bodies/authorities.
4. Ensure that all colleagues and employees assisting in the conduct of the study are informed of 
these obligations.
5. Secure prior approval of the study and any changes by an appropriate IRB/IEC that conform to 
21 Code of Federal Regulations (CFR) Part 56 ICH, and local regulatory requirements.
6. Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approval 
of the protocol. Promptly report to the IRB/IEC all changes in research activity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the study to the 
IRB/IEC and issue a final report within 3 months of study completion.
7. Ensure that requirements for informed consent, as outlined in 21 CFR Part 50 ICH and local 
regulations, are met.
8. Obtain valid informed consent from each subject who participates in the study, and document 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
version approved by the IRB/IEC. Each ICF should contain a subject authorization section that 
describes the uses and disclosures of a subject’s personal information (including personal 
health information) that will take place in connection with the study. If an ICF does not include 
such a subject authorization, then the Investigator must obtain a separate subject authorization 
form from each subject or the subject’s legally acceptable representative.
9. Prepare and maintain adequate case histories of all persons entered into the study, including 
eCRFs, hospital records, laboratory results, etc, and maintain these data for a minimum of 
2 years following notification by the sponsor that all investigations have been discontinued or 
that the regulatory authority has approved the marketing application. The Investigator should 
contact and receive written approval from the sponsor before disposing of any such 
documents.
10. Allow possible inspection and copying by the regulatory authority of GCP-specified essential 
documents.
11. Maintain current records of the receipt, administration, and disposition of sponsor-supplied 
drugs, and return all unused sponsor-supplied drugs to the sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 84 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
12. Report adverse reactions to the sponsor promptly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 85 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix C
Elements of the Subject Informed Consent 
In seeking informed consent, the following information shall be provided to each subject:
1. A statement that the study involves research.
2. An explanation of the purposes of the research.
3. The expected duration of the subject’s participation.
4. A description of the procedures to be followed, including invasive procedures.
5. The identification of any procedures that are experimental.
6. The estimated number of subjects involved in the study.
7. A description of the subject’s responsibilities.
8. A description of the conduct of the study.
9. A statement describing the treatment(s) and the probability for random assignment to each 
treatment.
10. A description of the possible side effects of the treatment that the subject may receive.
11. A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
12. A description of any benefits to the subject or to others that reasonably may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13. Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potential risks and benefits.
14. A statement describing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By signing a written ICF, the subject or the subject’s 
legally acceptable representative is authorizing such access.
15. For research involving more than minimal risk, an explanation as to whether any compensation 
and an explanation as to whether any medical treatments are available if injury occurs and, if so, 
what they consist of or where further information may be obtained.
16. The anticipated prorated payment(s), if any, to the subject for participating in the study.
17. The anticipated expenses, if any, to the subject for participating in the study.
18. An explanation of whom to contact for answers to pertinent questions about the research 
(Investigator), subject’s rights, and IRB/IEC and whom to contact in the event of a 
research-related injury to the subject.
19. A statement that participation is voluntary, that refusal to participate will involve no penalty or 
loss of benefits to which the subject otherwise is entitled, and that the subject may discontinue 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 86 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
participation at any time without penalty or loss of benefits to which the subject is otherwise 
entitled.
20. The consequences of a subject’s decision to withdraw from the research and procedures for 
orderly termination of participation by the subject.
21. A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely manner if information becomes available that may be relevant to the subject’s 
willingness to continue participation in the study.
22. A statement that results of pharmacogenomic analysis will not be disclosed to an individual, 
unless prevailing laws require the sponsor to do so.
23. The foreseeable circumstances or reasons under which the subject’s participation in the study 
may be terminated.
24. A written subject authorization (either contained within the ICF or provided as a separate 
document) describing to the subject the contemplated and permissible uses and disclosures of 
the subject’s personal information (including personal health information) for purposes of 
conducting the study. The subject authorization must contain the following statements 
regarding the uses and disclosures of the subject’s personal information:
a) that personal information (including personal health information) may be processed by or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assisting Takeda, its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, Takeda will make every effort to keep your personal information confidential, 
and your name will not be disclosed outside the clinic unless required by law;
c) that personal information (including personal health information) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safety and effectiveness of the study medication(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the study to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; and
e) that the subject’s identity will remain confidential in the event that study results are 
published.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 87 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
25. Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually active must use adequate contraception (as defined in the informed consent) 
from Screening throughout the duration of the study. Regular pregnancy tests will be 
performed throughout the study for all female subjects of childbearing potential. If a subject is 
found to be pregnant during study, study medication will be discontinued and the Investigator 
will offer the subject the choice to receive unblinded treatment information.
26. Male subjects must use adequate contraception (as defined in the informed consent) from 
Screening throughout the duration of the study. If the partner or wife of the subject is found to 
be pregnant during the study, the Investigator will offer the subject the choice to receive 
unblinded treatment information.
27. A statement that clinical trial information from this trial will be publicly disclosed in a publicly 
accessible website, such as ClinicalTrials.gov.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 88 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix D
Investigator Consent to Use of Personal Information
Takeda will collect and retain personal information of Investigator, including his or her name, 
address, and other personally identifiable information. In addition, Investigator’s personal 
information may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, US, and Japan), including the following:

Takeda, its affiliates, and licensing partners.

Business partners assisting Takeda, its affiliates, and licensing partners.

Regulatory agencies and other health authorities.

IRBs and IECs.
Investigator’s personal information may be retained, processed, and transferred by Takeda and 
these other parties for research purposes including the following:

Assessment of the suitability of Investigator for the study and/or other clinical studies.

Management, monitoring, inspection, and audit of the study.

Analysis, review, and verification of the study results.

Safety reporting and pharmacovigilance relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other medications used in other clinical studies that may contain 
the same chemical compound present in the study medication.

Inspections and investigations by regulatory authorities relating to the study.

Self-inspection and internal audit within Takeda, its affiliates, and licensing partners.

Archiving and audit of study records.

Posting Investigator site contact information, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Investigator’s personal information may be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in Investigator’s own 
country.
Investigator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 89 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix E
Collection, Shipment, and Storage of Pharmacokinetic Samples
Instructions for Processing of Plasma Samples for Pharmacokinetic Analysis of Alogliptin 
(SYR-322)
1. Collect 3 mL of venous blood into a chilled Becton-Dickinson vacutainer. For all alogliptin 
samples, blood samples should be collected into vacutainers containing potassium 
ethylenediamine tetraacetic acid (K2EDTA). 
2. Gently invert the vacutainer several times to mix the additive with the collected blood prior to 
centrifugation and place immediately on ice. 
3. Centrifuge the vacutainers for 10 minutes at approximately 1100 to 1300 (relative centrifugal 
force) at approximately 4°C in a refrigerated centrifuge. Note: if using a collection device other 
than Becton-Dickinson, refer to manufacturer’s instruction for proper centrifugation force and 
time. 
4. Immediately following centrifugation, gently remove plasma from the packed cells. To ensure 
a more homogeneous sample, all plasma should first be transferred into 1 aliquot. From there, 
split the plasma evenly between the 2 aliquots. A minimum of 0.6 mL needs to be obtained for 
each sample. Labeling may include protocol number (SYR322_309), matrix (ie, plasma), 
analyte (alogliptin), subject number, nominal day and time, and either “SET 1” (for original 
sample) or “SET 2” (for duplicate sample). 
5. Cap the labeled storage tubes and freeze the plasma samples immediately at approximately 
-20°C or lower. No more than 45 minutes will elapse between blood collection and freezing the
plasma sample. 
6. Keep samples frozen at approximately -20°C or lower until shipment to PPD central laboratory. 
SET 1 samples will be shipped first on dry ice, followed by shipment of duplicate SET 2 
samples after SET 1 samples have been received by the analytical laboratory.
Instructions for Shipping of Samples for Pharmacokinetic Analyses 
Site may adhere to the site’s Standard Operating Procedures on shipping samples if the Standard 
Operating Procedure differs from the sample instructions provided.
Biological samples should be shipped on dry ice to prevent thawing during transit. Ship samples 
only on Monday, Tuesday, or Wednesday, and at least 2 days prior to a national holiday, to 
minimize the possibility of samples in transit over a weekend or holiday. If duplicate samples are 
to be shipped, send SET 1 samples and await confirmation of arrival before shipping the duplicate 
SET 2 samples.
1. Before shipping, make sure the sample tubes are tightly sealed. Separate each subject’s 
samples as follows:
2. Separate the duplicate SET 2 samples from the SET 1 samples.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 90 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
3. Place SET 1 samples for each subject into zipper lock bag containing additional absorbent 
material.
4. Using a permanent marker, write the randomization number, sample matrix (ie, plasma), 
analyte, number of samples, and “SET 1” on each zipper lock bag.
5. Place the bags of individual subject’s samples into a larger plastic bag so that samples are 
double bagged. Duplicate SET 2 samples should be returned to the freezer for storage. Repeat 
steps 3-6 above when preparing duplicate samples for shipment, except zipper lock bags 
should be marked “SET 2.”
6. An inventory of individual samples should accompany each shipment and should include the 
sponsor’s name (Takeda), study drug (alogliptin), protocol number (SYR-322_309), 
Investigator’s name, sample type (ie, plasma, subject’s randomization number, nominal 
collection day and time, and intended sample storage conditions. When duplicate SET 2 
samples are being shipped, make a copy of the original SET 1 sample inventory and mark as 
“SET 2.” Place the inventory paperwork into a large zipper lock bag. SET 1 samples will be 
shipped first on dry ice, followed by shipment of duplicate SET 2 samples after SET 1 samples 
have been received by the analytical laboratory.
7. For sample packing, utilize dry ice generously (eg, 20-25 pounds per day of transit) to 
safeguard against longer than expected shipping times and delays. Use newspaper or other 
material to insulate the double-bagged samples from direct contact with the dry ice. Place the 
sample bundles into a Styrofoam container (or other suitable container) and fill the excess 
space with dry ice slabs or ice pellets (preferably the latter). Make a note of the estimated 
weight of the dry ice used per shipping container.
8. Place the inventory paperwork (in a large zipper lock bag) on top of the dry ice in the 
Styrofoam container. Place the lid on the Styrofoam container and seal completely with 
strapping tape. Place the Styrofoam container in a cardboard shipping carton and seal securely 
with strapping tape.
9. Mark the outside of shipping carton(s) with a tally number (eg, 1 of 5, 2 of 5).
10. Affix an address label to each shipping carton by send the samples to PPD central laboratory.
11. Affix a carbon dioxide label on each carton, specifically:
Carbon Dioxide Solid UN-1845
Class 9 PKG GR III
Quantity _____________________
(fill in weight to nearest lb/kg and specify unit of measure used)
12. Affix 2 dry ice symbol labels on opposite sides of the carton. Mark KEEP FROZEN on each 
carton. Specify a return address and contact person on the carton.
13. Obtain the airway bill number and a receipt of shipment from the carrier.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 91 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
14. After shipping of the samples, contact PPD central laboratory for all samples to notify them of 
next day delivery. When calling, provide the following information:
Name of courier or transport company
Time and date the shipment left the clinical site
Airway bill number
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 92 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix F
Collection, Shipment, and Storage of Pharmacogenomic Samples
Collect 1 mL whole blood for DNA isolation before dosing on Day 1 into plastic potassium 
ethylenediamine tetraacetic acid (K2EDTA) spray-coated tubes from each subject which signs the 
optional pharmacogenomic sample collection ICF.
Collect 2.5 mL whole blood for RNA isolation at predose on Day 1 and Week 12 into a PaxGene 
TM tube.
A saliva sample will also be obtained from the subject at Day 1.
For detailed instructions on sample collection and storage follow the laboratory manual provided 
by the central laboratory.
Sample Shipment
Ship samples only on Monday, Tuesday, or Wednesday, and at least 2 days prior to a national 
holiday, to minimize the possibility of samples in transit over a weekend or holiday. The 
laboratory must confirm arrival of the shipped samples.
For instructions on shipping and packing follow the laboratory manual and shipping instructions 
provided by the central laboratory.
Before shipping, ensure the sample tubes are tightly sealed.
Sample Storage
The DNA and RNA samples will be stored in a secure storage space with adequate measures to 
protect confidentiality. The samples will be retained while research on alogliptin continues for up
to but not longer than 15 years or as required by applicable law.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 93 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix G
Determination of Eligibility in Subjects With Elevated ALT Levels 
*Liver biopsies are not required, however, may be recommended by the investigator to confirm NAFLD and thereby, 
render the subject eligible for the study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 94 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix H
Recommendations for Home Glucose Monitoring
Subjects should be advised to check their blood glucose levels on a daily basis, at the following 
time points, at a minimum:

Two times per day.
–
In the morning upon awakening (fasting).
–
One additional time (for example, before dinner, or 2 hours after dinner).

Additional testing of blood glucose levels is recommended during periods of illness, or when 
signs or symptoms of hypoglycemia are thought to be experienced. 

Additional testing of blood glucose levels is also recommended during the study, such as when 
rescue medications are required and/or when rescue medications are being down-titrated.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 95 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Appendix I
Protocol History
Date
Amendment Number
Amendment Type
Region
17 August 2020
Amendment 9 IT v 1
Substantial
Italy
13 November 2019
Amendment 8
Substantial
Russia
28 November 2018
Amendment 7
Substantial
Brazil
27 June 2018
Amendment 6
Substantial
Germany
09 February 2018
Amendment 5
Substantial
Germany
17 January 2018
Amendment 4
Substantial
Italy
10 May 2017
Amendment 3
Nonsubstantial
Global
09 November 2016
Amendment 2
Substantial
Global
29 April 2016
Amendment 1
Substantial
Global
28 July 2015
Initial Protocol
Not applicable
Global
Protocol Amendments 5 through 8: 
Protocol Amendments 5 through 8 were local amendments applicable to single countries other 
than Italy; therefore, details of these amendments are not included in this local protocol 
amendment for Italy.
Protocol Amendment 4 Italy Summary and Rationale 
The primary purpose of this country-specific amendment for Italy was to incorporate suggested 
changes made by the central ethics committee (CEC) and the local regulatory authority in Italy.
In a letter dated 23 October 2017, the CEC stated the need to clarify the risk for treatment-naïve 
subjects in the event of assignment to the placebo group. In a letter dated 30 October 2017 (“A 
Denial of Authorisation” issued by the Agenzia Italiana del Farmaco [AIFA] for the Clinical Trial 
Application for Study SYR 322_309), AIFA provided feedback on exclusion criterion 7 (“The 
subject has had more than 1 episode of diabetic ketoacidosis at any time after diagnosis of T2DM”) 
and exclusion criterion 8 (“The subject has a history of more than 1 episode of pancreatitis”). 
Minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of 
the study are included for clarification and administrative purposes only.
Protocol Amendment 4 Italy
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
Section 2.0 STUDY SUMMARY
Section 6.1 Study Design
Figure 6.a Schematic of Study Design
Section 7.2 Exclusion Criteria
Section 7.3 Additional 
Randomization Criteria That Must Be 
Excluded treatment-naïve subjects.
The CEC raised objection to 
including naïve subjects (“The 
Committee does not consider the 
clarifications provided to be 
thorough and reiterates the need to 
clarify the risk for naïve patients in 
the event they are assigned to the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 96 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Protocol Amendment 4 Italy
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
Met Following Screening and/or 
Completion of the Pre-Randomization 
Stabilization Period
Section 13.1.3 Efficacy Analysis
placebo group”). In order to be 
compliant with CEC requests, 
treatment-naïve subjects were 
excluded in this local amendment 
for Italian subjects.
Section 7.2 Exclusion Criteria
Section 8.3 Randomization Code 
Creation and Storage
Excluded subjects with a history of 
diabetic ketoacidosis (DKA).
Because this is a clinical trial 
involving a pediatric population 
and DKA is a serious clinical 
disease, the benefit-risk ratio 
cannot be considered favorable in 
subjects with a history of DKA. 
This change ensures that the 
inclusion of subjects at risk for 
DKA will be minimized.
Section 7.2 Exclusion Criteria
Excluded subjects with a history of 
pancreatitis.
Because this is a clinical trial 
involving a pediatric population 
and pancreatitis is a serious clinical 
disease for which, in the vast 
majority of the cases, it is 
impossible to identify a cause in 
the target age group, the 
benefit-risk ratio cannot be 
considered favorable in subjects 
with a history of pancreatitis. This 
change ensures that the inclusion of 
subjects at risk for pancreatitis will 
be minimized.
Protocol Amendment 3 Summary and Rationale
This section describes the changes in reference to the protocol incorporating Amendment 3. The 
primary purpose of this amendment was to provide updated contact information. A number of 
editorial changes were made throughout the protocol to provide clarity. The following is a 
summary of the changes made in the amendment.
Protocol Amendment 3
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
Section 1.1 Contacts
Updated contact information.
To reflect personnel changes.
Section 1.2 Approval
Updated list of protocol approvers.
To reflect personnel changes.
8.1.1.2 Companion Medication
Removed the provision of pharmacy 
cards for companion medications by 
The use of pharmacy cards was 
removed to allow more flexibility 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 97 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Protocol Amendment 3
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
deleting Section 8.1.1.5 Pharmacy 
Card Supplied Drugs.
on how companion medications 
can be obtained. 
Section 8.1.1.3 Rescue Medication
Section 8.1.1.6 Rescue Medications
Combined text for rescue 
medications.
To consolidate text in 2 different 
sections for rescue medications. 
Protocol Amendment 2 Summary and Rationale
This section describes the changes in reference to the protocol incorporating Amendment 2. The 
primary purpose of this amendment is to enhance clarity, provide additional guidance, and remove 
unnecessary procedures. A number of editorial and administrative changes were made throughout 
the protocol to provide clarity. The following is a summary of the changes made in the 
amendment.
Protocol Amendment 2
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
Section 1.1 Contacts
Updated contact information.
To reflect personnel changes.
Section 1.2 Approval
Updated list of protocol approvers.
To reflect personnel changes.
Section 5.2.2 Secondary Endpoints
Section 2.0 Study Summary
Added respiratory tract infections 
and hypersensitivity reactions, in 
addition to total and urinary tract 
infections, to the “incidence of 
infections” in the safety endpoints.
To align with adverse events of 
special interest.
Section 5.2.2 Secondary Endpoints
Section 5.1.2 Secondary Objectives
Section 9.1 Study Procedures
Section 13.1.1 Analysis Sets
Appendix A Schedule of Study 
Procedures
Removed dual-energy x-ray
absorptiometry scans.
These scans are not needed as DPP-4 
inhibitors have not shown an impact 
on bone density in clinical studies.
Section 5.2.3 Exploratory Endpoints
Section 2.0 Study Summary
Table 9.a Clinical Laboratory Tests
Appendix A Schedule of Study 
Procedures
To align with planned analyses.
Section 6.2 Pre-Randomization 
Stabilization Period (if needed)
Modified the length of time for the 
maintenance of stable 
anti-hyperglycemic therapy from 
1 month to 2 months.
To allow more time for stabilization.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
f
of
o
cations
ations
m
in 2 diff
in 2 d
ue medic
e med
e T
ica
rating A
rating
dit
ditioional
na
e chang
chan
the cha
the ch
nt 2
nt 2
S
al Versio
Vers
nd
scription
cript
y a
On y
ntact inf
tact 
e O
d list of p
d list of
Us
ded respi
ed resp
and hy
nd hyper
p
y
additio
addit
infe
in
i
al
m
dpo
points
ints
Objectiv
Object
ocedures
cedur
nalysis Se
lysis 
Schedule 
chedu
C
n 5.2.3 Ex
n 5.2.3 E
tion 2.0 S
on 2.
Table 9.a
able 9
Appe
App
Pr
P
ke
pe
p


Alogliptin
Study No. SYR-322_309
Page 98 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Protocol Amendment 2
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
Section 6.2 Pre-Randomization 
Stabilization Period (if needed)
Added recommendations regarding 
managing insulin therapy.
To provide more guidance to the 
investigator.
Section 7.1 Inclusion Criteria and 7.3 
Additional Randomization Criteria 
That Must Be Met Following 
Screening and/or Completion of the 
Pre-Randomization Stabilization 
Period
Section 2.0 Study Summary
Table 9.a Clinical Laboratory Tests
Appendix A Schedule of Study 
Procedures
Clarified that inclusion criteria 
regarding C-peptide, autoantibodies, 
age, and BMI apply at randomization 
and that C-peptide, autoantibodies, 
and BMI criteria apply to subjects 
who have had the diagnosis of T2DM 
for less than 1 year and/or who are 
taking insulin.
Applied criteria to the pediatric 
diabetic population to those most at 
risk for misdiagnosis of type 1 
diabetes and to align with clinical 
practice guidelines. Also, clarified 
that these criteria are to be met prior 
to randomization.
Section 7.2 Exclusion Criteria
Section 7.9 Renal Safety Withdrawal 
Criteria
Table 9.a Clinical Laboratory Tests
Section 16.0 References
Changed eGFR calculations to be 
based on the Schwartz formula rather 
than Cockcroft-Gault.
The Schwartz formula is a more 
appropriate formula than the 
Cockcroft-Gault formula for the 
estimation of GFR in the pediatric 
population.
Section 7.2 Exclusion Criteria
Modified wording of exclusion 
criteria regarding sexual activity to 
align with Section 9.1.9.
Clarified wording to align with 
Section 9.1.9.
Section 7.3 Additional 
Randomization Criteria That Must 
Be Met Following Screening and/or 
Completion of the 
Pre-Randomization Stabilization 
Period
Section 2.0 Study Summary
Figure 6.a Schematic of Study 
Design
Section 6.2 Pre-Randomization 
Stabilization Period (if needed)
Appendix A Schedule of Study 
Procedures
Added a randomization criterion for 
subjects on insulin to require and 
HbA1c level of ≥7.0%.
This criterion threshold was raised 
for subjects on insulin to allow for 
additional therapy before they reach 
their treatment goal and to minimize 
the risk of hypoglycemia.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


Alogliptin
Study No. SYR-322_309
Page 99 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Protocol Amendment 2
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
Section 7.3 Additional 
Randomization Criteria That Must 
Be Met Following Screening and/or 
Completion of the 
Pre-Randomization Stabilization 
Period
Section 2.0 Study Summary
Table 9.a Clinical Laboratory Tests
Appendix A Schedule of Study 
Procedures
Updated laboratory testing 
terminology from ICA 512 antibody 
to IA-2 antibody.
To match the terminology used by 
the laboratory.
Section 7.4 Excluded Medications
Added clarification regarding the use 
of oral or parenteral steroids during 
the treatment period.
Chronic steroid use impacts glucose 
levels and therefore, may affect 
measurements of HbA1c, which is 
primary endpoint. For this reason, the 
chronic use of steroids should be 
avoided if possible.
Section 7.9 Renal Safety Withdrawal 
Criteria
Added wording to the renal safety 
withdrawal criteria to clarify that the 
confirmation by a repeat laboratory 
test is to be conducted within a 
maximum of 7 days.
Clarified that repeat testing should 
occur within a specified period of 
time.
Section 9.1.3 Physical Examination 
Procedure
Added details regarding assessment 
of pubertal development.
Added menarche and clarification of 
Tanner stage categories.
Section 9.1.4 Weight, Height and 
BMI
Added clarification regarding BMI 
measurements.
Clarified the process for BMI 
measurements.
Section 9.1.7 Documentation of 
Concurrent Medical Conditions
Added a recommendation for annual 
ophthalmologic examinations.
To monitor the subjects for 
retinopathy, one of the known 
complications of T2DM.
Section 9.1.8 Procedures for Clinical 
Laboratory Samples
Adjusted the volume of blood 
collected for clinical laboratory 
samples.
Blood volume was adjusted based on 
updated laboratory tests.
Table 9.a Clinical Laboratory Tests
Section 9.1.8.1 2-Hour Postprandial 
Glucose Test
Table 9.b 
Appendix A Schedule of Study 
Procedures
Removed insulin and proinsulin 
measurements and clarified that 
C-peptide will only be measured 
once prior to randomization.
These measurements were removed 
as they were expected to produce 
inconclusive results in pediatric 
patients treated with diet and 
exercise, insulin, and/or metformin.
Table 9.a Clinical Laboratory Tests
Appendix A Schedule of Study 
Procedures
Clarified that GAD and IA-2 
antibody testing may be performed 
by the central laboratory.
These tests may be performed by the 
central laboratory.
CCI
Clinical 
Clinica
n 9.1.8.1
n 9.1.8
cose Tes
ose T
Table 9.b
able 9
Appe
App
da: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
f
of
o
used by 
ed by
m
c
se 
ing 
ng 
Chro
Ch
le
ct
jec
o the rena
o the re
teria to c
ria to
n by
by a re
a
y
be condu
be con
mum of 7
um of 
ly
dded deta
ded de
of puber
of pub
ia
Add
Ad
m
m
m
of 
itions
ions
Co
dures for
dures 
ples
les
r
Pr
P
ed
pe
p


Alogliptin
Study No. SYR-322_309
Page 100 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
Protocol Amendment 2
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description
Rationale
Section 9.1.8.1 2-Hour Postprandial 
Glucose Test
Added clarification regarding 
postprandial glucose testing.
Approval of the meal is not required. 
Also, oral glucose tolerance testing 
was added as an option for measuring 
postprandial glucose at sites who to 
do not have the ability to perform 
standardized meal tests.
Section 12.1 CRFs (Electronic)
Made a correction to the eCRF 
process regarding data changes after 
database lock.
These statements were removed to 
reflect the data handling process.
Section 16.0 References
Added recent literature references.
To provide additional information.
Appendix A Schedule of Study 
Procedures
Added hematology and serum 
chemistry testing at the Week -1 
Visit.
To specify time point.
Appendix A Schedule of Study 
Procedures
Appendix A Schedule of Study 
Procedures
Table 9.a Clinical Laboratory Tests
Added eGFR measurements at 
Baseline and at Weeks 26 and 52.
To monitor for renal safety.
Appendix A Schedule of Study
Procedures
Added clarification regarding 
inclusion/exclusion criteria 
assessments and in-clinic dosing to 
the schedule of assessment.
Footnotes were added for 
clarification. 
Rationale for Amendment 1
The primary purpose of this amendment was to enhance clarity and simplify the study design to 
more closely align with standard of care practices and reduce the overall burden on subjects and 
caretakers throughout the duration of the study. A number of editorial and administrative changes 
were made throughout the protocol to provide clarity. 
Changes in Amendment 1
1. Study entry criteria were modified, including broadening glycosylated hemoglobin (HbA1c)
criteria and hepatic enzyme criteria, in order to better reflect the study population and allow 
subjects with non-alcoholic fatty liver disease (NAFLD) into the study.
2. The number of schedules was reduced in order to simplify the study design.
CCI
CCI
Property of Takeda: For Non-Commercial Use Only an
R measu
R me
and at W
and at
e O
Added cla
dded c
inclusi
inclus
asse
as
th
cia
d Subject to the Applicable Terms of Use
f
of
o
required
requir
nce testin
nce tes
n for mea
n for m
se at site
e at sit
ability to
ability t
meal tes
meal te
m
tements 
ements 
the data 
he da
pp
To provi
o pr
o t
To sp
To
t t
jec
Su
Com
mendm
mendm
purpos
purpo
selyly alal
y
igi
kers thro
kers thr
e m
e made 
ad
Chang
Chan
1.1
d Su
and 


Alogliptin
Study No. SYR-322_309
Page 101 of 101
Protocol Incorporating Amendment No. 9 IT v1
17 August 2020
3. A Pre-Randomization Stabilization Period was added for those subjects who are not yet 
stabilized on their current antidiabetic therapy or who have not yet met certain entry criteria.
4. The guidance for hepatic safety monitoring and withdrawal criteria was revised to reflect the 
potential inclusion of subjects with NAFLD. 
5. The assessment of retinopathy by fundus photography was removed as this microvascular 
complication is very unlikely to have manifested at this early stage in the natural history of 
T2DM in this population to warrant evaluation. 
6. Home glucose management and hyperglycemic rescue language were clarified to allow 
investigators to individualize glucose management based on the needs of the subject and 
according to local guidance. 
7. The schedule of assessments was adjusted to decrease the number of clinic visits, allow for 
telephone visits, and minimize fasting requirements in order to reduce the burden on subjects.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use



(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GF
䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢻䢢䣋䣖䢢䣸䢳䢢䣶䣱䢢䣃䢢䣏䣷䣮䣶䣫䣥䣧䣰䣶䣧䣴䢮䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰䣶䣴䣱䣮䣮䣧䣦䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧
䣇䣨䣨䣫䣥䣣䣥䣻䢢䣣䣰䣦䢢䣕䣣䣨䣧䣶䣻䢢䣱䣨䢢䣃䣮䣱䣩䣮䣫䣲䣶䣫䣰䢢䣅䣱䣯䣲䣣䣴䣧䣦䢢䣙䣫䣶䣪䢢䣒䣮䣣䣥䣧䣤䣱䢢䣫䣰䢢䣒䣧䣦䣫䣣䣶䣴䣫䣥䢢䣕䣷䣤䣬䣧䣥䣶䣵䢢䣙䣫䣶䣪䢢䣖䣻䣲䣧䢢䢴䢢䣆䣫䣣䣤䣧䣶䣧䣵䢢䣏䣧䣮䣮䣫䣶䣷䣵
%LRVWDWLVWLFV$SSURYDO
-XQ87&
&OLQLFDO6FLHQFH$SSURYDO
-XQ87&
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
e Te
ate 
te
ble T
HH:mm ‘U
H:mm
Ter
ble
87&
87&



SAP_001.pdf: 


Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the 
Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 
Diabetes Mellitus
NCT Number: NCT02856113
SAP Approve Date: 20Apr2021
Certain information within this Statistical Analysis Plan has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable (PPD) information 
or company confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.


1.0
TITLE PAGE
STATISTICAL ANALYSIS PLAN
STUDY NUMBER: SYR-322_309
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 
2 Diabetes Mellitus
Alogliptin Pediatric Study
PHASE 3 
Version: 1.0
Date: 20Apr2021
Prepared by:
Based on:
Protocol Version: Amendment 09
Protocol Date: 11 August 2020
PPD
Property of Takeda: For Non
rotocol
otocol
ial Use Only and Subject to the Applicable Terms of Use
tudy to
udy to
diatric 
diatric
dy
.0
Apr202
Apr20
Proto
Pro
n-Commercia
roperty


SYR-322_309
Page 2 of 28
Statistical Analysis Plan
20 Apr 2021
2.0
TABLE OF CONTENTS
1.0
TITLE PAGE ..................................................................................................................1
1.1
Approval Signatures ....................................................................................................
2.0
TABLE OF CONTENTS.................................................................................................2
3.0
LIST OF ABBREVIATIONS..........................................................................................4
4.0
OBJECTIVES .................................................................................................................5
4.1
Primary Objectives ....................................................................................................5
4.2
Secondary Objectives.................................................................................................5
4.3
Exploratory Efficacy Objectives ................................................................................5
4.4
Study Design .............................................................................................................6
5.0
ANALYSIS ENDPOINTS...............................................................................................7
5.1
Primary Endpoint.......................................................................................................7
5.2
Secondary Endpoints .................................................................................................7
5.2.1
Secondary Efficacy Endpoints..............................................................................7
5.2.2
Safety Endpoints..................................................................................................7
5.3
Exploratory Endpoints ...............................................................................................7
6.0
DETERMINATION OF SAMPLE SIZE.........................................................................9
7.0
METHODS OF ANALYSIS AND PRESENTATION...................................................10
7.1
General Principles....................................................................................................10
7.1.1
Definition of Study Days and Baseline...............................................................10
7.1.2
Definition of Study Visit Windows ....................................................................11
7.2
Analysis Sets ...........................................................................................................11
7.3
Disposition of Subjects ............................................................................................12
7.4
Demographic and Other Baseline Characteristics.....................................................12
7.5
Medical History and Concurrent Medical Conditions...............................................13
7.6
Prior, Concomitant, and Post-treatment Medications................................................13
7.7
Study Drug Exposure and Compliance.....................................................................14
7.8
Efficacy Analysis.....................................................................................................14
7.8.1
Primary Efficacy Endpoint.................................................................................14
7.8.2
Secondary Efficacy Endpoints............................................................................16
7.8.3
.......................................................................................16
7.9
..........................................................19
7.9.1
..................................................................................19
7.9.2
...............................................................................19
7.10
Safety Analysis........................................................................................................19
CCI
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
.....
.......
..... .2
.........
....
.........
.....
........
.......
.........
.....
........
..
........
....
.........
....
........
.......
.........
.....
........
.
........
.....
.........
......
ZE.....
D PRES
PRE
.........
....
Days a
Days 
y
udy
dy Vis
Vi
y
........
....
of Subje
f Sub
aphic an
phic a
cal Hist
cal His
ior, Con
or, C
Study
Study
Eff
E
7.8
7


SYR-322_309
Page 3 of 28
Statistical Analysis Plan
20 Apr 2021
7.10.1 Pre-treatment Events and Adverse Events ..........................................................20
7.10.2 Clinical Laboratory Evaluations .........................................................................21
7.10.3 Vital Signs .........................................................................................................22
7.10.4 Physical Examination.........................................................................................22
7.10.5 12-Lead ECGs ...................................................................................................22
7.10.6 Other Observations Related to Safety.................................................................22
7.11
Interim Analysis ......................................................................................................23
7.12
Changes in the Statistical Analysis Plan...................................................................23
8.0
REFERENCES..............................................................................................................24
LIST OF APPENDICES
Appendix A
Criteria for Identification of Markedly Abnormal Laboratory Values .................25
Appendix B
Criteria for Markedly Abnormal Values for Vital Signs......................................27
Appendix C
Reference code in SAS.......................................................................................27
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 4 of 28
Statistical Analysis Plan
20 Apr 2021
3.0
LIST OF ABBREVIATIONS
AE
adverse event
ATC
anatomical therapeutic chemical
BMI
body mass index
COVID-19
Coronavirus disease 2019
CI
confidence interval
CTX
C-terminal telopeptide
ECG
electrocardiogram
eCRF
electronic case report form
FAS
full analysis set
HbA1c
glycosylated hemoglobin
LLN
lower limit of normal
MAV
markedly abnormal value
MedDRA
medical dictionary for regulatory activities
MMRM
mixed model for repeated measures
MODY
maturity-onset diabetes of the young
OR
odds ratio
PK
pharmacokinetics
PPG
postprandial glucose
PPS
per protocol set
PT
preferred term
PTE
pretreatment event
QD
once daily
SAE
serious adverse event
SAP
statistical analysis plan
SD 
standard deviation 
SE
standard error
SI
International System of Units
SOC
system organ class
T2DM
type 2 diabetes mellitus
ULN
upper limit of normal
WHODrug
world health organization drug dictionary
CCI
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only a
regulato
egulat
epeated m
peate
t diabetes
diabe
macokine
acokin
ostprandi
tpran
per pr
per p
pr
SI
SOC
SOC
bje
T
ubj
o the Applicable Terms of Use
to th
ct to
bject
CCI


SYR-322_309
Page 5 of 28
Statistical Analysis Plan
20 Apr 2021
4.0
OBJECTIVES
4.1
Primary Objectives
The primary objective of this study is to evaluate the efficacy of alogliptin 25 mg once daily 
(QD) compared to placebo when administered as monotherapy, or when added onto a 
background of metformin alone, insulin alone, or as combination of metformin and insulin, as 
measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in 
pediatric subjects with type 2 diabetes mellitus (T2DM).
4.2
Secondary Objectives
To evaluate the HbA1c change from Baseline after treatment with alogliptin as compared with 
placebo at Weeks 12, 18, 39, and 52.
To evaluate the safety of alogliptin compared to placebo by assessing:
•
The incidence of hypoglycemic events, treatment emergent adverse events (TEAEs),
clinical laboratory parameters, electrocardiogram (ECG) readings, physical examinations, 
and vital signs for Weeks 26 and 52.
•
The effects on biomarkers of bone turnover (bone-specific alkaline phosphatase and C-
terminal telopeptide [CTX]) markers at Weeks 26 and 52.
•
The effects on CD26 surface antigen levels at Weeks 26 and 52.
CCI
Property of Takeda: For Non-Commercial Use O
n 
Only and Subject to the Applicable Terms of Use
y
sulin, as
lin, a
26 in
26 in
lipt
liptin as
in a
essing:
sing:
mergent 
ergent
(ECG) 
ECG
er (bone
r (bon
Weeks 
Weeks
levels
leve
operty of Takeda: For Non-Commercial U


SYR-322_309
Page 6 of 28
Statistical Analysis Plan
20 Apr 2021
4.4
Study Design
This is a multicenter, randomized, double-blind, placebo-controlled study with 52-week double-
blind treatment period to evaluate the efficacy and safety of alogliptin 25 mg QD compared to 
placebo in children and adolescents 12 to 17 years in Russia and 10 to 17 years in all other 
countries, inclusive, at the time of randomization, with a confirmed diagnosis of T2DM and who 
are experiencing inadequate glycemic control. 
Subjects who have completed all required Screening Procedures, and who meet all entry criteria 
may proceed to randomization. Subject randomization will be stratified by background 
antidiabetic regimen. Eligible subjects will be assigned to 1 of 2 Schedules (ie, Schedules A and 
B), based on the antidiabetic therapy they have been receiving for the 12 weeks prior to the 
Screening Period, as follows:
•
Schedule A: Subjects who are naïve to antidiabetic therapy.
•
Schedule B: Subjects who are receiving metformin and/or insulin.
Subjects who have not met all of the additional randomization criteria listed in protocol Section 7
will be allowed to enter a Pre-Randomization Stabilization Period described in protocol Section 
6.2.
If randomized, then, in addition to receiving double-blind study medication, subjects will be 
required to maintain their background antidiabetic therapy (if applicable), at the same dose at the 
day of randomization (eg, baseline insulin doses, if applicable), throughout the first 26 weeks of 
the Double-Blind Treatment Period. Subjects who complete the 52-Week Double-Blind 
Treatment Period will complete an End-of-Treatment Visit and Follow-Up Visit, 2 weeks after 
the End-of-Treatment Visit. Subjects who terminate double-blind study drug prematurely will 
complete an End-of-Treatment Visit and Follow-Up Visit, 2 weeks after the End-of-Treatment 
Visit, and will continue to be followed for the 52-week duration of the study and complete a 
projected Week 52 visit.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 7 of 28
Statistical Analysis Plan
20 Apr 2021
5.0
ANALYSIS ENDPOINTS
5.1
Primary Endpoint
The primary endpoint of this study is HbA1c change from Baseline to Week 26.
5.2
Secondary Endpoints
5.2.1
Secondary Efficacy Endpoints
The secondary efficacy endpoints are HbA1c changes from Baseline at Weeks 12, 18, 39, and 
52.
5.2.2
Safety Endpoints
The safety endpoints of this study are:
!
Physical examination findings.
!
Vital sign measurements.
!
12-lead ECG abnormalities.
!
Adverse events (AEs).
!
Incidence of infections (Total and urinary and respiratory tract infections) and 
hypersensitivity reactions. 
!
Incidence of hypoglycemia.
!
Clinical laboratory evaluations (hematology, serum chemistry, and urinalysis).
!
Changes from Baseline in biomarkers of bone turnover (bone-specific alkaline 
phosphatase and CTX) at Weeks 26 and 52.
!
Changes from Baseline in CD26 surface antigen levels at Weeks 26 and 52.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
ks 12, 18
12, 1
urinary
inary a
y
uatatioions 
ns
ine in b
ne in 
CTX)
TX) a
m Basel
Base
Property of Takeda: For N


SYR-322_309
Page 8 of 28
Statistical Analysis Plan
20 Apr 2021
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
d Subject to the Applicable Terms of Us


SYR-322_309
Page 9 of 28
Statistical Analysis Plan
20 Apr 2021
6.0
DETERMINATION OF SAMPLE SIZE
The primary efficacy variable will be the change from Baseline in HbA1c at Week 26. The 
primary analysis set will be the full analysis set (FAS) defined in Section 7.2. For this variable 
and set, a total of 75 randomized subjects per treatment group will ensure at least 90% power to 
detect a difference in mean change from Baseline in HbA1c at Week 26 between alogliptin 25 
mg QD and placebo assuming a treatment effect of 0.5%, a SD of 0.9%, a 2-sided false-rejection 
rate of 5%.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 10 of 28
Statistical Analysis Plan
20 Apr 2021
7.0
METHODS OF ANALYSIS AND PRESENTATION
7.1
General Principles 
A masked data review of tables, listings, and figures presented with surrogate treatment codes 
will be conducted prior to unblinding of subjects’ treatment assignments. This review will assess 
the accuracy and completeness of the study database, subject evaluability (including definition of 
analysis sets), and appropriateness of the planned statistical methods.
All statistical analyses will be conducted using SAS® Version 9.2, or higher.
All confidence intervals, statistical tests, and resulting P-values will be reported as 2-sided and 
will be assessed at the α=0.05 significance level unless otherwise stated. P-values will be 
rounded to 3 decimal places prior to assessment of statistical significance.   
Means and medians will be presented to 1 more decimal place than the recorded data. Standard 
deviations (SDs) will be presented to 2 more decimal places than the recorded data. Confidence 
intervals about a population parameter estimate will be presented using the same number of 
decimal places as the estimate.
Where appropriate, numbers of patients will be summarized by Schedule A or B based on 
antidiabetic therapy and variables will be summarized by scheduled study visit. For the 
categorical variables, the counts and proportions of each possible value will be tabulated by 
treatment group. For continuous variables, the number of subjects with non-missing values (n), 
mean, median, SD, minimum, and maximum values will be tabulated.
Mixed model for repeated measures (MMRM) will be used for several endpoints and unless 
otherwise specified the following general practices will be employed when using MMRM 
analysis. An unstructured covariance matrix will be used to model the correlation among 
repeated measurements; parameter estimates will be calculated using restricted maximum-
likelihood estimation (REML). Degrees of freedom will be estimated using the Kenward-Roger 
approximation. The Shapiro-Wilk test will be used to test the normality of the residuals from 
each continuous endpoint that is examined using an MMRM model. If the hypothesis of 
normality is rejected, the natural logarithm will be applied to the measurements at each 
timepoint, the model will be re-fit, and model-based quantities will be back-transformed and 
expressed on the ratio scale.
7.1.1
Definition of Study Days and Baseline
Study Day 1 is defined as the date on which a subject is administered the first dose of the study 
medication. Other study days are defined relative to the Study Day 1 with Day 2 being the day 
after Study Day 1 and Day -1 being the day prior to Study Day 1.
For all the endpoints, baseline is defined as the last non-missing measurement prior to first dose 
of study drug unless otherwise stated.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 11 of 28
Statistical Analysis Plan
20 Apr 2021
7.1.2
Definition of Study Visit Windows
All scheduled study visits will be defined relative to Study Day 1. For example, the appropriate 
day for the scheduled Week 8 visit should be: Day 1 + 56 = Day 57.
A windowing convention will be used to determine the analysis value for a given study visit and 
will be applicable for all by-visit summaries and analyses. The windowing conventions for all 
efficacy and safety variables are summarized in Table 1.
Table 1.
Visit Windows for Efficacy and Safety Endpoints
Visit ID (Scheduled Study Day)
Window Interval (day) for 
Efficacy Endpoints
Window Interval (day) for 
Safety Endpoints
Baseline (Day 1)
1
1
Week 4 (Day 29)
27 –31  
2 –57  
Week 12 (Day 85)
78 – 92
58 – 106
Week 18 (Day 127)
120 – 134
107 – 155
Week 26 (Day 183)
176 – 190
156 – 204
Week 32 (Day 225)
218 –232
205 –250
Week 39 (Day 274 )
267 – 281
251 – 295
Week 45 (Day 316 )
309 – 323
296 – 341
Week 52 (Day 365)
358 – 372
342 – 372
Week 54 (Day 378)
376 – 380
373 – 380
For efficacy variables, a 2-day rule will be applied to Week 4 and Week 54 visits, and a 7 day 
rule will be applied all other scheduled visits; ie, the lower bound of the window will be either 2 
or 7 days before the scheduled study day, and the upper bound of the window will be either 2 or 
7 days after the scheduled study day, as applicable. For safety variables, visit windows are 
exhaustive; the bounds of each window are the midpoints between the scheduled days for the 
current visit and the adjacent visits, with the exception that, for Week 54, the upper bound of the 
window will be 2 days after the scheduled study day. One or more results for a particular 
efficacy or safety variable may be obtained in the same visit window. If more than one are
obtained, the result with the date closest to the scheduled visit date will be used. In the event that 
multiple observations are equidistant from the scheduled visit date then the later observation will 
be used.
7.2
Analysis Sets
The safety set will include all subjects who took at least 1 dose of study medication. In safety 
summaries, subjects will be analyzed according to the treatment most often received.
The full analysis set (FAS) will include all randomized subjects in the safety set. For a particular 
variable, the FAS analysis will consist of all subjects who receive at least one dose of study 
treatment. In FAS efficacy summaries, subjects will be analyzed as randomized. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 12 of 28
Statistical Analysis Plan
20 Apr 2021
The per protocol set (PPS) will include all FAS subjects who had no major protocol violations. 
Relevant major protocol violations will be finalized prior to database lock, if the final criteria is 
different from the criteria presented here below. Major protocol deviations criterion for initial 
consideration include the following: any violations of study inclusion criteria; exclusion criteria
1, 3, 4, 8, 9, 10; drug compliance < 80% or > 120%; receiving incorrect randomized treatment; 
not completing the Week 26 assessment (including HbA1C value). If a subject has titration (up 
or down) of the background antidiabetic therapy while on study treatment, this subject will be 
excluded from the PPS. Final criteria will be documented prior to unblinding if different from the
above preliminary criteria.
The pharmacokinetic (PK) set will include all randomized subjects who had at least 1 blood draw 
taken for pharmacokinetic assessments during the course of this trial. 
7.3
Disposition of Subjects
A summary of total number of subjects who failed the screening, and the reason for failure will 
be provided in the screen failures table. 
Subject disposition will be summarized for all randomized subjects. The numbers and 
percentages of subjects randomized but not treated, subjects who completed study drug, and 
subjects who prematurely discontinued study drug by “Reason for discontinuation from study 
drug” will be displayed. 
In addition, the numbers and percentages of randomized subjects who completed planned study 
visits, and who prematurely discontinued the study visits by “reason for discontinuation of study 
visits” and “reason for discontinuation from study” will be summarized separately.
The number and percentage of subjects with at least 1 significant protocol deviation, and the 
number and percentage of subjects within each deviation category will be summarized based on 
all randomized subjects in separate table.
All randomized subjects breakdown by the stratification factor (antidiabetic therapy (Y/N)) will 
also be summarized.
7.4
Demographic and Other Baseline Characteristics
Summary statistics will be provided for continuous variables (age, height, weight, and body mass 
index (BMI), BMI Z score, Baseline HbA1c, Baseline Blood Glucose) measured at Baseline. 
The BMI (in kg/ m2) is defined as the subject’s weight (in kg) divided by the square of their 
height (in m). BMI Z score calculations use the reference provided by Centers for Disease 
Control and Prevention 3rd to 97th Percentile growth charts to determine BMI-for-age 
percentiles (http://www.cdc.gov/growthcharts/clinical_charts.htm#Set2). The reported values 
will be rounded to 2 decimal places. BMI percentiles will be listed for each subject. 
The numbers and percentages of subjects will be presented for the following categorical 
variables: race, ethnicity, gender, age group (10-13 years, 14-17 years), BMI group (<25 kg/m2, 
25 kg/ m2 to <30 kg/ m2, ≥30 kg/ m2), Tanner Stage Score, and prior antidiabetic therapy 
(Schedule A or B).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 13 of 28
Statistical Analysis Plan
20 Apr 2021
Subjects with non-alcoholic fatty liver disease (NAFLD) will be recorded in the medical history 
and be summarized as well. 
Demographic and other baseline characteristics data will be summarized by treatment group and 
total based on the FAS. 
7.5
Medical History and Concurrent Medical Conditions
Summaries of medical history and concurrent medical conditions will be presented for the safety 
set. Medical history will consist of any significant conditions or diseases that stopped at or prior 
to the time of signing the informed consent. Ongoing conditions will be considered concurrent 
medical conditions. Concurrent medical conditions are significant ongoing conditions or diseases 
present at time of informed consent through end of study. These include clinically significant 
laboratory, ECG, or physical examination abnormalities.
Medical history and concurrent medical conditions will be coded using the latest version of 
Medical Dictionary for Drug Regulatory Activities (MedDRA). The numbers and percentages of 
subjects with medical history and concurrent medical conditions will be reported by system 
organ class (SOC) and preferred term (PT) in separate tables.
7.6
Prior, Concomitant, and Post-treatment Medications
Any non-study medication that was stopped prior to the first study drug dose date (Day 1) will be 
considered prior medication. Any non-study medication with a start date between Day 1 and on 
or prior to the last study drug dose date, inclusive, or with a start date before Day 1 and an end 
date after Day 1 or ongoing, will be considered concomitant medication. Any medication with a 
start date after the last study drug dose date will be considered post-treatment medication. For 
summary purpose, if the medication’s start or stop dates are missing or partially missing and the 
medication is not checked as ongoing, the following imputation rules will be applied:

If the year is present but the month and day are missing, then 01JAN will be imputed for 
the start date and 31DEC for the stop date.

If the year and month are present but the day is missing, then 01 will be imputed for the 
start date and the last day of the month for the stop date.

If the year is missing or the date otherwise cannot be imputed, then the date will be 
treated as missing and the medication will be treated as a concomitant medication.
All non-study medication will be coded by Anatomical Therapeutic Chemical (ATC) code and 
PT using the latest version of World Health Organization Drug Dictionary (WHODrug). All the 
medication history, concomitant medications, and post-treatment medications will be 
summarized for the safety set in frequency tabulations (subject counts and percentages) and by 
ATC first level and PT in separate tables.
A listing of non-study medication will also be provided, to include dose, unit, frequency, route of 
administration, start and end dates, and reason for use.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 14 of 28
Statistical Analysis Plan
20 Apr 2021
7.7
Study Drug Exposure and Compliance
A subject’s drug exposure, measured in days, will be defined as (date of last dose - date of first 
dose+1). Drug exposure in weeks will be calculated by dividing the exposure in days by 7, and
be summarized as a continuous variable. The numbers and percentages of subjects within
exposure categories (<12 weeks, 12 to <26 weeks, ≥26 weeks) will also be presented.
If the date of last dose is missing and a subject has discontinued from the study, then, for 
summary purposes, the last dose date will be estimated using the earliest of the following after 
the last available drug dispensation: date of death, date of last contact (recorded on eCRF).
A subject’s study drug compliance (%) will be calculated as {(number of tablets dispensed -
number of tablets returned)/ (number of tablets dispensed)}*100%.  This compliance will be 
summarized with descriptive statistics and subject counts within compliance categories (<80%, 
80 to <90%, ≥90%). If the number of returned capsules and/or the return date are missing, then 
100% compliance will be assigned for each day up to the number of capsules dispensed, the date 
of return, or the date of last dose, whichever is earliest.
Summaries of study drug exposure and compliance will be based on the safety set.
7.8
Efficacy Analysis
The primary analysis set for all the efficacy analyses will be the FAS. Supportive analyses will 
be conducted with the PPS for the primary and secondary efficacy endpoints. Efficacy values 
collected >1 day after the last dose of double-blind study drug (>7 days for HbA1c) will be 
considered post-treatment values and will be listed but not analyzed. If maturity-onset diabetes of 
the young (MODY) has been observed in the study from adverse event reports, 
a.
a description of the results will be provided separately for each individual subject with 
MODY, and 
b. the mixed modeling for the primary and secondary efficacy endpoints will be repeated, 
excluding the MODY subjects.
If subjects have been observed to down-titrate background antidiabetic therapy while continuing
study treatment, a sensitivity analysis will be conducted for primary and secondary endpoints by 
excluding data collected after the down-titration based on PPS.
7.8.1
Primary Efficacy Endpoint
The primary endpoint is HbA1c change from Baseline at Week 26. In the primary efficacy 
analysis, the corresponding 2-sided hypotheses tested are:  

H0: µ(alogliptin) = µ(Placebo)  
versus

H1: µ(alogliptin) ≠ µ(Placebo)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 15 of 28
Statistical Analysis Plan
20 Apr 2021
where µ(treatment)  is the population mean HbA1c change from Baseline at Week 26 of the 
corresponding treatment. The primary analysis will be conducted using the FAS. A contrast at 
Week 26 derived from the MMRM analysis will be used for the statistical inference. Any 
significant p-value (< 0.05) from the contrast of the model (alogliptin minus placebo), and 
corresponding 95% confidence interval (CI), with upper confidence limit below 0, will permit 
concluding better treatment effect of alogliptin 25 mg QD compared to placebo. 
In this MMRM model, change from Baseline in HbA1c will be the response variable; 
randomized treatment, scheduled visit (Weeks 12, 18, 26, 39, and 52), antidiabetic therapy (Y/N
also known as Schedule B/A), and visit-by-treatment interaction will be fixed categorical effects;
and baseline HbA1c and visit-by-baseline HbA1c interaction will be continuous covariates. An 
unstructured covariance matrix will be used to model the correlation among repeated 
measurements; parameter estimates will be calculated using restricted maximum-likelihood 
estimation (REML). Degrees of freedom will be estimated using the Kenward-Roger 
approximation. Data collected following discontinuation of double-blind study medication or 
hyperglycemic rescue will not be included in the analysis.
A table of descriptive statistics (n, mean, SD, median, and range) will be provided for the 
observed HbA1c as well as the change form baseline for each of the above scheduled visits. 
Similar presentation will be provided by subgroups, e.g. Schedule (A or B), gender (M/F), race 
(White/Black/Other), age group (10-13 years, 14-17 years), and BMI group (<25 kg/m2, 25 kg/ 
m2 to <30 kg/ m2, ≥30 kg/ m2).
7.8.1.1
Sensitivity Analysis of Handling of Dropouts or Missing Data by Washout Imputation
In washout-imputation, the missing data in an endpoint from both arms will be imputed using 
observed endpoint data from the placebo. When the missing values in the Alogliptin arm are 
imputed, no intermediate endpoint values will be used and only baseline data and covariates will 
be included in the model. When missing values in the placebo arm are imputed, baseline data, 
intermediate endpoint values, and covariates will be included in the model. This imputation 
method will only impute the time point at Week 26 using multiple imputation regression with 
gender, background antidiabetic therapy (ie. Schedule A or B) and baseline HbA1c as the 
covariates. Sensitivity analysis for HbA1c at other time points will be conducted if the week 26 
analysis indicates lack of robustness in the primary analysis.
Twenty imputed datasets will be generated by the aforementioned Washout imputation. 
ANCOVA will be used as the analytical method for each imputed dataset. Estimates obtained 
from multiple imputed datasets will be combined based on Rubin’s combination rules (Little R., 
Rubin D.B. 2002).
7.8.1.2    Tipping Point Analysis
Conditional of statistically significant results for the primary analysis, a tipping point analysis 
will be performed to investigate the robustness of the primary analysis. The tipping point is 
defined as the difference in the average glycosylated hemoglobin (HbA1c) change between a 
treatment arm and placebo at which the study conclusion changes from statistical significance to 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 16 of 28
Statistical Analysis Plan
20 Apr 2021
non-significance. To find this tipping point, a systematic shift will be applied to the imputed 
values in both treatment arms for weeks missing HbA1c measurements. The multiple imputation 
process (ie, missing not at random adjustments in the multiple imputation process) will be 
performed with each shift applied until the values result in a change of the significance of the 
primary hypothesis test, the tipping point.
Twenty imputed datasets will be generated for each of the shift parameters. MMRM will be used 
as the analytical method for each imputed dataset. Estimates obtained from multiple imputed 
datasets will be combined based on Rubin’s combination rules. The tipping point can be 
identified when the result is no longer statistically significant.
7.8.1.3    Supplemental Analysis of COVID-19
A supplemental analysis that excludes subjects affected by COVID-19 will be performed on the 
primary endpoint. Information concerning a subject being impacted due to COVID-19 before or 
on week 26 visit for sensitivity analysis for primary endpoint will be collected as protocol
deviation, including but not limited to site closure, missingness, self-withdrawal, adverse event, 
concomitant medications, etc. Prior to unblinding data, meeting will be held to identify those 
subjects who will be classified as “impacted by COVID-19”.
7.8.2
Secondary Efficacy Endpoints
Each secondary efficacy endpoint will be analyzed using the MMRM analysis specified for the 
primary efficacy endpoint, stated in Section 7.8.1.
Summary statistics of observed values at each visit will be presented,  and the corresponding 
estimate, standard error (SE), 95% CI, and p-value of the contrast from the mixed model will be 
reported on the table. Figures, i.e. a plot of point estimate with SE error bars, of HbA1c over 
time will be presented by treatment group for both the LS means estimates and changes from 
baseline.   
Descriptive statistics will be provided, including subgroups, as provided for the primary 
endpoint.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
e
will be u
ll be
le imput
e impu
nt can b
nt can b
19 will b
9 wil
ed due t
d due
will be c
will be 
ness, sel
ss, se
meeting 
meeting
D-19”.
19
alyzed u
lyzed
on 7.8.1
n 7.8
s atat eac
ea
CI, and
CI, an
e. a pl
e. a plo
atment g
ent
will be p
will b
For No
perty of Takeda: Fo


SYR-322_309
Page 17 of 28
Statistical Analysis Plan
20 Apr 2021
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 18 of 28
Statistical Analysis Plan
20 Apr 2021
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
perty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 19 of 28
Statistical Analysis Plan
20 Apr 2021
7.9.2
Pharmacodynamic Analysis
Not applicable.
7.10
Safety Analysis
All safety summary tables will be presented for all subjects in the safety set, unless otherwise 
stated. Separate summaries using (1) data collected from baseline through the date of last dose + 
7 days for labs (+ 14 days for AEs) or date of hyperglycemic rescue (if applicable), whichever is 
earlier and (2) all data collected at or after baseline throughout the study will be conducted. No
statistical tests will be performed for the safety analyses, unless otherwise stated.
CCI
Property of Take
Phar
Pha
Not app
ot ap
7.1
7
Use
keda: For Non-Commercial Use Only and Subject to the Applicable Terms of Us


SYR-322_309
Page 20 of 28
Statistical Analysis Plan
20 Apr 2021
7.10.1 Pre-treatment Events and Adverse Events
A pretreatment event (PTE) is defined as any untoward medical occurrence prior to 
administration of any study medication; it does not necessarily have to have a causal relationship 
with study participation. An adverse event (AE) is defined as any untoward medical occurrence 
on or after the first administration date of the study medication, it does not necessarily have to 
have a causal relationship with this treatment. Adverse event verbatim reported terms will be 
coded by system organ class (SOC) and preferred term (PT) using the latest version of MedDRA.
AE summary tables will include numbers and percentages of subjects experiencing at least one 
AE by SOC and PT. Unless otherwise specified AEs will be sorted by relative frequency (highest 
to lowest) in the alogliptin arm, unless where the AE summary is two-tiered the AE will be 
sorted alphabetically at the first tier (eg. SOC) and relative frequency at the second tier (eg. PT). 
The following AE summary tables will be generated: 

Overview of AE

AEs by SOC, PT and SOC and PT

Serious AE (SAE) by SOC and PT

Relationship of AEs to Study Drug by SOC and PT

Relationship of AEs to Study Procedure by SOC and PT

Drug-Related AEs by SOC and PT

Procedure-Related AEs by SOC and PT

Drug-Related SAE by SOC and PT

Procedure-Related SAE by SOC and PT

Most Frequent AEs (excluding SAEs) by PT

Intensity of AEs by SOC and PT

Severe AEs by SOC and PT

Intensity of Drug-Related AEs by SOC and PT

Intensity of Procedure -Related AEs by SOC and PT

AE with Action of Dose Interrupted by SOC and PT

AE with Action of Drug Withdrawn SOC and PT

Adverse events of special interest, including serious hepatic abnormalities, pancreatitis, 
infections (including urinary tract infections), and severe hypersensitivity reactions 
including angioedema, anaphylaxis, and Stevens-Johnson Syndrome
Other AE/SAE summary tables may be added as appropriate. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 21 of 28
Statistical Analysis Plan
20 Apr 2021
A subject with 2 or more different adverse events within the same level of the MedDRA term 
will be counted only once in that level using the most extreme incident (most intense for the 
intensity tables, and related for the relationship to study drug tables). For the AE with missing 
relationship to drug/procedure will be imputed as related.
Most Frequent AEs are defined as the adverse events occurring in at least 5% of the safety set. If 
no AEs satisfy the 5% criteria then 3% or 2% maybe be used. 
For summary table purposes, it is assumed that AEs with missing/incomplete start dates have 
occurred during the treatment period if there is not enough information to determine that the AEs 
occurred prior to the first dose date.  Specifically, the missing/incomplete onset dates will be 
imputed as follows:
1. If the onset date is completely missing, then impute the date as the first dose date.
2. If the onset date is partially missing, the following scenarios will be considered:
1) If the year is the year of the first dose, and month and day are missing, then impute month 
and day as the month and day of the first dose date. 
2) If month and year are present and day is missing:
i)
If month is equal to the month of first dose date then set day to the day of first dose 
date;
ii) If month is before the month of first dose date then set day to the last day of the 
month of AE start date;
iii) If month is after the month of first dose date then set day to the first day of the month 
of AE start date.
3) If year and day are present and month is missing:
i)
If day is on or after the first dose date, then set month to the same month of first dose 
date;
ii) If day is before the first dose date, then set month to the next month of first dose date.
After imputation, if the imputed AE start date is after the available AE end date, death date or 
last visit date, that imputed date will be re-set as the earliest of AE end date, death date and last 
visit date. Partial dates will be presented as they are in the listings.
PTEs, AEs, SAEs, AEs leading to study drug withdrawn, AEs leading to study discontinuation, 
and AEs resulting in death will be listed separately.
7.10.2 Clinical Laboratory Evaluations
Clinical safety laboratory evaluations include clinical hematology, serum chemistry, and 
urinalysis.  
These evaluations will be summarized for baseline, post-dosing, and change from baseline at 
each visit. Only the scheduled measurements will be included in the summaries. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 22 of 28
Statistical Analysis Plan
20 Apr 2021
Individual results for hematology and serum chemistry laboratory evaluations will be evaluated 
against the Takeda predefined laboratory markedly abnormal value (MAV) criteria (Appendix 
A) using the result and criteria in SI units.  The number and percentage of subjects with at least 
one postdose MAV will also be summarized. All postdose clinical lab results, including 
scheduled and unscheduled measurements, will be included in the MAV summaries. 
All clinical laboratory data will be presented in both SI and conventional units in data listings.
7.10.3 Vital Signs
Vital sign measurements include body temperature (oral or tympanic measurement), respiratory 
rate, blood pressures (resting more than 5 minutes), and pulse 
These measurements will be summarized for baseline, post-dosing, and change from baseline at 
each visit. Only the vital signs collected at the scheduled visits or time points will be included in 
the summary. 
All individual vital signs that meet Takeda’s predefined corresponding MAV criteria (Appendix 
B) will be listed. The number and percentage of subjects with at least one post first dose of study 
drug markedly abnormal vital sign measurement will be summarized. All postdose vital signs,
including both scheduled and unscheduled measurements, will be included in the MAV 
summaries.
7.10.4 Physical Examination 
Complete physical examinations will be performed at Baseline, Week 26 and Week 52. Brief 
physical examinations will be performed at Week 12 and Week 39. The body system will be 
assessed as normal, abnormal, or not examined at each scheduled visit, and the percentage of 
subjects with abnormal physical examination findings at each time point will be summarized by 
body system and by treatment arm.
7.10.5 12-Lead ECGs
Interpreted ECGs will be recorded in the database using 1 of the following categories: within 
normal limits, abnormal but not clinically significant, or abnormal and clinically significant. 
Shift tables will be provided to summarize interpretation status changes from baseline to each 
scheduled post-baseline measurement. Interpreted ECG will also be listed by visit.
7.10.6 Other Observations Related to Safety
7.10.6.1 Incidence of infections and hypersensitivity reactions
Numbers and percentages of subjects experiencing at least one infection/ hypersensitivity 
reaction, and numbers of infections/ hypersensitivity reactions at each post-dose visit, will be 
summarized. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 23 of 28
Statistical Analysis Plan
20 Apr 2021
7.10.6.2 Incidence of hypoglycemia
Hypoglycemia is defined in the protocol Section 9.1.16.2. Hypoglycemic events will be 
summarized, including tabulating numbers and percentages of subjects experiencing at least one 
hypoglycemic event, the number of hypoglycemic events per day, and the numbers and 
percentages of days having ≥1 events between each pair of consecutive post-screening visits 
(e.g., between Day 1 and Week 4, between Week 4 and Week 12, etc). Total number and 
percentage of days having ≥1 events throughout the treatment phase will also be summarized.
Listings will also be provided to include additional information such as Blood Glucose Value, 
and Symptoms.
7.10.6.3 Change from Baseline in biomarkers of bone turnover (bone-specific alkaline 
phosphatase and CTX at Weeks 26 and 52
Biomarkers of bone turnover will be summarized for baseline, post-dosing, and change from 
baseline at each visit for each parameter. If data permit an MMRM model of the same form as 
the model specified for the primary endpoint in Section 7.8.1 will be fit to each parameter, and 
similar quantities will be extracted. 
7.10.6.4 Change from Baseline in CD26 surface antigen levels at Weeks 26 and 52.
CD26 surface antigen levels will be summarized for baseline, post-dosing, and change from 
baseline at each visit for each parameter. If data permit an MMRM model of the same form as 
the model specified for the primary endpoint in Section 7.8.1 will be fit to each parameter, and 
similar quantities will be extracted. 
7.11
Interim Analysis
Not applicable.
7.12
Changes in the Statistical Analysis Plan 
In general, the analyses described in the statistical analysis plan do not differ from the plan 
specified in the protocol; an exception is given below.
1. In the protocol, we defined “FAS analysis will consist of all subjects who have a baseline 
assessment and at least 1 postbaseline assessment for the variable.” In this updated SAP, we 
defined “FAS analysis will consist of all subjects who receive at least one dose of study 
treatment”
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 24 of 28
Statistical Analysis Plan
20 Apr 2021
8.0
REFERENCES
1.
Protocol: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to 
Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric 
Subjects With Type 2 Diabetes Mellitus. Amendment number 02, 09 November 2016.
2.         Little, R. J. A., & Rubin, D. B. (2002). Statistical Analysis with Missing Data. Hoboken, 
NJ: John Wiley & Sons.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 25 of 28
Statistical Analysis Plan
20 Apr 2021
Appendix A
Criteria for Identification of Markedly Abnormal Laboratory Values
This appendix provides lists of values for selected laboratory parameters that will be used to 
identify markedly abnormal values (MAV). The final MAVs used in the statistical presentations 
may deviate from these predefined lists. However final MAVs will be documented in the 
statistical presentations and where applicable justifications will be provided in the clinical study 
report.
Hematology—Criteria for Markedly Abnormal Values
Parameter
Unit
Low Abnormal
High Abnormal
Hemoglobin
Both 
< 0.8 × LLN
> 1.2 × ULN
Hematocrit
Both
< 0.8 × LLN
> 1.2 × ULN
RBC count 
Both
< 0.8 × LLN 
> 1.2 × ULN
WBC count 
Both 
<0.5 x LLN
>1.5 x ULN
Platelet count
Conventional
<75 x 103/L
>600 x 103/L
SI
<75 x 109/L
>600 x 109/L
Mean Corpuscular 
Volume
Both
<70 fL
>100 fL
LLN=lower limit of normal, RBC=red blood cell, ULN=upper limit of normal, WBC=white blood cell. 
Serum Chemistry—Criteria for Markedly Abnormal Values
Parameter
Unit 
Low Abnormal
High Abnormal
ALT
Both
--
≥3x ULN
AST
Both
--
≥3x ULN
GGT
Both
--
≥3x ULN
Alkaline phosphatase
Both
--
≥3x ULN
Calcium
Conventional
<7.0 mg/dL
>11.5 mg/dL
SI
<1.75 mmol/L
>2.88 mmol/L
Chloride
Conventional
<75 mEq/L
>126 mEq/L
SI
<75 mmol/L
>126 mmol/L
Total bilirubin
Conventional
--
>2.0 mg/dL
SI
--
>34.2 mol/L
Direct bilirubin
Both
--
≥2x ULN
Albumin
Conventional 
<2.5 g/dL
--
SI 
<25 g/L
--
Total protein
Both
<0.8x LLN
>1.2x ULN
Creatinine
Conventional 
--
>2.0 mg/dL
SI
--
>177 mol/L
Blood urea nitrogen
Conventional 
--
>30 mg/dL
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 26 of 28
Statistical Analysis Plan
20 Apr 2021
Parameter
Unit 
Low Abnormal
High Abnormal
SI
--
>10.7 mmol/L
Sodium
Conventional
<130 mEq/L
>150 mEq/L
SI
<130 mmol/L
>150 mmol/L
Potassium
Conventional
<3.0 mEq/L
>6.0 mEq/L
SI
<3.0 mmol/L
>6.0 mmol/L
CPK
Both
--
≥5x ULN
Glucose
Conventional
< 50 mg/dL
>350 mg/dL
SI
< 2.8 mmol/L
>19.4 mmol/L
Bicarbonate
Conventional
<8.0 mEq/L
SI
<8.0 mmol/L
Uric Acid
Conventional
--
>13.0 mg/dL
SI
--
>773 mol/L
Magnesium
Conventional
<1.2 mg/dL
>3.0 mg/dL
SI
<0.5 mmol/L
>1.2 mmol/L
Phosphorus
Conventional
<1.6 mg/dL
>6.2 mg/dL
SI
<0.52 mmol/L
>2.00 mmol/L
Total Cholesterol
Conventional
--
>300 mg/dL
SI
--
>7.72 mmol/L
Triglycerides
Both
--
>2.5x ULN
ALT=alanine aminotransferase, AST=aspartate aminotransferase, CPK=creatine phosphokinase, GGT=-glutamyl 
transferase, LLN=lower limit of normal, ULN=upper limit of normal.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 27 of 28
Statistical Analysis Plan
20 Apr 2021
Appendix B
Criteria for Markedly Abnormal Values for Vital Signs
This appendix provides a list of values for selected vital signs parameters that will be used to 
identify markedly abnormal values (MAV). The final MAVs used in the statistical presentations 
may deviate from this predefined list. However final MAVs will be documented in the statistical 
presentations and where applicable justifications will be provided in the clinical study report.
Parameter
Unit
Lower Criteria
Upper Criteria
Pulse
Bpm
<50 
>120
Systolic blood pressure
mm Hg
<85
>150 
Diastolic blood pressure
mm Hg
<40
>95
Body temperature
oC
oF
< 35.6
<96.1
>37.7
>99.9
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


SYR-322_309
Page 28 of 28
Statistical Analysis Plan
20 Apr 2021
Appendix C
Reference code in SAS
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Subject to the Applicable Terms of Use



(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GDHHI
䣕䣛䣔䣡䢵䢴䢴䣡䢵䢲䢻䢢䣕䣃䣒䢢䣥䣮䣧䣣䣰䢢䣸䣧䣴䣵䣫䣱䣰䢢䢳䢰䢲䢢䢴䢲䢴䢳䢯䢲䢶䢯䢴䢲
6WDWLVWLFDO$SSURYDO
0D\87&
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
e Te
ate 
te
ble T
HH:mm ‘U
H:mm
Ter
ble
87&
87